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RNA NANOPARTICLES AND METHOD OF 
USE THEREOF 
RELATED APPLICATIONS 
This application is a § 371 National State Application of 
PCT/US2016/028012 filed Apr. 17, 2016 which claims the 
benefit of U.S. Provisional Patent Application No. 62/149, 
117, filedApr. 17, 2015 and 62/150,233, filed Apr. 20, 2015, 
the entire disclosures of which are hereby incorporated by 
reference in their entirety. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
U01CA151648, R01EB019036 and R01EB003730 awarded 
by the National Institutes of Health. The government has 
certain rights in the invention. 
SEQUENCE LISTING 
The instant application contains a Sequence Listing which 
has been submitted electronically in ASCII format and is 
hereby incorporated by reference in its entirety. Said ASCII 
copy, createdonApr.11, 2018, isnamed2935720-10_SL.txt 
and is 9,863 bytes in size. 
TECHNICAL FIELD 
2 
In some embodiments, the presently disclosed subject 
matter relates to an artificial RNA nanostructure molecule. 
The molecule includes a RNA junction motif comprising a 
plurality of branches and at least one imaging module, 
5 wherein a branch of the RNA junction motif comprises at 
least one RNA oligonucleotide. Non-limiting examples of 
the imaging module includes fluorescence dyes, radionu-
clides, and/or contrast agents. Non-limiting examples of 
fluorescent dye include Alexa dyes, Cy dyes or Near Infrared 
10 dyes. Further non-limiting examples of fluorescent dye 
include Alexa dye, Cy dyes, Near Infrared (Near IR or NIR) 
dyes, including but not limited to, IRdye800, Alexa647, Cy5, 
Cy5.5, Alexa680, Iowa Black RQ, QSY21, IRDyeQC, 
BBQ650, BHQ-3, Indocyanine green (ICG). In some 
15 embodiments, the imaging module comprises a reporter 
imaging module. In some embodiments, the imaging mod-
ule comprises a reference imaging module. In some embodi-
ments, the reference imaging module comprises a reference 
dye and a quencher. In some embodiments, the RNA mol-
20 ecule further includes at least one cancer targeting module 
coupled to the RNA junction motif. In some embodiments, 
the molecule further includes at least one therapeutic module 
coupled to the RNA junction motif. In some embodiments, 
the imaging module is coupled to at least one branch of the 
25 RNA junction motif. In some embodiments, the imaging 
module is coupled to any branch of the RNA junction motif. 
In some embodiments, the imaging module is coupled to the 
cancer targeting module. In some embodiments, the imaging 
module is coupled to the therapeutic module. In some 
The presently-disclosed subject matter relates to an arti- 30 embodiments, the plurality of branches comprises three 
ficial RNA nanostructure and method of use thereof. In branches, four branches, five branches, six branches, seven 
particular, the presently-disclosed subject matter relates to 
RNA nanoparticles and RNA dendrimers, and methods of 
disease diagnosis and treatments using RNA nanostructure 
and RNA dendrimers. 
INTRODUCTION 
Cancer is a broad class of diseases featuring uncontrol-
lable cell growth, invasion, and destruction of nearby tissues 
and metastasis [1, 2]. Cancer has become one of the leading 
causes of death in the world, accounting for about 7.6 
million deaths in 2008 [3]. The economic burden of cancer 
is also very high, to both the person with cancer and for the 
whole society. According to the estimation by the National 
Institutes of Health (NIH), the overall annual cost of cancer 
in 2008 was $201.5 billion [ 4]. Thus, an effective, efficient, 
and safe treatment for cancer is urgently needed. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
branches eight or more branches. In one embodiment, the 
plurality of branches comprising the RNA junction motif 
includes a three-branched RNA junction motif. In one 
35 embodiment, the plurality of branches comprising the RNA 
junction motif comprises a four-branched RNA junction 
motif. 
In some embodiment of the presently disclosed subject 
matter, the RNA nanostructure includes a radionuclide. In 
40 some embodiments, the term "radionuclide" includes radio-
label peptides and proteins with various isotopes. Nonlim-
iting examples of the radioisotopes includes 177Lu, 111 In, 
64Cu, 99mTc, 230Pb, issRe, 212Pb/212Bi. In some embodi-
ments, the radionuclide is coupled to more than one branch 
45 of the RNA junction motif. In some embodiment, the 
radionuclide is chelated by a chelating agent. In some 
embodiments, the chelating agent is conjugated to at least 
one branch of the RNA junction motif. Nonlimiting 
examples of the chelating agent is EDTA, DOTA, NOTA. 
50 [0058] In some embodiments, the RNA molecule includes a 
contrast agent. In some embodiments, the contract agent is 
a MRI contrast agent. In some embodiments, the MRI 
contract agent is gastrointestinal MRI, intravenous MRI, 
intravascular (blood pool) MRI tumor-specific MRI, hepa-
55 tobiliary MRI and reticuloendothelial MRI. One non-limit-
ing example of the MRI contrast agent is a gadolinium This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea- 60 
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
contrast agent. 
In some embodiments, the nanostructure comprises at 
least one chemical modification at a 2' position of the RNA 
oligonucleotide. In some embodiments, the chemical modi-
fication comprises 2'Fluoro, 2'Amine, and 2'O-Methyl. 
In some embodiments of the presently disclosed subject 
matter, a branch of the three-branched RNA junction motif 
is an a3WJ RNA module (SEQ ID NO: 1), a b3WJ RNA 
module (SEQ ID NO: 2), or a c3WJ RNA module (SEQ ID 
NO: 3). In one embodiment, the three-branched RNA junc-
tion motif comprises an a3WJ RNA module (SEQ ID NO: 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. This Sum- 65 
mary does not list or suggest all possible combinations of 
such features. 
US 10,828,381 B2 
3 
1 ), a b3 WJ RNA module (SEQ ID NO: 2), and a c3 WJ RNA 
module (SEQ ID NO: 3). In some embodiments, SEQ ID 
NO: 1 has at least 90% identity to nucleotide sequence 
5'-UUG CCA UGU GUA UGU GGG-3'. In one embodi-
4 
embodiments, a branch of the three-branched RNA junction 
motif includes an a3WJ RNA module (SEQ ID NO: 1), a 
b3WJ RNA module (SEQ ID NO: 2), or a c3WJ RNA 
ment, SEQ ID NO: 1 comprises nucleotide sequence 5 
5'-UUG CCA UGU GUA UGU GGG-3'. In some embodi-
module (SEQ ID NO: 3). In some embodiments, the three-
branched RNA junction motif comprises an a3WJ RNA 
module (SEQ ID NO: 1), a b3WJ RNA module (SEQ ID 
ments, SEQ ID NO: 2 has at least 90% identity to nucleotide 
sequence 5'-CCCACA UAC UUU GUU GAUCC-3'. In one 
embodiment, SEQ ID NO: 2 comprises nucleotide sequence 
5'-CCC ACA UAC UUU GUU GAUCC-3'. In some 
embodiments, SEQ ID NO: 3 has at least 90% identity to 
nucleotide sequence 5'-GGA UCAAUC AUG GCAA-3'. In 
one embodiment, SEQ ID NO: 3 comprises nucleotide 
sequence 5'-GGA UCAAUC AUG GCAA-3'. 
In some embodiments of the presently disclosed subject 
matter, the RNA nanostructure includes a cancer targeting 
module. In some embodiments, the presently disclosed 
subject matter provides that the targeting module in the 
artificial RNA nano structure molecule includes a ligand that 
binds to at least one cancer cell surface marker. In some 
embodiments, the cancer targeting module is a colon cancer 
targeting module. Non-limiting examples of folate include 
5-methyltetrahydro folate, 5-formyltetrahydrofolate, dihy-
drofolate, tetrahydrofolate, folic acid and other folate com-
pounds. In some embodiments, the therapeutic module com-
prises a siRNA, a miRNA, an anti-mRNA, a ribozyme RNA, 
or an antisense RNA. In some embodiments, In some 
embodiments, the therapeutic module comprises a chemo-
therapeutic drug, a riboswitch, or an endosome disrupting 
agent. In some embodiments, the therapeutic module is a 
siRNA sequence. In one embodiment, the siRNA directly 
binds to survivin. In some embodiments, the siRNA directly 
binds to PI3K, Akt, or mTOR. In some embodiments, the 
therapeutic module is a microRNA sequence. In some 
embodiments, the therapeutic module is an anti-miRNA 
molecule directed to a miRNA comprising miR-9, miR-1 Ob, 
miR-21, or miR-26. In some embodiments, the therapeutical 
module is a miRNA molecule for a miRNA comprising 
let-7a, miR-l0b, miR-25, miR-34a, miR-124, miR-145, or 
miR-181b. In some embodiments, the therapeutic module is 
NO: 2), and a c3WJ RNA module (SEQ ID NO: 3). In some 
embodiments, SEQ ID NO: 1 has at least 90% identity to 
nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG-
10 3'. In some embodiments, SEQ ID NO: 1 comprises nucleo-
tide sequence 5'-UUG CCA UGU GUA UGU GGG-3'. In 
some embodiments, SEQ ID NO: 2 has at least 90% identity 
to nucleotide sequence 5'-CCC ACA UAC UUU GUU 
GAUCC-3'. In some embodiments, SEQ ID NO: 2 com-
15 prises nucleotide sequence 5'-CCC ACA UAC UUU GUU 
GAUCC-3'. In some embodiments, SEQ ID NO: 3 has at 
least 90% identity to nucleotide sequence 5'-GGA UCA 
AUCAUG GCAA-3'. In some embodiments, SEQ ID NO: 
3 comprises nucleotide sequence 5'-GGA UCA AUC AUG 
20 GCAA-3'. In some embodiments, the cancer-targeting mod-
ule is a cancer cell-specific ligand. In some embodiments, 
the cancer-targeting module is folate. In some embodiments, 
cancer-targeting module is an RNA aptamer. In some 
embodiments, the radiation-based therapeutic module 
25 include a isotope. Nonlimiting examples of the isotope 
include 177Lu, lllln, 64Cu, 99mTc, 203Pb, 188Re, 212Pb, 
212Bi, I-125, or Cs-131. 
Further, in another aspect of the present subject matter, a 
RNA dendrimer molecule is provided. The molecule 
30 includes (a) a central core multi-branched RNA junction 
motif, wherein the central core motif comprises a plurality 
of branches, and wherein a branch comprises at least one 
RNA oligonucleotide; and (b) an outer surface multi-
branched RNA junction motif comprising at least one 
35 repeating multi-branched RNA junction motif unit, wherein 
the repeating unit comprises a plurality of branches, and 
wherein a branch comprises at least one RNA oligonucle-
otide. In some embodiments, the dendrimer further includes 
at least one imaging module. In some embodiments, the 
40 dendrimer includes at least one targeting module. In some 
embodiments, the dendrimer further includes at least one 
therapeutic module. In some embodiments, the plurality of 
branches includes the central core multi-branched RNA 
a cytotoxic drug. In some embodiments, the cytotoxic drug 
comprises doxorubicin, paclitaxel, paclitaxel derivatives and 
analogues, cytochalasin D, rapamycin, rapamycin deriva-
tives and analogues, camptothecin, dexamethasone, and 
5-fluorouracil, a quinazolinone derivative, metallic silver, 45 
tranilast, everolimus and/or related compounds. 
junction motif comprises a three-branched RNA junction 
motif, a four-branched RNA junction motif, five-branched 
RNA junction motif, a six-branched RNA junction motif, 
In another aspect, the presently disclosed subject matter 
provides an artificial RNA nanostructure molecule includes 
a RNA junction motif comprising a plurality of branches and 
a radiation-based therapeutic module coupled to the RNA 50 
junction motif, and a branch of the RNA junction motif 
includes at least one RNA oligonucleotide. In some embodi-
ments, the molecule further includes a cancer targeting 
module coupled to the RNA junction motif. In some embodi-
ments, the molecule further includes an imaging module 55 
coupled to the RNA junction motif. In some embodiments, 
the nanostructure comprises at least one chemical modifi-
cation at 2' position of the RNA oligonucleotide. In some 
embodiments, the chemical modification comprises 
2'Fluoro, 2'Amine, and 2'O-Methyl. In some embodiments, 60 
the plurality of branches comprises three branches, four 
branches, five branches, six branches, seven branches, eight 
or more branches. In some embodiments, the plurality of 
branches comprising the RNA junction motif includes a 
three-branched RNA junction motif. In some embodiments, 65 
the plurality of branches comprising the RNA junction motif 
comprises a four-branched RNA junction motif. In some 
seven-branched RNA junction motif, an eight or more 
branched RNA junction motif. In some embodiments, the 
plurality of branches comprising the repeating multi-
branched RNA junction motif unit includes a three-branched 
RNA junction motif, a four-branched RNA junction motif, 
five-branched RNA junction motif, a six-branched RNA 
junction motif, seven-branched RNA junction motif, an 
eight or more branched RNA junction motif. In some 
embodiments, a branch of the three-branched RNA junction 
motif comprises an a3WJ RNA module (SEQ ID NO: 1); a 
b3WJ RNA module (SEQ ID NO: 2); or a c3WJ RNA 
module (SEQ ID NO: 3). In one embodiments, the three-
branched RNA junction motif comprises an a3WJ RNA 
module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID 
NO: 2); and a c3WJ RNA module (SEQ ID NO: 3). In some 
embodiments, SEQ ID NO: 1 has at least 90% identity to 
nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG-
3'. In some embodiments, SEQ ID NO: 2 has at least 90% 
identity to nucleotide sequence 5'-CCC ACA UAC UUU 
GUU GAUCC-3'. In some embodiments, SEQ ID NO: 3 has 
at least 90% identity to nucleotide sequence 5'-GGA UCA 
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Further, in some embodiments, the presently disclosed 
subject matter provide a method of image-guided drug 
delivery of a therapeutic agent to a subject in need thereof. 
The method include administering a therapeutically effec-
5 tive amount of RNA nanostructure molecule and RNA 
AUC AUG GCA A-3'. In some embodiments, the central 
core multi-branched RNA junction motif is a polygon 
shaped architecture comprising a three-branched RNA junc-
tion motif at each comer. In some embodiments, the imaging 
module comprises a fluorescent dye, a radionuclide, or a 
contrast agent. In some embodiments, fluorescent dye is a 
Alexa dye, Cy dyes or Near IR dyes. Nonlimiting of 
fluorescent dye include IRdye800, Alexa647, Cy5, Cy5.5, 
Alexa680, Iowa Black RQ, QSY21, IRDyeQC, BBQ650, 
BHQ-3, Indocyanine green (ICG). In some embodiments, 10 
the imaging module comprises a reporter imaging module. 
In some embodiments, the imaging module comprises a 
reference imaging module. In some embodiments, the ref-
erence imaging module comprises a reference dye and a 
15 
quencher. In some embodiments, the imaging module com-
prises at least one fluorescent dye. In some embodiments, 
the imaging module include a radionuclide and/or a contrast 
agent. A nonlimiting example of contrast agent is a MRI 
contrast agent. In one embodiment, the imaging module 20 
includes at least one gadolinium contrast agent. In some 
embodiments, the targeting module includes a cancer tar-
geting module. In some embodiments, the cancer targeting 
module is a ligand that binds to at least one cancer cell 
surface marker. In some embodiments, the RNA dendrimer 25 
contains a targeting module comprises a chemical ligand 
and/or a RNA aptamer. A nonlimiting example of the ligand 
includes folate. In some embodiments, the cell surface 
markers comprises a folate receptor. In some embodiments, 
the ligand binds to an epithelial cell adhesion molecule 30 
(EpCAM). In some embodiments, the cell surface marker 
comprises an epithelial cell adhesion molecule (EpCAM). In 
some embodiments, the cancer targeting module comprises 
an aptamer. A non-limiting example of the aptamer is an 
EpCAM RNA aptamer. In some embodiments, the cancer 35 
targeting module is a folate. Nonlimiting examples of the 
folate include folic acid, 5-methyltetrahydro folate, 5-form-
yltetrahydrofolate, dihydrofolate, tetrahydrofolate, or a 
combination thereof. In some embodiments, the therapeutic 
module comprises a siRNA, a miRNA, an anti-mRNA, a 40 
ribozyme RNA, or an antisense RNA. In some embodi-
ments, the therapeutic module comprises a chemotherapeu-
dendrimer as disclosed above and herein, and applying an 
imaging detection apparatus to the subject. In some embodi-
ments, the imaging detection apparatus is an MRI imaging 
system. In some embodiments, the imaging detection appa-
ratus is an NIRF imaging system. In some embodiments, the 
imaging detection apparatus is an CT/PET/SPECT imaging 
system. 
In some embodiments of the present subject matter, is a 
method of diagnosing and/or treating a disease in a subject 
having or at risk of having the disease. The method com-
prising administering to the subject a therapeutically effec-
tive amount of a composition comprising a RNA nano struc-
ture and/or RNA dendrimer as disclosed herein. In some 
embodiments, the composition further comprises a pharma-
ceutically acceptable carrier. In some embodiments, the 
subject is a mammal or a non-mammal vertebrate. In some 
embodiments, the subject is a human. In some embodiments, 
the disease includes but not limited to ovarian cancer, brain 
cancer, bone cancer, lung cancer, colorectal cancer. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows structure, assembly and characterization of 
RNA 3WJ nanoparticles. A. Secondary structure of the 
pRNA 3WJ (FIG. lA discloses SEQ ID NOS 1, 3 and 2, 
respectively, in order of appearance). B. Eight representative 
images of RNA 3WJ-pRNA nanoparticles are shown in 
magnified view and the images reveal a three-branch shape 
of the RNA nanoparticles. The AFM images of the RNA 
nanoparticles were obtained on APS-modified mica surface 
by a Veeco MultiMode AFM NanoScope IV system. (Scale 
bar: 10 nm). C. 12% native PAGE demonstrates the step-
wise assembly of RNA 3WJ nanoparticles, stained by 
ethidium bromide (upper) and SYBR Green II (lower). 
Lane: 1: 3WJa (SEQ ID NO: 1); 2: 3WJ6 (SEQ ID NO: 2); 
3: 3WJc (SEQ ID NO: 3); 4: 3WJa+3WJb (SEQ ID NO: 1, 
SEQ ID NO: 2); 5: 3WJa+3WJc (SEQ ID NO: 1, SEQ ID 
NO: 3); 6: 3WJb+3WJC (SEQ ID NO: 2, SEQ ID NO: 3); 7: 
3WJa+3WJb+3WJc (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID 
NO: 3). D. The thermodynamic stability of assembled RNA 
3WJ nanoparticles was revealed by using the TGGE system. 
The temperature gradient was set from 36 to 80° C., and the 
direction was set as perpendicular to the electric field. The 
left two lanes are the 3WJ fragments and the 3WJ complex 
starts at the third lane. 
FIG. 2 shows targeting, uptake, and cytotoxicity of RNA 
3WJ nanoparticles. A. Confocal images showing the uptake 
comparison of the folate-3WJ RNA nanoparticles and 3WJ 
tic drug, a riboswitch, or an endosome disrupting agent. In 
some embodiments, the therapeutic module is a cytotoxic 
drug. Nonlimiting examples of the cytotoxic drug include 45 
doxorubicin, paclitaxel, paclitaxel derivatives and ana-
logues, cytochalasin D, rapamycin, rapamycin derivatives 
and analogues, camptothecin, dexamethasone, and 5-fluo-
rouracil, a quinazolinone derivative, metallic silver, tranil-
ast, everolimus and related compounds, or other agents that 50 
inhibit cell proliferation and or migration and/or inflamma-
tory processes. In some embodiments, the plurality of 
branches of the multi-branched comprises at least 90% 
identity to nucleotide sequences of at least one of SEQ ID 
NOS: 1-20. 55 only RNA nanoparticles to colon cancer HT29 cells by 
colocalization of nucleus (blue), actin (green) andAlexa647-
labeled RNAnanoparticles (red) signals. B. Flow cytometry 
analysis showing the binding of folate labeled 3 WJ 2'F RNA 
nanoparticles to folate receptor over-expressed KB cells. 
In another aspect of the presently disclosed subject matter, 
is a composition comprising a therapeutically effective 
amount of the RNA nanostructure molecule and RNA den-
drimer as disclosed above and herein. In some embodiments, 
the composition further includes a pharmaceutically accept-
able carrier. 
60 Black curve: cell only control; blue curve: 3WJ RNA 
nanoparticles without folate; red curve: 3WJ RNAnanopar-
ticles with folate. C. Effect of the folate-3WJ RNA nano-
particles on HT29 cells viability. The cells were incubate 
Yet in another aspect of the presently disclosed subject 
matter, is a drug delivery system, the system comprising a 
therapeutically effective amount of the RNA nanostructure 
and the RNA dendrimer molecule as disclosed above and 65 
herein. In some embodiments, drug delivery system further 
includes a pharmaceutically acceptable carrier. 
with three different concentration (100 nM, 200 nM and 400 
nM) of the folate-3WJ RNA nanoparticles. D. The folate-
3WJ-Alexa647 were injected intravenously into nude mice 
with HT29 subcutaneous xenografts. Accumulation of fluo-
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rescently labeled folate-3WJ nanoparticles in tumor, liver 
and lung was evaluated by IVIS Spectrum station. 
FIG. 3 show stability assay ofRNA3WJ nanoparticles for 
urea, serum and irradiation. A. 12% native PAGE demon-
strates the stability ofRNA3WJ nanoparticles against 2 M-8 5 
M Urea denaturation. The gel was stained by ethidium 
bromide. Lane: 1: 3WJa (SEQ ID NO: 1); 2: 3WJ6 (SEQ ID 
NO: 2); 3: 3WJc (SEQ ID NO: 3); 4: 3WJa+3WJb (SEQ ID 
NO: 1, SEQ ID NO: 2); 5: 3WJa+3WJc (SEQ ID NO: 1, SEQ 
ID NO: 3); 6: 3WJb+3WJC (SEQ ID NO: 2, SEQ ID NO: 3); lO 
7: 3WJa+3WJb+3WJc (SEQ ID NO: 1, SEQ ID NO: 2, SEQ 
ID NO: 3). B. Nanoparticle stability in serum was compared 
between 2'F modified and non-modified RNA 3WJ nano-
8 
injection [G18]: (A) whole body (B) confocal images of the 
retina showing RNA accumulation after 4 hrs. 
FIG. 11 includes (A-B) Upon systemic injection, pRNA-
3WJ nanoparticles were located specifically at the cancer 
xenografts expressing the cancer receptors and were not 
detected in any vital organs in the body [G9-ll]. 
FIG. 12 includes conjugation of 'reference' dye IRdye800 , 
quencher Iowa Black, and 'reporter' dye Alexa647 to pRNA-
3WJ scaffold for fluorescence imaging. Alternatively, radio-
nuclides will be incorporated as 'reference' module for 
simultaneous PET/SPECT and fluorescence imaging. Figure 
discloses SEQ ID NOS 1, 3 and 2, respectively, in order of 
appearance. 
FIG. 13 shows emission spectra of the 'reporter' dye 
Alexa647 , and 'reference' dye IRdye800 , showing no spectral 
overlaps. 
FIG. 14 shows step-wise preparative scheme for labeling 
DOTA conjugated RNA nanoparticles with a radionuclide 
(1 77Lu or 111In) or contrast agent Gd3 +. For 64Cu, NOTA-
20 SCN will be used instead. The radiolabeled strand will then 
particles for up to 36 hr. Black square: RNA nanoparticle; 
15 
red sphere: 2'F RNA nanoparticle. C. RNA 3WJ nanopar-
ticles were resistant to radiation. 2'F-modified RNA 3WJ 
nanoparticles were examined by 12% native PAGE with 
TBM running buffer after 7-day irradiation with Cs-131 or 
18-day irradiation with I-125. A dose of30 Gy was given by 
both Cs-131 and I-125. No obvious change was detected 
after 7-day or 18-day irradiation. Lane: 1: RNA nanopar-
ticles without irradiation; 2: RNA nanoparticles after 7-day 
irradiation (30 Gy) with Cs-131; 3: RNAnanoparticles after 
18-day irradiation (30 Gy) with I-125. D. Plasmid DNA was 25 
damaged by radiation. Plasmid DNA was examined by 0.7% 
agarose gel with TAE running buffer after 7-day irradiation 
(30 Gy) with Cs-131 or 18-day irradiation (30 Gy) with 
I-125. Plasmid DNA was damaged after both 7-day and 
18-day irradiation. Lane: 1 & 3: Plasmid DNA without 30 
irradiation; 2: Plasmid DNA after 7-day irradiation (30 Gy) 
with Cs-131; 4: Plasmid DNA after 18-day irradiation (30 
Gy) with I-125. 
FIG. 4 includes diagrams illustrating comparison of (A) 
conventional molecular beacon and (B) RNA nanotechnol- 35 
ogy-based 3WJ-Beacons. FIG. 4B discloses SEQ ID NOS 1, 
3 and 2, respectively, in order of appearance. 
FIG. 5 includes construction of pRNA-3WJ based RNA 
Dendrimers (G0-G3) for harboring multiple gadolinium 
contrast agents for MRI Imaging and radionuclides for 40 
PET/SPECT imaging. 
FIG. 6 includes (A) phi29 DNA packaging motor. (B) 
pRNA hexamer derived from the crystal in (D)14. (C) 
Hexameric pRNA nanoparticles. (D) pRNA-3WJ crystals 
and X-ray diffraction pattern14. (E) pRNA monomer (SEQ 45 
ID NO: 33). Box: 3WJ domain. (F) 3WJ domain9 composed 
of three fragments a3wJ, b3wJ, and c3wJ. Hl-3: helical 
segments (FIG. 6F discloses SEQ ID NOS 1, 3 and 2, 
respectively, in order of appearance). 
FIG. 7 includes competition and dissociation assays of 50 
pRNA-3WJ nano-particles [G9] (A) Temperature effects: 
Fixed concentration of Cy3-pRNA-3WJ core [ ab*c h wJ was 
incubated with varying concentrations of unlabeled b3 wJ at 
37° C. (B) Urea denaturing effects: A fixed concentration of 
Cy3-[ ab*c h wJ was incubated with unlabeled b3 wJ at a 1: 1 55 
ratio in the presence of 0-6 M urea at 25° C. (C) Serial 
dilution assay: The [32P]pRNA-3WJ complex remains intact 
even at 160 pM. (D) After 2'-F modification, RNA nano-
particles are chemically stable [G13]. 
FIG. 8 shows that, compared to 11 different RNA 3WJ 60 
core motifs, the 3 WJ-pRNA motif displayed the highest Tm 
with the steepest slope [G9]. 
FIG. 9 shows RNA nanotechnology approach for con-
structing polyvalent RNA nanoparticles with various shapes 
and sizes [G9-Gll]. 
FIG. 10 includes (A-B) Ocular delivery of pRNA nano-
particles to cornea and retina following subconjunctival 
65 
be mixed with the other 3WJ component strands to assemble 
the 3WJ nanoparticles. Figure discloses SEQ ID NOS 34, 
34, 34, 1, 34 and 2, respectively, in order of appearance. 
FIG. 15 shows confocal images showing strong binding 
and entry ofpRNA-3WJ-FAnanoparticles into HT29 colon 
cancer cells. Magnification: 180x. 
FIG. 16 shows confocal images showing strong binding 
and entry of Cy5 labeled pRNA-3WJ-EpCAM aptamer 
constructs into HT29 colon cancer cells. The aptamer was 
selected from our novel 2'-F 3WJ library based on RNA 
nanotechnology. 
FIG. 17 shows enhanced gene silencing effects of tetrava-
lent pRNA-X nanoparticles harboring different siRNAs tar-
geting different loci on the same gene10. RLU: Relative 
Luciferase Units. 
FIG. 18 (A) shows construction of miR-21-luciferase 
reporter system. (B) Schematic of pRNA-3WJ-FA-anti-
miR21 nanoparticles (FIG. 18A discloses SEQ ID NO: 35). 
(C) Upon incubation, specific knock-down miR-21 in KB 
cells was observed, compared to controls (without FA or 
anti-miR21). 
FIG. 19 shows conjugation of Paclitaxel to pRNA-3WJ 
using 'click chemistry' approach and acid-labile bonds. 
Figure discloses SEQ ID NOS 1, 3 and 2 respectively, in 
order of appearance. 
FIG. 20 shows preliminary data of Caspase 3 assay 
demonstrating cell apoptosis induced by the CPT-RNA 
strand. Inset: Design of pRNA-3WJ constructs carrying 
Camptothecin (CPT). 
FIG. 21 shows working principle ofpRNA-3WJ-Beacon. 
Once internalized into the cells and released from the 
endosome, the RNA-3WJ-Beacon is processed by RISC and 
the siRNA component will be released from the 3WJ com-
plex and away from the quencher, thereby restoring the 
fluorescence of 'reporter' dye Alexa647 for real-time imag-
ing 
FIG. 22 shows (A) Whole body and (B) Internal organ 
images showing that upon systemic injection, pRNA-3WJ-
FAnanoparticles specifically targeted Folate receptor+HT29 
colon cancer subcutaneous xenografts and were not detected 
in any vital organs in the body, after 8 hrs. (C) Confocal 
imaging of fixed frozen tumor xenografts sections confirmed 
binding and accumulation of pRNA nanoparticles in vivo. 
Control: PBS. 
FIG. 23 shows Micro-SPECT/CT imaging ofMDA-MB-
435 breast cancer subcutaneous xenograft bearing mice119 . 
(A) The whole body SPECT images were fused with con-
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ventional micro-CT images to validate regions of increased 
uptake of radiolabeled 111 In-DOTA(GSG)-KCCYSL pep-
tide (SEQ ID NO: 31). (B) The trans-axial SPECT/CT image 
focusing on tumor uptake in the xenograft. (Kumar S R, et 
al., Clin. Cancer Res. 2007 Oct. 15; 13(20):6070-9). 
FIG. 24 shows targeting of metastatic liver cancer by 
pRNA-3WJ-Folate nanoparticles. (A) Bio-luminescence 
images confirming liver metastasis. The pRNA-3WJ-FA-
Alexa647 nanoparticles specifically targeted HT29 liver 
metastatic cells, but not the normal liver parenchyma cells 10 
after systemic injection, as shown by macroscopic (B) and 
histological (C) assays. Control: PBS treated mice. Green: 
cancer cells; blue: DAPI for nucleus; magenta: Alexa647 
RNA; White arrows: Folate-pRNA-Alexa647 accumulation 
and binding; Yellow arrows: normal liver parenchyma. 15 
FIG. 25 shows pRNA nanoparticles did not induce inter-
feron response12, as assayed by (A) IFN of KB cells; (B) 
TLR-3,7 and 9 gene for human blood mononuclear cells; (C) 
TLR-3 pathway of HEK-Blue-hTLR3 reporter cells. 
FIG. 26 shows (A-B) Schematic and AFM images of 20 
RNA dendrimers composed mainly of RNA by branch 
extension11 . (C) 2D structure of Generation-3 RNA Den-
drimers using pRNA-3WJ as scaffold for harboring DOTA-
chelated Gd3 +, radionuclides and/or folate. 
10 
PDB viewer) of G-0 to G-4 RNA dendrimers. (B) 2% 
agarose gel showing assembly of G-0 to G-4 RNA dendrim-
ers. (C) Serum stability assay of G-4 RNA dendrimers 
assayed in 2% agarose gel and quantified by ImageJ. 
FIG. 33 shows (A) Flow cytometry data of G-4 RNA 
dendrimers at different concentrations (1 nM, 3 nM and 6 
nM) with KB cells. Cell only (black), G-4 dendrimer with no 
folate (red); and G-4 with 16 folates (blue). Right: Summary 
of binding results. (B) Confocal microscope images of G-4 
RNA dendrimers incubated with KB cells, nuclear staining 
by DAPI (blue), cell membrane staining by phalloidin 
Alexa488 (green), Cy5-labeled folate-G4 dendrimer (red) 
and a overlay of three panels. Bottom: Magnified view of 
overlayed image section boxed in red. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. 
FIG. 27 shows In vivo assessment ofliver metastases. (A) 25 
HT29-Luc cells were injected into the spleen to induce liver 
metastases. Representative bioluminescence images of mice 
with Luc-expressing liver metastases (B) T2 weighted 
images acquired on the University of Kentucky small animal 
Clinscan MRI scanner depicting multiple liver metastases 
(arrows). 
In certain instances, nucleotides and polypeptides dis-
30 closed herein are included in publicly-available databases, 
such as GENBANK® and SWISSPROT. Information 
FIG. 28 shows (A-B) 2D sequence; assembly in 15% 
native PAGE and stability in 8 M urea 15% PAGE; and 
thermodynamic properties of pRNA-3WJ (A) and pRNA-
3WJ-rev (B) scaffold. (FIG. 28A-B discloses SEQ ID NOS 35 
36, 3, 2, 37, 5 and 6, respectively, in order of appearance). 
FIG. 29 shows step-wise assembly of three modules used 
as building blocks for RNA dendrimer construction. Mod-
ule-I assembles for three strands: 3WJ-a, 3WJ-b, and 3WJ-
c. Module-2 assembles from three units: pRNA-3WJ har- 40 
boring a_rev, pRNA-3WJ harboring b_rev, and pRNA-3WJ 
harboring c_rev sticky-ends. Module-3 assembles from 
three units: pRNA-3WJ harboring a_rev, pRNA-3WJ har-
boring b_rev, and pRNA-3WJ harboring three c_rev sticky 
ends. Right panel: AFM images of the modular building 45 
blocks. For module-I, theAFM image is for 3WJ with three 
pRNA subunits at the three branches. 
including sequences and other information related to such 
nucleotides and polypeptides included in such publicly-
available databases are expressly incorporated by reference. 
Unless otherwise indicated or apparent the references to 
such publicly-available databases are references to the most 
recent version of the database as of the filing date of this 
Application. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
set forth to facilitate explanation of the presently-disclosed 
subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
FIG. 30 shows construction of multifunctional RNA 
dendrimers. Functionalization of module-3 with varieties of 
moieties for targeting (chemical ligand or RNA aptamer), 
imaging (fluorophore or radiolabel), and therapeutic 
(siRNA, miRNA, anti-miRNA, chemotherapeutic drugs, 
ribozyme, riboswitch, endosome disrupting agents) units. 
50 methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
55 forth. 
FIG. 31 shows assembly of G-1 to G-4 RNA dendrimers 
from component strands. G-0 assembles for three strands: 
3WJ-a, 3WJ-b, and 3WJ-c, as shown in FIG. 2A module 1. 
(A) G-1 assembles from five strands: A, B, C, D and E with 
complementary linkers (black) and 3WJ strands (red). (B) 
G-2 assembles from G-1 harboring four 3WJ-b sticky ends, 
and 3WJ-a and 3WJ-c strands. (C) G-3 assembles from G-2 60 
harboring eight 3WJ-b_rev sticky ends, and 3WJ-a_rev and 
3WJ-c_rev strands. (D) G-4 assembles from G-2 harboring 
eight 3WJ-b_rev sticky ends, and a dimer module harboring 
3WJ-a_rev and 3WJ-c_rev strands. Please refer to Table 4 
for defining characteristics. 
FIG. 32 shows (A) 2D structure (left), AFM images 
(middle), and 3D model (right) (using Pymol and Swiss 
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Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
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tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1%, in some embodiments ±0.5%, and in some embodi-
ments ±0.1 % from the specified amount, as such variations 
are appropriate to perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
As used herein, the abbreviations for any protective 
groups, amino acids and other compounds, are, unless 
indicated otherwise, in accord with their common usage, 
recognized abbreviations, or the IUPAC-IUB Commission 
12 
90° indicates an extremely low free energy (li.G) and coop-
erative assembly of the three component strands (FIG. 8). 
2'-Fluoro (2'-F) modification [G9,G13,G56-58] resulted in 
RNA nanoparticles resistant to RNase degradation, while 
5 retaining authentic folding and biological activities [G9, 
G10,G13] (FIG. 7D). Varieties of RNA nanoparticles were 
constructed using the pRNA-3WJ as a scaffold and demon-
strated that each functional module retained their folding 
and independent functionalities for specific cell binding and 
10 entry, gene silencing, and catalytic function in vitro and in 
animal trials [G9-12] (FIG. 9-11). The pRNA-3WJ nano-
particles displayed favorable biodistribution and pharma-
cokinetic profiles, and avoided interferon responses and 
cytokine production in mice [G12] (FIG. 25). The in vivo 
15 half-life ofour 2'-F functional RNAs is 6-12 hr, compared to 
0.25-0.75 hr of 2'-F bare siRNA [G12,G59,G60]. Recently 
the crystal structure of the pRNA-3WJ core was obtained 
[G14], which will facilitate the design of multifunctional 
RNA nanoparticles. 
on Biochemical Nomenclature (see, Biochem. (1972) 11(9): 20 
1726-1732). 
RNA nanoparticles can be fabricated with a level of 
simplicity characteristic of DNA, while possessing versatile 
tertiary structures and catalytic functions that mimic some 
proteins [G8,G49,G61-66]. RNA nanotechnology refers to 
the design, fabrication, and application of RNA architectures 
The presently-disclosed subject matter includes an artifi-
cial RNA nanostructures and RNA dendrimers and methods 
of use thereof. 
RNA nanotechnology is an unique field [G8,G24], dis-
tinct from the classical studies of RNA structure and folding 
[G25-31]. In 1998, the feasibility of constructing RNA 
nanoparticles by bottom-up self-assembly was first demon-
strated. RNA dimer, trimer, and hexamer nanoparticles were 
assembled using re-engineered RNA fragments from the 
pRNA, a viral component gearing the phi29 DNA packaging 
motor (FIG. 6A-C [G32]). This finding (published in 
Molecular Cell, and featured in Cell (G32-33)) was the 
proof-of-concept for RNA nanotechnology. Generally 
speaking, RNA is unique in several aspects: (1) RNA 
contains varieties of motifs such as helices, loops, stems, 
hairpins, and pseudo-knots to specify rich 3D architectures; 
(2) RNA possesses both canonical, noncanonical base pair-
ings(G34-38), as well as base stacking capabilities for inter-
or intra-molecular interactions(G39-40); (3) RNA is ther-
modynamically more stable than DNA [G9,G10,G39,G40]; 
( 4) RNA displays unique features in transcription, termina-
tion, splicing, and self-processing producing RNA frag-
ments that are able to self-assemble into nanoparticles in 
vitro and in vivo [G32,G41-45]; and (5) RNA exhibits 
functional entities, such as siRNA [G46,G47], ribozyme 
[G48,G49], riboswitch [GS0-51], and miRNA [G52-53]. As 
disclosed herein, RNA nanotechnology is an important field 
due to finding of its high thermodynamic stability, favorable 
and distinctive in vivo attributes (US 2014/0179758, hereby 
incorporate by reference in its entirety). In some embodi-
ments of the present disclosure, as disclosed in US2014/ 
0179758, the RNA molecules form dimers, trimers, hexam-
ers, and patterned superstructures. 
In nature, several RNA molecules form unique multimers 
with diverse functions. In one embodiment, bacteriophage 
phi29 pRNA forms dimers and hexamers, via hand-in-hand 
interactions, between right- and left-interlocking loops 
[G20,G32,G54,G55] (FIG. 6A-C). Unusual properties of an 
ultra-stable pRNA 3-way junction (3WJ) motif was recently 
discovered (FIG. 6E-F) (Nature Nanotechnology, 2011; 
Nano Today, 2012) [G9-10]. The 3WJ assembles from three 
RNA oligos with unusually high affinity in the absence of 
metal salts; is resistant to denaturation by 8 M urea; displays 
thermodynamically stable properties; and does not dissoci-
ate at ultra-low concentrations (FIG. 7) [G9-12]. Without 
being bound by theory, a melting curve with a slope close to 
25 primarily made up of RNA via bottom-up self-assembly 
(FIG. 9), in contrast to other widely studied drug delivery 
systems conjugating functional RNA modules to polymer, 
lipid, dendrimer, gold, or other nanomaterial based nano-
particles. Properties of the RNAnanoparticles created in the 
30 presently disclosed subject matter include: (1) the body 
treats RNA particles as its own, avoids phagocytosis by 
macrophages and minimizes accumulation in normal 
organs; (2) the polyanionic nature of RNA can avoid non-
specific cell entry since it is unfavorable for it to cross the 
35 negatively charged cell membranes [G67-70]; (3) RNA is a 
polymer (polynucleic acid). RNAnanoparticles have defined 
size, structure, and stoichiometry (FIG. 9). Unpredictable 
side effects from heterogeneous particles can thus be 
avoided (FIG. 9) [GS-10, G20,G24]; (4) RNAnanoparticles 
40 was designed that are 10-60 nm in size and sufficient to 
harbor siRNAs, ribozymes, miRNAs, and aptamers (FIG. 9). 
The nanoparticles are large enough to avoid renal excretion 
(as is the case for bare siRNA), yet small enough to enter 
cells by receptor-mediated endocytosis [71] and avoid 
45 entrapment by liver Kupffer cells and lung macrophages 
[G3,G8]; (5) the branched ratchet shape of our RNA nano-
particle design (FIG. 9) facilitates tumor penetration and 
EPR (Enhanced Permeability and Retention) effects [G3, 
GS]; (6) economic large scale production is possible in a 
50 cell-free system; (7) RNA is highly soluble, not prone to 
aggregation, and do not require linkage to PEG or serum 
albumins [G8,G24], typically used for a wide range of 
nanoparticles; (8) the multivalent nature of RNA nanopar-
ticles allows integration of targeting, imaging and therapeu-
55 tic modules for achieving synergistic effects without using 
any cross-linking approaches (FIG. 9) [G8,G9] Modular 
design allows self-assembly of engineered RNA fragments 
[G8,G24]; (9) It has been demonstrated that 2'-F chemically 
modified RNA is resistant to RNase degradation while 
60 retaining authentic folding and biological functions [G9, 
G10,G13]; (10) pRNA-3WJ nanoparticles are thermody-
namically stable, and therefore will remain intact in vivo at 
ultra-low concentrations (FIG. 7-8) [G9,G10]; (11) the 
pRNA-3WJ based nanoparticles has favorable pharmacoki-
65 netic and pharmacodynamic profiles in vivo; is non-toxic 
and does not induce interferon (FIG. 25) or cytokine pro-
duction in mice [G9,G10,G12]; (12) systemic injection of 
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the stable RNA nanoparticles into mice has revealed that 
RNA nanoparticles strongly and specifically bind to cancers 
with little accumulation in vital organs or tissues [G9,G10, 
G12] (FIG. 11); (13) RNA nanoparticles do not induce 
host-antibody responses, which will allow for repeated treat-
ment of cancer. This is particularly applicable to patients 
who develop neutralizing antibodies in response to protein-
based reagents; (14) RNA is a chemical reagent. Therefore, 
the regulatory processes are expected to be more favorable 
compared to protein-based clinical reagents [G8,G24]. 
In some embodiments, the presently disclosed subject 
matter relates to an artificial RNA nanostructure molecule. 
The molecule includes a RNA junction motif and at least one 
imaging module. The RNA junction motif includes a plu-
rality of branches, and a branch of the RNA junction motif 
comprises at least one RNA oligonucleotide. In some 
embodiments, the plurality of branches includes three 
branches, four branches, five branches, six branches, seven 
branches, eight or more branches (US 2014/0179758, herein 
incorporated by reference by its entirety). 
Nonlimiting examples of the imaging module includes 
fluorescence dyes, radionuclides, and/or contrast agents. 
Non-limiting examples of fluorescent dye include Alexa 
dyes, Cy dyes or Near Infrared dyes. Further nonlimiting 
examples of fluorescent dye include Alexa dye, Cy dyes, 
Near Infrared (Near IR or NIR) dyes, including but not 
limited to, IRdye800, Alexa647, Cy5, Cy5.5, Alexa680, Iowa 
Black RQ, QSY21, IRDyeQC, BBQ650, BHQ-3, Indocya-
nine green (ICG). In some embodiments, the imaging mod-
ule comprises a reporter imaging module. In some embodi-
ments, the imaging module comprises a reference imaging 
module. In some embodiments, the reference imaging mod-
ule comprises a reference dye and a quencher. In some 
embodiments, the RNA molecule further includes at least 
one cancer targeting module coupled to the RNA junction 
motif. In some embodiments, the molecule further includes 
at least one therapeutic module coupled to the RNA junction 
motif. In some embodiments, the imaging module is coupled 
to at least one branch of the RNA junction motif. In some 
embodiments, the imaging module is coupled to any branch 
of the RNA junction motif. In some embodiments, the 
imaging module is coupled to the cancer targeting module. 
In some embodiments, the imaging module is coupled to the 
therapeutic module. In one embodiment, the plurality of 
branches comprising the RNA junction motif includes a 
three-branched RNA junction motif. In one embodiment, the 
plurality of branches comprising the RNA junction motif 
comprises a four-branched RNA junction motif. 
Also, as used herein, the term "couple," as used herein, 
refers to the joining of two molecules together. Non-limiting 
examples include a covalent attachment between an RNA 
nanoparticle a ligand moieties such as folate, or of labeling 
moieties, or of therapeutic agents, or by incorporation of 
nuclease-resistant nucleotides (WO/2002/016596; U.S. Pat. 
No. 7,655,787; WO/2005/003293; WO/2007/016507, which 
are expressly incorporated by reference herein.) 
NIR dyes or fluorophores are particularly attractive since 
they can penetrate deep into tissues and more importantly, 
auto-fluorescence from tissues is greatly reduced. without 
being bound by theory, a robust RNA nanotechnology will 
be developed utilizing the pRNA-3WJ motif for monitoring 
the in vivo delivery of therapeutics non-invasively by NIRF 
and PET/SPECT imaging. In some embodiments, the RNA 
nanostructure molecule is used for in vivo imaging, 
14 
label peptides and proteins with various isotopes. Nonlim-
iting examples of the radioisotopes includes 177Lu, 111 In, 
64Cu, 99mTc, 203Pb, issRe, 212Pb/212Bi. In some embodi-
ments, the radionuclide is coupled to more than one branch 
5 of the RNA junction motif. In some embodiment, the 
radionuclide is chelated by a chelating agent. In some 
embodiments, the chelating agent is conjugated to at least 
one branch of the RNA junction motif. Nonlimiting 
10 
examples of the chelating agent is EDTA, DOTA, NOTA. 
In some embodiments, the RNA molecule includes a 
contrast agent. The term "contrast agent," as used herein, 
refers to a compound employed to improve the visibility of 
internal body structures in an image, including but not 
limited to, an X-ray image or a scanning image (e.g., CAT 
15 (Computerized Axial Tomography) scan, MRI (Magnetic 
Resonance Imaging) scan). The term contrast agent is also 
referred to herein as a radiocontrast agent. Contrast agents 
are employed in various diagnostic (e.g., cardiac catheter-
ization) and therapeutic (e.g., vascular shunt placement) 
20 procedures. Magnetic resonance imaging (MRI) is a pow-
erful noninvasive technique that provides high quality three 
dimensional images of tissues, including information on 
anatomy, function, and metabolism of tissue in vivo. Gado-
linium is a common T 1-weighted MRI contrast agent. In 
25 some embodiments, the contract agent is a MRI contrast 
agent. In some embodiments, the MRI contract agent is 
gastrointestinal MRI, intravenous MRI, intravascular (blood 
pool) MRI tumor-specific MRI, hepatobiliary MRI and 
reticuloendothelial MRI. One non-limiting example of the 
30 MRI contrast agent is a gadolinium contrast agent. 
Biological macromolecules, as natural building blocks, 
are critical for the functioning of living organisms. RNA is 
one of the five most important biological macromolecules in 
addition to DNA, proteins, lipids and carbohydrates. With 
35 some aspects similar to DNA, RNA, composed of four 
nucleotides including adenosine (A), cytosine (C), guanos-
ine (G) and uridine (U), is special in its homogeneity. RNA 
is a homopolymer of nucleotide, but is also a heteropolymer 
of A, U, G, and C. Each nucleotide contains a ribose sugar, 
40 a nucleobase, and a phosphate group. The nucleotides are 
covalently linked together through 3'=5' phosphodiester 
bonds between adjacent ribose units, giving the direction-
ality to the sugar-phosphate backbone that defines RNA as 
a polynucleic acid. The phosphate moieties in the backbone 
45 are negatively charged, making RNA a polyanionic macro-
molecule at physiological pH. RNA molecules are typically 
single-stranded; however, Watson-Crick ( canonical) base-
pair interactions (A:U and G:C), wobble base pairing (such 
as G:U) [G. Varani, W. H. McClain, EMBO Rep., 1 (2000), 
50 pp. 18-23] or other non-canonical base pairing such as 
twelve basic geometric families of edge-to-edge interaction 
(Watson-Crick, Hoogsteen/CH or sugar edge) with the ori-
entation of glycosidic bonds relative to the hydrogen bonds 
(cis or trans) [U. Nagaswamy, et., al., Nucleic Acids Res., 30 
55 (2002), pp. 395-397], all together give rise to various 
structural conformations exhibiting loops, hairpins, bulges, 
stems, pseudoknots, junctions, etc., which are essential 
elements to guide and drive RNA molecules to assemble into 
desired structures [Y. Xin, et al., RNA, 14 (2008), pp. 
60 2465-2477; Y. Xin, et al., RNA, 14 (2008), pp. 2465-2477; 
C. Laing, et al., PLoS ONE, 8 (2013), p. e71947; and C. 
Laing, et al., Nucleic Acids Res., 40 (2012), pp. 487-498]. 
In some embodiment of the presently disclosed subject 65 
matter, the RNA nanostructure includes a radionuclide. In 
some embodiments, the term "radionuclide" includes radio-
The characteristic of RNA that defines and differentiates 
it from DNA is the 2'-hydroxyl on each ribose sugar of the 
backbone. The 2'-OH group offers RNA a special property, 
which can be either an advantage or a disadvantage. From a 
structural point of view, the advantage of this additional 
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hydroxyl group is that it locks the ribose sugar into a. 
3'-endo chair conformation. As a result, it is structurally 
favorable for the RNA double helix to adopt the A-form 
which is -20% shorter and wider rather than the B-form that 
is typically present in the DNA double helix. Moreover, the 5 
2'-OH group in RNA is chemically active and is able to 
initiate a nucleophilic attack on the adjacent 3' phosphodi-
ester bond in an SN2 reaction. This cleaves the RNA 
sugar-phosphate backbone and this chemical mechanism 
underlies the basis of catalytic self-cleavage observed in 10 
ribozymes. The disadvantage is that the 2'-OH group makes 
the RNA susceptible to nuclease digestion since many 
RNases recognize the structure of RNAs including the 
2'-OH group as specific binding sites. However, such enzy-
matic instability has been overcome by applying chemical 15 
modification of the 2'-OH group. For example, the substi-
tution of the 2' hydroxyl group with a Fluorine (2'-F), 
O-methyl (2'-O-Me) or Amine (2'-NH2) dramatically 
increases the stability of RNA in vivo by preventing deg-
radation by RNases [48] [49 and [51]. Recent studies also 20 
showed that the stability of siRNA in serum is also highly 
depended on the specific RNA sequences and the degrada-
tion of both short and long RNA duplexes mostly occurred 
at UA/UA or CA/UG sites [G 112] [Hui Li et al., Nanotoday, 
volume 10, Issue 5, October 2015, pp 631-655, herein 25 
incorporated by reference in its entirety]. 
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surface of the cell. As such, cell surface markers are not 
limited to markers physically on the surface of a cell. For 
example, cell surface markers may include, but are not 
limited to surface antigens, transmembrane receptors or 
coreceptors, macromolecules bound to the surface, such as 
bound or aggregated proteins or carbohydrates, internal 
cellular components, and the like. Non-limiting examples of 
the surface marker includes folate receptor, epithelial cell 
adhesion molecule (EpCAM), EGFR, transferrin receptor, 
and an RGD. In some embodiments, the ligand includes an 
aptamer. In some embodiments, the aptamers binds against 
EpCAM, EGFR (EGFR protein [Homo sapiens] GenBank: 
AAI18666.1), PDGFR (platelet-derived growth factor 
receptor beta precursor [Homo sapiens] NCBI Reference 
Sequence: NP _002600.1), or folate receptor (folate receptor 
[Homo sapiens] GenBank: AAB05827.1). In some embodi-
ments, the targeting module is a folate. 
The term "folate" as used herein can comprise a genus of 
well-defined B-vitamin compounds, including but not lim-
ited to, 5-methyltetrahydro folate, 5-formyltetrahydrofolate, 
dihydrofolate, tetrahydrofolate, folic acid and other folate 
compounds. As disclosed herein, the targeted delivery sys-
tems call for a ligand-receptor pair that is specifically found 
in cancer cells. Many cancer cells, including but not limited 
to, stomach, ovary, lung, breast, kidney, endometrium, colon 
and hematopoietic cells, over-expressed folate receptors 
(FRs) than normal cells for high uptake of folate, since folate 
is essential component during DNA replication and meth-
ylation in highly proliferating cells. Folic acid (FA), a 
In some embodiments, the nanostructure comprises at 
least one chemical modification at a 2' position of the RNA 
oligonucleotide. In some embodiments, the chemical modi-
fication comprises 2'Fluoro, 2'Amine, and 2'O-Methyl. 
In some embodiments of the presently disclosed subject 
matter, a branch of the three-branched RNA junction motif 
30 synthetic oxidized form of folate, has been widely used as a 
ligand conjugate in various cancer targeting materials. 
In some embodiments, the therapeutic module comprises 
is an a3WJ RNA module (SEQ ID NO: 1), a b3WJ RNA 
module (SEQ ID NO: 2), or a c3WJ RNA module (SEQ ID 
NO: 3). In one embodiment, the three-branched RNAjunc- 35 
tion motif comprises an a3WJ RNA module (SEQ ID NO: 
a siRNA, a miRNA, an anti-mRNA, a ribozyme RNA, or an 
antisense RNA. In some embodiments, In some embodi-
ments, the therapeutic module comprises a chemotherapeu-
tic drug, a riboswitch, or an endosome disrupting agent. In 
1 ), a b3 WJ RNA module (SEQ ID NO: 2), and a c3 WJ RNA 
module (SEQ ID NO: 3). In some embodiments, SEQ ID 
NO: 1 has at least 90% identity to nucleotide sequence 
5'-UUG CCA UGU GUA UGU GGG-3'. In one embodi- 40 
some embodiments, the therapeutic module is a siRNA 
sequence. Non-limiting examples of the siRNA are siRNA 
is directed to Survivin, Bcl-2, XIAP, BCL-XL, or BRCAAl. 
In some embodiments, the siRNA directly binds to PI3K, 
Akt, or mTOR. In some embodiments, the therapeutic ment, SEQ ID NO: 1 comprises nucleotide sequence 
5'-UUG CCA UGU GUA UGU GGG-3'. In some embodi-
ments, SEQ ID NO: 2 has at least 90% identity to nucleotide 
sequence 5'-CCCACA UAC UUU GUU GAUCC-3'. In one 
embodiment, SEQ ID NO: 2 comprises nucleotide sequence 
5'-CCC ACA UAC UUU GUU GAUCC-3'. In some 
embodiments, SEQ ID NO: 3 has at least 90% identity to 
nucleotide sequence 5'-GGA UCAAUC AUG GCAA-3'. In 
one embodiment, SEQ ID NO: 3 comprises nucleotide 
sequence 5'-GGA UCA AUC AUG GCA A-3'. In some 
embodiments, the imaging module attaches to any one of the 
a, b, and c module disclosed above. In some embodiments, 
the targeting module attached to any one of the a, b, and c 
module disclosed above. In some embodiments, the thera-
peutic module any one of the a, b, and c module disclosed 
above. 
In some embodiments of the presently disclosed subject 
matter, the RNA nanostructure includes a cancer targeting 
module. In some embodiments, the presently disclosed 
subject matter provides that the targeting module in the 
artificial RNA nano structure molecule includes a ligand that 
binds to at least one cancer cell surface marker. In some 
embodiments, the cancer targeting module is a colon cancer 
targeting module. 
As used herein, cell surface markers include any cellular 
component that may be detected within or on the surface of 
a cell, or a macromolecule bound or aggregated to the 
module is a microRNA sequence. 
The terms "small interfering RNA", "short interfering 
RNA", "small hairpin RNA", "siRNA", and shRNA are 
45 used interchangeably and refer to any nucleic acid molecule 
capable of mediating RNA interference (RNAi) or gene 
silencing. See e.g., Bass, Nature 411 :428-429, 2001; 
Elbashir et al., Nature 411 :494-498, 2001a; and PCT Inter-
national Publication Nos. WO 00/44895, WO 01/36646, 
50 WO 99/32619, WO 00/01846, WO 01/29058, WO 
99/07409, and WO 00/44914. In one embodiment, the 
siRNA comprises a double stranded polynucleotide mol-
ecule comprising complementary sense and antisense 
regions, wherein the antisense region comprises a sequence 
55 complementary to a region of a target nucleic acid molecule 
(for example, a nucleic acid molecule encoding Survivin). In 
another embodiment, the siRNA comprises a single stranded 
polynucleotide having self-complementary sense and anti-
sense regions, wherein the antisense region comprises a 
60 sequence complementary to a region of a target nucleic acid 
molecule. In another embodiment, the siRNA comprises a 
single stranded polynucleotide having one or more loop 
structures and a stem comprising self-complementary sense 
and antisense regions, wherein the antisense region com-
65 prises a sequence complementary to a region of a target 
nucleic acid molecule, and wherein the polynucleotide can 
be processed either in vivo or in vitro to generate an active 
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siRNA capable of mediating RN Ai. As used herein, siRNA 
molecules need not be limited to those molecules containing 
only RNA, but further encompass chemically modified 
nucleotides and non-nucleotides. 
In some embodiments, the presently disclosed subject 5 
matter takes advantage of the ability of short, double 
stranded RNA molecules to cause the down regulation of 
cellular genes, a process referred to as RNA interference. As 
used herein, "RNA interference" (RNAi) refers to a process 
18 
antagonist or agonist to the microRNA would be useful in 
preventing or treating the disease or condition. 
In some embodiments, the present disclosure provides 
inhibitors of miRNAs (e.g., anti-miR-21). Compositions 
comprising such inhibitors and methods for inhibiting miR-
21 using such inhibitors are also disclosed herein. Any 
miRNA inhibitor may be used alone, or with other miRNA 
inhibitor(s) known in the art. In some embodiments, the 
miRNA inhibitor comprises an antisense molecule. In some 
embodiments, the antisense molecule could be a single or a 
double stranded sequence. Examples of antisense molecule 
include, but are not limited to, siRNAs, triple-helix-forming 
agents, ribozymes, RNAi, synthetic peptide nucleic acids 
(PNAs), antigens (agRNAs), LNA/DNA copolymers, small 
of sequence-specific post-transcriptional gene silencing 10 
mediated by a small interfering RNA (siRNA). See Fire et 
al., Nature 391:806-811, 1998 and U.S. Pat. No. 6,506,559, 
each of which is incorporated by reference herein in its 
entirety. The process of post-transcriptional gene silencing is 
thought to be an evolutionarily conserved cellular defense 
mechanism that has evolved to prevent the expression of 
foreign genes (Fire, Trends Genet 15:358-363, 1999). 
15 molecule chemical compounds, and antisense oligonucle-
otides. 
Disclosed herein are non-limiting examples of siRNA 
including Survivin-specific, Bcl-2, XIAP, and BCL-XL 20 
siRNA sequences. The Survivin-specific siRNA includes 
sense sequence: 5' GGACCACCGCAUCUCUACAdTdT 3' 
(SEQ ID NO: 21) and antisense sequence: 5' dTdTCCUG-
GUGGCGUAGAGAUGU 3' (SEQ ID NO: 22) (See, e.g., 
Cancer Gene Ther. 2004 March; 11(3):186-93. Knockdown 25 
of survivin expression by small interfering RNA reduces the 
clonogenic survival of human sarcoma cell lines indepen-
dently of p53.); the Bcl-2 siRNA includes sense sequence: 
5'-AAGCUGuCACAGAGGGGCUAC-3' (SEQ ID NO: 
23), and antisense sequence: 5'-GUAGCCCCUCU- 30 
GUGACAGCUU-3 (SEQ ID NO: 24) (See, e.g., Nucleic 
Acids Res. 2012 July; 40(13):6319-37. doi: 10.1093/nar/ 
gks294. Epub 2012 Mar. 30. Delivery of chemo-sensitizing 
siRNAs to HER2+-breast cancer cells using RNA aptam-
ers.); XIAP siRNA includes sense sequence: 5'-CCAU- 35 
GUGCUAUACAGUCAUUACUUU-3 (SEQ ID NO: 25), 
and antisense sequence: 5'-AAAGUAAUGACUGUAUAG-
CACAUGG-3 (SEQ ID NO: 26) (See, e.g., Mal Cancer. 
2006 Sep. 5; 5:34. Specific down-regulation of XIAP with 
RNA interference enhances the sensitivity of canine tumor 40 
cell-lines to TRAIL and doxorubicin); and BCL-XL siRNA 
includes sense sequence: 5'-UUGGACAAUGGACUG-
GUUGA-3 (SEQ ID NO: 27), antisense sequence: 
5'-UCAACCAGUCCAUUGUCCAA-3 (SEQ ID NO: 28) 
(See, e.g., Acta Biochim Biophys Sin (Shanghai). 2005 45 
August; 37(8):555-60. Silencing of Bel-XL expression in 
human MGC-803 gastric cancer cells by siRNA.) Further, in 
one embodiment, siRNA is a BRCAAl siRNA. A non-
limiting example is a siRNA sequence 5'-CCA-
CAUAAAGGGCCCACUA-3' (SEQ ID NO: 29). Another 50 
non-limiting example is a siRNA sequence 
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 30). 
In some embodiments, the bioactive agent is a microRNA 
sequence. The term "Micro RN As (miRNAs )" as used herein 
are single-stranded, or double stranded non-coding RN As, at 55 
least about 6 nucleotide in length that can regulate gene 
expression at the post-transcriptional level by either degrad-
ing their target mRNAs or inhibiting their translation(l,2). 
MiRNAs play important roles in regulating cell cycle, 
proliferation, differentiation, metabolism, and apoptosis(l). 60 
A compendium of microRNA and respective microRNA 
binding sequences is available at the miRNA registry. (See, 
e.g., Griffiths-Jones et al. (2006) Nucl. Acids Res. 34:D140-
D144; US20140045709, herein incorporate by reference in 
their entireties.) In particular embodiments, the microRNA 65 
and microRNA binding sequence employed in the present 
assay are associated with a disease or condition, wherein an 
In some embodiments, the microRNA sequence is at least 
6 nucleotide in length. In some embodiments, the miRNA 
molecule or an equivalent, or a mimic thereof is from about 
6 to about 30 nucleotides in length. In some embodiments, 
the miRNA is about 12 to about 30 nucleotides in length. In 
some embodiments, the miRNA is from about 15 to about 28 
nucleotides in length. In some embodiments, the miRNA is 
about 19 to about 25 nucleotides in length. In some embodi-
ments, the miRNA molecule has a length of at least about 6, 
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 
24, 25, 26, 27, 28, 29, about 30 nucleotides or more. In some 
embodiments, an antagomir of a miRNA molecule is from 
about 6 to about 30 nucleotides in length, from about 10 to 
about 30 nucleotides in length, from about 12 to about 28 
nucleotides in length. In some embodiments, the antagomir 
of a miRNA molecule has a length of at least about 6, 7, 8, 
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 
25, 26, 27, 28, 29, about 30 nucleotides or more. 
In some embodiments, the miRNA interferes oncogenic 
miRNA to regress cancer growth. The RNA nanostructure 
molecule contains anti-miRNA that silences oncogenic miR-
NAs, including but not limited to, miR-9, miR-l0b, miR-21, 
miR-17, and miR-26. In some embodiments, the miRNA 
rescues down-regulated cancer suppressive miRNAs, where 
the RNA nanostructure introduces cancer suppressive miR-
NAs, including but not limited to, let-7a, miR-l0b, miR-25, 
miR-34a, miR-124, miR-145, and miR-181b. Further 
examples is disclosed in US20140045709, which herein 
incorporate by reference in its entirety. 
In some embodiments, the therapeutic module is a cyto-
toxic drug. The terms "cytotoxic drug" used herein refers to 
agents that have the property of inhibiting the growth or 
proliferation (e.g., a cytostatic agent), or inducing the kill-
ing, of hyper proliferative cells. Non-limiting examples 
include doxorubicin, paclitaxel, paclitaxel derivatives and 
analogues, cytochalasin D, rapamycin, rapamycin deriva-
tives and analogues, camptothecin, dexamethasone, and 
5-fluorouracil, a quinazolinone derivative, metallic silver, 
tranilast, everolimus and related compounds, or other agents 
that inhibit cell proliferation and or migration and/or inflam-
matory processes. 
In another aspect, the presently disclosed subject matter 
provides an artificial RNA nanostructure molecule includes 
a RNA junction motif comprising a plurality of branches and 
a radiation-based therapeutic module coupled to the RNA 
junction motif, and a branch of the RNA junction motif 
includes at least one RNA oligonucleotide. In some embodi-
ments, the molecule further includes a cancer targeting 
module coupled to the RNA junction motif. In some embodi-
ments, the molecule further includes an imaging module 
coupled to the RNA junction motif. In some embodiments, 
US 10,828,381 B2 
19 20 
therapy handles radiation sources mechanically and has 
significant uncertainty in localizing the radioactive sources. 
Although certain ionizing radiopharmaceuticals, such as 
I-131 and Y-90 used in nuclear medicine, can target certain 
the nanostructure comprises at least one chemical modifi-
cation at 2' position of the RNA oligonucleotide. In some 
embodiments, the chemical modification comprises 
2'Fluoro, 2'Amine, and 2'O-Methyl. In some embodiments, 
the plurality of branches comprises three branches, four 
branches, five branches, six branches, seven branches, eight 
5 organs and tumors, variation in biodistribution caused by 
metabolism and excretion of the pharmaceuticals and local-
ization errors produce uncertainties and limitations in tar-
geting tumor and dosimetry, and thus increase damages to 
or more branches. In some embodiments, the plurality of 
branches comprising the RNA junction motif includes a 
three-branched RNA junction motif. In some embodiments, 
the plurality of branches comprising the RNA junction motif 10 
comprises a four-branched RNA junction motif. In some 
embodiments, a branch of the three-branched RNA junction 
motif includes an a3WJ RNA module (SEQ ID NO: 1), a 
b3WJ RNA module (SEQ ID NO: 2), or a c3WJ RNA 
module (SEQ ID NO: 3). In some embodiments, the three-
branched RNA junction motif comprises an a3WJ RNA 
module (SEQ ID NO: 1), a b3WJ RNA module (SEQ ID 
NO: 2), and a c3WJ RNA module (SEQ ID NO: 3). In some 
embodiments, SEQ ID NO: 1 has at least 90% identity to 
nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG-
normal tissues [8]. 
The RNA nanoparticle-based nano-carrier platform can 
overcome aforementioned limitations for conventional 
radiation therapy and diagnosis and opens new opportunities 
for specific delivering radiation to cancer without damaging 
healthy organs and tissues, reducing the toxicity and side 
15 effect, improving the therapeutic effect, and exhibiting great 
potential in clinical cancer therapy and diagnosis. 
Recently, nanoparticles have been found to be able to 
accurately target cancer cells and thus, can be used for 
cancer targeting and treatment [9-14]. Nanoparticles are 
3'. In some embodiments, SEQ ID NO: 1 comprises nucleo-
tide sequence 5'-UUG CCA UGU GUA UGU GGG-3'. In 
some embodiments, SEQ ID NO: 2 has at least 90% identity 
20 typically within several hundred nanometers in size, and 
comparable to large biological molecules such as enzymes, 
receptors, and antibodies. Because of small size, nanopar-
ticles can interact with biomolecules both on the surface of 
to nucleotide sequence 5'-CCC ACA UAC UUU GUU 
GAUCC-3'. In some embodiments, SEQ ID NO: 2 com- 25 
prises nucleotide sequence 5'-CCC ACA UAC UUU GUU 
GAUCC-3'. In some embodiments, SEQ ID NO: 3 has at 
least 90% identity to nucleotide sequence 5'-GGA UCA 
AUC AUG GCAA-3'. In some embodiments, SEQ ID NO: 
3 comprises nucleotide sequence 5'-GGA UCA AUC AUG 30 
GCAA-3'. In some embodiments, the cancer-targeting mod-
ule is a cancer cell-specific ligand. In some embodiments, 
the cancer-targeting module is folate. In some embodiments, 
cancer-targeting module is an RNA aptamer. In some 
embodiments, the radiation-based therapeutic module 35 
include a isotope. Nonlimiting examples of the isotope 
include 177Lu, lllln, 64Cu, 99mTc, 203Pb, 188Re, 212Pb, 
212Bi, I-125, or Cs-131. In some embodiments, the RNA 
nanoparticles derived from the pRNA 3WJ are substantially 
stable under irradiation with clinically relevant doses rang- 40 
ing from about 1 Gy, 5 Gy, 10 Gy, 15 Gy, 20 Gy, 25 Gy, 30 
Gy, 35 Gy, 40 Gy, 45 Gy, 50 Gy, 55 Gy, 60 Gy, 65 Gy, 70 
Gy, 75 Gy, 80 Gy, 85 Gy, to about 90 Gy. 
Cancer is a broad class of diseases featuring uncontrol-
lable cell growth, invasion, and destruction of nearby tissues 45 
and metastasis. An effective, efficient, and safe treatment for 
cancer is urgently needed. Radiation therapy represents a 
major modality for anticancer therapy, which utilizes ioniz-
ing radiation produced by linear accelerators ( external beam 
therapy) or radioactive isotopes (brachytherapy and nuclear 50 
medicine) to kill cancer cells, inhibit tumor growth, and 
prevent recurrence of the tumor [5]. However, radiation not 
only kills cancer cells, but also damages healthy cells. The 
side effects associated with current radiation therapy sig-
nificantly limit the doses delivered to the patients [ 6, 7]. The 55 
goal of radiation therapy is to deliver a high dose of radiation 
to the target to kill cancer cells while sparing the surround-
ing healthy tissues. But, this is not easy to achieve using 
current techniques. Medical imaging including CT and MRI 
is used to accurately identify and locate or track tumor 60 
before, during and even after treatment. Since such imaging 
can only recognize balky lesions, it is very difficult to find 
and locate all the cancer cells especially microscopic dis-
ease. In addition to that, it is also very difficult to avoid 
normal tissue damages during dose delivery. External beam 65 
therapy uses ionization particles that may have to pass 
through the normal tissue before reaching the target. Brachy-
and inside the cells, participate in molecular, biochemical, 
and biological processes, and thus, can be used as agents for 
medical imaging and targeted cancer treatment [15]. The 
most common well-studied nanoparticles include quantum 
dots, carbon nanotubes, paramagnetic nanoparticles, lipo-
somes, gold nanoparticles, and many others. However, there 
are concerns regarding the biocompatibility of these nano-
particles especially when they are exposed to radiation and 
their ability to escape the reticuloendothelial system, which 
could lead to short- and long-term toxicity [16, 17]. 
A new discovery in nanotechnology has led to the devel-
opment of novel RNA nanoparticles that are mainly com-
posed of RNA that are capable of strongly binding to tumors 
without accumulation in other vital organs or tissues [18-
20]. Since the first proof-of-concept in 1998 [21], RNA 
nanotechnology has emerged as a popular and rapidly-
growing field that is at the interface of nanotechnology, 
molecular biology, medicine, and biomedical engineering 
[13, 20, 22-26]. RNA nanotechnology holds significant 
translational potential in medicine and features that could 
make RNA nanoparticles desired pharmaceutical agents and 
radioisotope carriers. First of all, RNA nanoparticles can be 
produced with a known stoichiometry with a high reproduc-
ibility [21, 26, 27]. The simplicity of RNA, being composed 
of only four nucleic acid bases, allows for predictable and 
addressable formation of various nanostructures harboring 
different functional groups by bottom-up self-assembly. Sec-
ondly, RNA nanoparticles can target specific cell groups by 
targeting cell surface receptors through the use of RNA 
aptamers that function like protein or chemical ligands [18, 
28, 29]. These structures do not induce antibody production, 
allowing for repeated delivery and therapy [28]. Thirdly, 
RNA nanoparticles that have been produced have a size 
range of 10-50 nm, which is the perfect size not only to be 
retained within the body by avoiding rapid renal excretion, 
but also to pass through leaky blood vessels in cancer 
tumors, as well as cell membranes, by cell surface receptor-
mediated endocytosis [18-20]. 
To have clinical applications, RNA nanoparticles and 
those properties must remain stable and unchanged under 
the clinical conditions. The bacteriophage phi29 packaging 
RNA (pRNA) represents an attractive platform for bottom-
up assembly of RNA nanoparticles [18-20, which are incor-
porated by reference by their entirety]. The molecular struc-
US 10,828,381 B2 
21 
ture of pRNA contains a helix domain, a central domain 
containing right and left-hand loops, and a three-way junc-
tion (3WJ) core [30]. A recent study has indicated that the 
pRNA 3WJ has thermodynamical stability, and RNA nano-
particles constructed based on the pRNA 3WJ core are also 
thermodynamically and chemically stable [27]. In addition, 
a receptor-binding ligand, an aptamer, a short interfering 
RNA and a ribozyme can be incorporated in the pRNA 3WJ 
nanoparticle and retain their correct folding and function. 
The pRNA nanoparticles also display a favorable pharma-
cokinetics profile for in vivo target delivery (half-life of 5-10 
hr compared to 0.25-0.75 hr of 2'F siRNA counterparts) [28, 
which is incorporated by reference in its entirety]. To be 
used as radioisotope carriers, the stability of RNA nanopar-
ticles will be further tested under irradiation with clinically 
relevant doses. 
In some embodiments, the molecule is substantially stable 
under radiation treatment. As used herein, the term "sub-
stantially stable" can refer to physical and/or chemical 
stability. As will be recognized by those of ordinary skill in 
the art, the term "substantially stable" can refer to stability 
of the composition under certain conditions, relative to an 
initial composition (i.e., when a particular batch of the 
composition is initially prepared). In this regard, as will be 
recognized by those of ordinary skill in the art, one manner 
in which stability of a particular embodiment of the com-
position can be determined is as follows: preparing a batch 
of the embodiment of the composition, making an initial 
assessment of a sample of the composition ( control sample), 
subjecting a sample of the composition to conditions of 
interest ( e.g., storage at a particular temperature for a 
particular time period) (test sample), making an assessment 
of the test sample, and comparing the assessment of the 
control sample to the assessment of the test sample. Calcu-
lations can be made to determine whether the amounts 
present in the test sample are 100%±20, 19, 18, 17, 16, 15, 
14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, or 0.1 % of the 
amount that is in the control sample. 
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perquisite for utilizing these RNA nanoparticles as carriers 
for targeted radiation therapy. pRNA 3WJ nanoparticles 
were constructed and characterized and the stability of these 
nanoparticles under I-125 and Cs-131 irradiation with clini-
5 cally relevant doses was examined. RNA nanoparticles 
derived from the pRNA 3WJ targeted tumors specifically 
and they were stable under irradiation ofI-125 and Cs-131 
with clinically relevant doses ranging from about 1 Gy to 
about 90 Gy over a significantly long time up to 20 days, 
10 while control plasmid DNA was damaged at 20 Gy or 
higher. 
The RNA nanoparticle-based nano-carrier platform for 
radiation therapy and diagnosis is expected to outperform 
current radiation systems or other strategies in several 
15 aspects: (1) RNA nanoparticles have defined size, structure 
and stoichiometry; unpredictable side effects arising from 
heterogeneous particles can thus be avoided; (2) nanoscale 
size of the RNA nanoparticles will facilitate tissue penetra-
tion and target to tumor; (3) RNA nanoparticles are easy to 
20 construct by self-assembly, highly soluble and not prone to 
aggregation; ( 4) the RNA nanoparticles are thermodynami-
cally stable and, therefore, the entire construct will remain 
intact at ultra-low concentrations in the body; (5) the poly-
valent nature of the RNA nanoparticle allows for easy 
25 integration of targeting modules, imaging modules and 
therapeutic modules into a single form; (6) RNA nanopar-
ticles display low or no immunogenicity and/or toxicity even 
at high doses. The 3WJ-pRNA scaffold displays favorable 
pharmacokinetic and pharmacodynamic profiles in vivo 
30 (half-life of 5-10 hours compared to 0.25-0.75 hours of the 
most stable 2'F modified siRNA counterparts); non-toxic; 
and no induction of interferon or cytokines; (7) systemic 
injection of the thermodynamically and chemically stable 
RNA nanoparticles into the tail-vein of mice revealed that 
35 the RNA nanoparticles remain intact. They strongly and 
specifically bind to cancers without entering liver, lung, or 
any other vital organs or tissues. This is particularly an 
advantage for targeting solid tumors previously inaccessible 
due to penetration problems through the vasculature and In one embodiment, the present disclosure proposes to use 
the 3WJ RNA nanoparticles to carry radioisotope. In one 
embodiment, the present disclosure proposes to use a four-
way junction (4WJ) RNA nanoparticles to carry radioiso-
tope. Non limiting examples of the radioisotope are I-125 or 
Cs-131. Using such RNA nanoparticles, cancer cells can be 
targeted and treated by I-125 or Cs-131 [31]. In nuclear 45 
medicine, several radioactive isotopes, such as I-131, P-32, 
and Y-90, have been used for targeted radionuclide therapy, 
but those isotopes are only applied to very limited types of 
cancer [32-36]. Also, most of isotopes used for nuclear 
medicine therapy are beta emitters and not suitable for 
imaging. Accurate dose estimation is almost impossible 
without accurate imaging. On the other hand, I-125 and 
Cs-131 have been widely used in permanent implant brachy-
therapy and successfully treated various types of cancer. The 
idea of using I-125 or Cs-131 with 3WJ RNAnanoparticles 
40 dispersion against an interstitial pressure; (8) RNA nano-
particles derived from the pRNA 3WJ are stable under 
irradiation of I-125 and Cs-131 with clinically relevant 
doses ranging from 1 Gy to 90 Gy over a significantly long 
time up to 20 days. 
Further, in another aspect of the present subject matter, a 
RNA dendrimer molecule is provided. The molecule 
includes (a) a central core multi-branched RNA junction 
motif, wherein the central core motif comprises a plurality 
of branches, and wherein a branch comprises at least one 
50 RNA oligonucleotide; and (b) an outer surface multi-
branched RNA junction motif comprising at least one 
repeating multi-branched RNA junction motif unit, wherein 
the repeating unit comprises a plurality of branches, and 
wherein a branch comprises at least one RNA oligonucle-
55 otide. In some embodiments, the dendrimer further includes 
at least one imaging module. In some embodiments, the 
dendrimer includes at least one targeting module. In some 
embodiments, the dendrimer further includes at least one 
therapeutic module. In some embodiments, the plurality of 
is to increase the accuracy of tumor targeting and enhance 
the effectiveness in treating a broad range of tumors and 
sparing normal tissues. Also, both I-125 and Cs-131 emit 
photons that will help with in vivo nuclear imaging and 
studying the biodistribution of those isotopes for estimation 60 branches includes the central core multi-branched RNA 
of patient-specific dose. The stabilities of the pRNA 3WJ 
nanoparticles that are essential for in vivo cancer targeting 
and treatment are investigated in this study. 
This study further investigates whether chemically modi-
fied RNA nanoparticles derived from pRNA Three-Way 65 
Junction (3 WJ) of phi29 DNA-packaging motor are resistant 
to potent I-125 and Cs-131 radiation, which is a required 
junction motif comprises a three-branched RNA junction 
motif, a four-branched RNA junction motif, a five-branched 
RNA junction motif, a six-branched RNA junction motif, a 
seven-branched RNA junction motif, an eight or more 
branched RNA junction motif. In some embodiments, the 
plurality of branches comprising the repeating multi-
branched RNA junction motif unit includes a three-branched 
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RNA junction motif, a four-branched RNA junction motif, a 
five-branched RNA junction motif, a six-branched RNA 
junction motif, a seven-branched RNA junction motif, an 
eight or more branched RNA junction motif. In some 
embodiments, a branch of the three-branched RNA junction 5 
motif comprises an a3 WJ RNA module (SEQ ID NO: 1 ); a 
b3WJ RNA module (SEQ ID NO: 2); or a c3WJ RNA 
module (SEQ ID NO: 3). In one embodiments, the three-
branched RNA junction motif comprises an a3WJ RNA 
module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID 10 
NO: 2); and a c3WJ RNA module (SEQ ID NO: 3). In some 
embodiments, SEQ ID NO: 1 has at least 90% identity to 
nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG-
3'. In some embodiments, SEQ ID NO: 2 has at least 90% 
identity to nucleotide sequence 5'-CCC ACA UAC UUU 15 
GUU GAUCC-3'. In some embodiments, SEQ ID NO: 3 has 
at least 90% identity to nucleotide sequence 5'-GGA UCA 
AUC AUG GCA A-3'. In some embodiments, the central 
core multi-branched RNA junction motif is a polygon 
shaped architecture comprising a three-branched RNAjunc- 20 
tion motif at each comer. In some embodiments, the imaging 
module comprises a fluorescent dye, a radionuclide, or a 
contrast agent. In some embodiments, fluorescent dye is a 
Alexa dye, Cy dyes or Near IR dyes. Nonlimiting of 
fluorescent dye include IRdye800, Alexa647, Cy5, Cy5.5, 25 
Alexa680, Iowa Black RQ, QSY21, IRDyeQC, BBQ650, 
BHQ-3, Indocyanine green (ICG). In some embodiments, 
the imaging module comprises a reporter imaging module. 
In some embodiments, the imaging module comprises a 
reference imaging module. In some embodiments, the ref- 30 
erence imaging module comprises a reference dye and a 
quencher. In some embodiments, the imaging module com-
prises at least one fluorescent dye. In some embodiments, 
the imaging module include a radionuclide and/or a contrast 
agent. A nonlimiting example of contrast agent is a MRI 35 
contrast agent. In one embodiment, the imaging module 
includes at least one gadolinium contrast agent. In some 
embodiments, the targeting module includes a cancer tar-
geting module. In some embodiments, the cancer targeting 
module is a ligand that binds to at least one cancer cell 40 
surface marker. In some embodiments, the RNA dendrimer 
contains a targeting module comprises a chemical ligand 
and/or a RNA aptamer. A nonlimiting example of the ligand 
includes folate. In some embodiments, the cell surface 
markers comprises a folate receptor. In some embodiments, 45 
the ligand binds to an epithelial cell adhesion molecule 
(EpCAM). In some embodiments, the cell surface marker 
comprises an epithelial cell adhesion molecule (EpCAM). In 
some embodiments, the cancer targeting module comprises 
an aptamer. A non-limiting example of the aptamer is an 50 
EpCAM RNA aptamer. In some embodiments, the cancer 
targeting module is a folate. Nonlimiting examples of the 
folate include folic acid, 5-methyltetrahydro folate, 5-form-
yltetrahydrofolate, dihydrofolate, tetrahydrofolate, or a 
combination thereof. In some embodiments, the therapeutic 55 
module comprises a siRNA, a miRNA, an anti-mRNA, a 
ribozyme RNA, or an antisense RNA. In some embodi-
ments, the therapeutic module comprises a chemotherapeu-
tic drug, a riboswitch, or an endosome disrupting agent. In 
some embodiments, the therapeutic module is a cytotoxic 60 
drug. Nonlimiting examples of the cytotoxic drug include 
doxorubicin, paclitaxel, paclitaxel derivatives and ana-
logues, cytochalasin D, rapamycin, rapamycin derivatives 
and analogues, camptothecin, dexamethasone, and 5-fluo-
rouracil, a quinazolinone derivative, metallic silver, tranil- 65 
ast, everolimus and related compounds, or other agents that 
inhibit cell proliferation and or migration and/or inflamma-
24 
tory processes. In some embodiments, the plurality of 
branches of the multi-branched comprises at least 90% 
identity to nucleotide sequences of at least one of SEQ ID 
NOS: 1-20. 
In recent years, extensively branched 3D structures called 
dendrimers[Dl-3] have become an attractive platform for 
building multifunctional macromolecular nanomaterials as 
diagnostic and therapeutic agents[D4-8]. This is primarily 
because of the polyvalent nature, nanoscale size, highly 
branched, and void-space containing framework of dendrim-
ers, which offers high loading capacity of desired function-
alities. The attractive and intriguing dendrimers were con-
ceptualized over four decades ago[Gl]; however, 
improvements are desirable for realizing their commercial 
availability in clinical settings. For example, the multi-step 
synthetic reactions necessary to generate defect-free den-
drimer that impact product yield and purity. Incorporation of 
different functional modules to generate a multifunctional 
framework often requires series of protection-deprotection 
steps that affects synthetic yield, water solubility and even 
functionality. Traditional small molecule building blocks, 
such as high molecular weight carrier poly(amidoamine) 
(PAMAM) and poly (propyleneimine) (PPI) dendrimers are 
mostly smaller than 10 nm with angstrom level size differ-
ences within successive generations, make it desirable to 
seek alternate building blocks to enhance their size in order 
to avoid rapid renal clearance for in vivo applications. 
Larger building blocks such as nucleic acids can over-
come the size limitation. The self-assembly properties of 
nucleic acids can prevail over the complex synthetic routes 
to generate precisely assembled dendrimers under control. It 
has been proposed that DNA can serve as building blocks 
[D3], and the construction of DNA dendrimers by enzymatic 
ligation[D9], and recently, by hybridization using sticky end 
segments [D6,D10-13] have been reported. RNA dendrim-
ers have not been realized to date due to challenges in 
predicting intra- and inter-molecular RNA folding involving 
canonical and non-canonical base pairing, base stacking, and 
tertiary interactions[D14,D15], as well as concerns regard-
ing the chemical stability of RNA[Dl 6-18]. 
Recent progress in RNA nanotechnology has enabled 
construction of varieties ofRNAnanostructures with precise 
control of size, shape and stoichiometry[D16-21]. Several 
structural RNA motifs have been used as scaffold to con-
struct varieties of 2D and 3D architectures including, 
branched RNA nanoparticles[D22-24], packaging RNA 
(pRNA) hexamers [D24,D25], nanorings [D26,D27], tri-
angles [D28,D29], square[D30-32], pentagons[D33]; cube 
[D34], and origami structures[D35]. Recently we discovered 
a robust 3WJ (three-way junction) motif derived from 
pRNA[D36] of the phi29 bacteriophage DNA packaging 
motor[D22] that can serve as a scaffold for fabricating RNA 
nanoparticles. The pRNA-3WJ assembles from three pieces 
of RNA oligonucleotides, is unusually thermodynamically 
stable (Tm of 59° C.; llG0 37" c. of -28 kcal/mo!), is resistant 
to denaturation even in presence of 8 M urea, and remains 
intact at ultra-low concentrations in vivo[D22,23,37]. We 
have functionalized the pRNA-3WJ with targeting, imaging 
and therapeutic modules, and the resulting RNA nanopar-
ticles have been used for cancer targeting[D22-24,D38-40] 
and therapy[D41,D42], as well as for resistive biomemory 
applications [D43]. More recently, we solved the crystal 
structure of the pRNA-3WJ scaffold[D44], which has facili-
tated the designs of multifunctional RNA nanoparticles. 
RNA has also been reported as a boiling-resistant anionic 
polymer material to build robust structures with defined 
shape and stoichiometry[D28,D45]. 
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As disclosed herein, the presently disclosed subject matter 
provides the construction of RNA dendrimers utilizing the 
highly stable pRNA-3WJ motif as core scaffold. Each of the 
component strands were synthesized by transcription or 
chemically using phosphoramidite chemistry and then self- 5 
assembled sequentially to construct 3D globular Generation-
0-4 (G-O-G-4) RNA dendrimers. The assembly of RNA 
dendrimers employs modular design principles and is highly 
controllable. Functional groups can be introduced with 
relative ease both internally as well as at the peripheral ends 10 
of the component strands prior to the assembly process, thus 
resulting in homogenous (monodisperse) RNA dendrimers 
with high yield and purity. 
As disclosed herein, RNA dendrimers have the following 
features: (1) monodisperse; (2) polyanionic nature; (3) tun- 15 
able shape with defined 3D structure (GO-G3); ( 4) tunable 
nanoscale size (5-100 nm) (GO-G3); (5) polyvalent nature 
that allows conjugation of multiple therapeutic payloads and 
detection modules without any cross-linking; (6) large num-
ber of readily accessible terminal functional groups; (7) 20 
modular design that allows self-assembly of engineered 
RNA fragments; (8) biocompatible; (9) thermodynamic 
stable; hence, the entire construct will remain intact at 
ultra-low concentrations in the body; (10) chemically stable, 
after 2'-F modifications and therefore resistant to RNase 25 
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multiple CT contrast agents, multiple PET tracers, multiple 
NIR imaging agents. In some embodiments, RNA dendrim-
ers harboring radioactive isotopes for disease detection. In 
some embodiments, RNA dendrimers carry electropositive 
proton sponge reagents such as imidazoles or amines for 
endosome escape, and electronegative therapeutic RNA 
such as siRNA, miRNA, riboswitch, and ribozyme for 
therapy of cancers and other diseases including disease 
diagnosis including, but not limited to cancer, immunology, 
respiratory, central nervous system, inflammatory, and infec-
tious diseases. In some embodiments, RNA dendrimer is 
used for transdermal drug delivery, oral drug delivery, ocular 
drug delivery, pulmonary drug delivery, tissue engineering 
and organ scaffolding. In some embodiments, RNA den-
drimer is used for disease treatment, including, but not 
limited to cancer, immunology, respiratory, central nervous 
system, inflammatory, and infectious diseases. In some 
embodiments, RNA dendrimers are used for disease diag-
nosis including, but not limited to cancer, immunology, 
respiratory, central nervous system, inflammatory, and infec-
tious diseases. 
In another aspect of the presently disclosed subject matter, 
is a composition comprising a therapeutically effective 
amount of the RNA nanostructure molecule and RNA den-
drimer as disclosed above and herein. In some embodiments, 
the composition further includes a pharmaceutically accept-
able carrier. 
Yet in another aspect of the presently disclosed subject 
matter, is a drug delivery system, the system comprising a 
30 therapeutically effective amount of the RNA nanostructure 
and the RNA dendrimer molecule as disclosed above and 
degradation while retaining correct folding and biological 
functions; (11) longer plasma half-life using chemically 
modified RNA; (12) reproducible manufacturing framework 
for generating homogenous RNA nanoparticles, which 
avoids immune responses and non-specific side effects; (13) 
economic industrial scale production is possible in a cell-
free system; (14) highly soluble and not prone to aggrega-
tion. They do not require any additional steps, such as 
linkage to PEG or serum albumins; (15) display low or no 
immunogenicity and/or toxicity even at high doses; (16) 35 
displays favorable pharmacokinetic and pharmacodynamic 
profiles in vivo (half-life of 5-10 hrs compared to 0.25-0.75 
hrs of 2'F siRNA counterparts) in mice; (17) systemic 
injection of the thermodynamically and chemically stable 
RNA nanoparticles into mice revealed that the RNA nano- 40 
particles strongly and specifically bind to cancers without 
accumulating in liver, lung, or any other vital organs or 
tissues; (18) minimal induction of antibody production will 
allow for repeated treatment of cancer. This is particularly 
applicable to patients who develop neutralizing antibodies to 45 
the protein-based reagents following repeated administra-
tions. 
As disclosed herein, RNA as construction material for 
fabricating GO, Gl, G2 andG3 dendrimers. In some embodi-
ments, RNA dendrimers harbor cytotoxic drugs (hydrophilic 50 
and hydrophobic) to kill tumors in a controlled and sustained 
manner. In some embodiments, RNA dendrimers harbor 
siRNA to knockdown genes involved in disease progression. 
In some embodiments, RNA dendrimers harbor anti-miRNA 
to knock-down oncogenic genes. In some embodiments, 55 
RNA dendrimers harbor miRNA to increase the endogenous 
tumor-suppressor miRNA. In some embodiments, RNA 
dendrimers harbors aptamers or chemical ligands for bind-
ing to cell surface receptors. In some embodiments, RNA 
dendrimers harbor aptamers or chemical ligands for inter- 60 
nalization of RNA dendrimers into target cells via endocy-
tosis. In some embodiments, RNA dendrimers harbor 
ribozymes for cleaving target substrates. In some embodi-
ments, RNA dendrimers harbor riboswitch for modulating 
cellular pathways in response to stimuli. In some embodi- 65 
ments, RNA dendrimers harbor multiple MRI contrast 
agents. In some embodiments, RNA dendrimers harbor 
herein. In some embodiments, drug delivery system further 
includes a pharmaceutically acceptable carrier. 
Further, in some embodiments, the presently disclosed 
subject matter provide a method of image-guided drug 
delivery of a therapeutic agent to a subject in need thereof. 
The method include administering a therapeutically effec-
tive amount of RNA nanostructure molecule and RNA 
dendrimer as disclosed above and herein, and applying an 
imaging detection apparatus to the subject. In some embodi-
ments, the imaging detection apparatus is an MRI imaging 
system. In some embodiments, the imaging detection appa-
ratus is an NIRF imaging system. In some embodiments, the 
imaging detection apparatus is an CT/PET/SPECT imaging 
system. 
Development of image-guided drug delivery systems for 
real-time monitoring, and validating the effect of delivery 
and response is very important for research and clinical 
applications[Gl]. In the last decade, multifunctional nano-
particles of varying materials and physiochemical properties 
have been pursued as imaging and therapeutic platforms; 
however, effective strategies to quantitatively evaluate deliv-
ery of therapeutic payloads to tumors and metastatic cancer 
cells are challenging due to low efficiency in specific cancer 
targeting, non-specific accumulation in vital organs such as, 
liver and lungs, particle heterogeneity, dissociation after 
systemic injection due to dilution, and unfavorable pharma-
cokinetic and pharmacodynamic profiles [G 1-7]. The goal is 
to adopt an innovative RNA nanotechnology approach (The 
Emerging Field of RNA Nanotechnology, Nature Nanotech-
nology 2010, 5:833)[G8] to construct ultrastable multifunc-
tional RNA Beacons and RNA Dendrimers for quantitative 
assessment of tumor and metastatic cancer targeted thera-
peutic delivery, distribution, uptake and response. As 
reported in recent publications [G9-23], the RNA constructs 
are non-toxic, non-immunogenic and capable of penetrating 
across heterogeneous biological barriers to deliver high 
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doses of therapeutics to solid tumors and metastatic cells in 
mice with little accumulation in normal organs and tissues 
[G9-23]. This provides an ideal system to non-invasively 
image delivery of cancer therapeutics in vivo. 
28 
solutions and aqueous dextrose and glycerol solutions can 
also be employed as liquid carriers, particularly for inject-
able solutions. Suitable pharmaceutical carriers also include 
excipients such as glucose, lactose, sucrose, glycerol monos-
5 tearate, sodium chloride, glycerol, propylene, glycol, water, 
ethanol, and the like. The present compositions, if desired, 
can also contain minor amounts of wetting or emulsifying 
agents, or pH buffering agents. The present compositions 
advantageously may take the form of solutions, emulsion, 
The presently disclosed subject matter will employ mul-
timodal imaging techniques (NIRF, PET/SPECT and/or 
MRI) that provide anatomic and quantitative functional 
measures of the drug delivery process at various spatial and 
temporal resolutions in real-time. This approach is based on 
the consideration that each of these three modalities has 
advantages, and an integrated approach will lead to syner-
gistic imaging benefits. For instance, MRI using contrast 
agents harbored in RNA Dendrimers and RNA Beacons 
(FIG. 4-5) offers a high spatial resolution and can provide a 
better description of the particle distribution pattern than 15 
either PET or NIRF. PET provides a better signal-to-noise 
ratio because of the use of radiotracers. NIRF, on the other 
hand, can be visualized both in vivo by an IVIS system and 
10 sustained release formulations, or any other form suitable for 
use. 
The term "therapeutically effective amount," as used 
herein, refers to the amount of a composition containing 
administered to a patient already suffering from a disease, 
condition, or disorder, sufficient to cure or at least partially 
arrest, or relieve to some extent one or more of the symp-
toms of the disease, disorder, or condition being treated. The 
effectiveness of such compositions depend upon conditions 
including, but not limited to, the severity and course of the ex vivo, by fluorescence microscopy, playing a unique role 
of bridging the in vivo and histological observations. 
In some embodiments, the presently disclosed subject 
matter provides a kit for detecting, determining and/or 
localizing a biological substances of interest. The kit 
includes a RNA nanostructure and/or a RNA dendrimer as 
disclosed herein. In some embodiments, the kit further 
included a suitable means of detection. In some embodi-
ments, the kit includes the RNA-3WJ-Beacon as disclosed 
herein. Non-limiting examples of suitable means of detec-
tion include MRI, nuclear imaging ( e.g. PET or SPECT), 
optical imaging, sonoluminence imaging or photoacoustic 
imaging (ultrasound). The skilled in the art will appreciate 
that the particular imaging module of the present disclosure 
should be compatible with the particular imaging modality 
being used. 
In some embodiments, the presently disclosed subject 
matter provides a method of diagnosing and/or treating a 
disease in a subject having or at risk of having the disease, 
the method comprising administering to the subject a thera-
peutically effective amount of a composition comprising a 
RNA nanostructure molecule and RNA dendrimer as dis-
closed above and herein. In some embodiments, the com-
position further comprises a pharmaceutically acceptable 
carrier. In some embodiments, the subject is a manimal or a 
non-mammal vertebrate. In some embodiments, the subject 
is a human. In some embodiments, the disease is a cancer. 
In some embodiments, the cancer is a colon cancer. Non-
limiting examples of the disease include cancer, immunol-
ogy, respiratory, central nervous system, inflammatory, and 
infectious diseases. Non-limiting examples of a cancer 
include but not limited to ovarian cancer, brain cancer, bone 
cancer, lung cancer, colorectal cancer. 
The term "pharmaceutically acceptable carrier" as used 
herein refers to a diluent, adjuvant, excipient, or vehicle with 
which a heterodimeric probe of the disclosure is adminis-
tered and which is approved by a regulatory agency of the 
federal or a state government or listed in the U.S. Pharma-
copeia or other generally recognized pharmacopeia for use 
in animals, and more particularly in humans. Such pharma-
ceutical carriers can be liquids, such as water and oils, 
including those of petroleum, animal, vegetable, or synthetic 
origin, such as peanut oil, soybean oil, mineral oil, sesame 
oil, and the like. The pharmaceutical carriers can be saline, 
gum acacia, gelatin, starch paste, talc, keratin, colloidal 
silica, urea, and the like. When administered to a patient, the 
heterodimeric probe and pharmaceutically acceptable carri-
ers can be sterile. Water is a useful carrier when the 
heterodimeric probe is administered intravenously. Saline 
20 disease, disorder, or condition, previous therapy, the 
patient's health status and response to the drugs, and the 
judgment of the treating physician. By way of example only, 
therapeutically effective amounts may be determined by 
routine experimentation, including but not limited to a dose 
25 escalation clinical trial. 
The specific therapeutically effective dose level for any 
particular patient will depend upon a variety of factors 
including the disorder being treated and the severity of the 
disorder; the specific composition employed; the age, body 
30 weight, general health, sex and diet of the patient; the time 
of administration; the route of administration; the rate of 
excretion of the specific compound employed; the duration 
of the treatment; drugs used in combination or coincidental 
with the specific compound employed and like factors well 
35 known in the medical arts. For example, it is well within the 
skill of the art to start doses of a compound at levels lower 
than those required to achieve the desired therapeutic effect 
and to gradually increase the dosage until the desired effect 
is achieved. If desired, the effective daily dose can be 
40 divided into multiple doses for purposes of administration. 
Consequently, single dose compositions can contain such 
amounts or submultiples thereof to make up the daily dose. 
The dosage can be adjusted by the individual physician in 
the event of any contraindications. Dosage can vary, and can 
45 be administered in one or more dose administrations daily, 
for one or several days. Guidance can be found in the 
literature for appropriate dosages for given classes of phar-
maceutical products. In further various aspects, a prepara-
tion can be administered in a "prophylactically effective 
50 amount"; that is, an amount effective for prevention of a 
disease or condition. 
Suitable methods for administering to a subject an effec-
tive amount of the composition in accordance with the 
methods of the present disclosure include but are not limited 
55 to systemic administration, parenteral administration (in-
cluding intravascular, intramuscular, intraarterial adminis-
tration), oral delivery, buccal delivery, subcutaneous admin-
istration, inhalation, intratracheal installation, surgical 
implantation, transdermal delivery, local injection, and 
60 hyper-velocity injection/bombardment. Where applicable, 
continuous infusion can enhance drug accumulation at a 
target site (see, e.g., U.S. Pat. No. 6,180,082). 
As used herein, the term "subject" refers to a target of 
administration of the pharmaceutical composition. The sub-
65 ject of the herein disclosed methods can be a vertebrate, such 
as a mammal, a fish, a bird, a reptile, or an amphibian. Thus, 
the subject of the herein disclosed methods can be a human 
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or non-human. Thus, veterinary therapeutic uses are pro-
vided in accordance with the presently disclosed subject 
matter. As such, the presently disclosed subject matter 
provides for administration to mammals such as humans and 
non-human primates, as well as those mammals of impor- 5 
tance due to being endangered, such as Siberian tigers; of 
economic importance, such as animals raised on farms for 
consumption by humans; and/or animals of social impor-
tance to humans, such as animals kept as pets or in zoos. 
Examples of such animals include but are not limited to: 10 
carnivores such as cats and dogs; swine, including pigs, 
hogs, and wild boars; ruminants and/or ungulates such as 
cattle, oxen, sheep, giraffes, deer, goats, bison, and camels; 
rabbits, guinea pigs, and rodents. Also provided is the 
treatment of birds, including the treatment of those kinds of 15 
birds that are endangered and/or kept in zoos, as well as 
fowl, and more particularly domesticated fowl, i.e., poultry, 
such as turkeys, chickens, ducks, geese, guinea fowl, and the 
like, as they are also of economic importance to humans. 
Thus, also provided is the treatment of livestock, including, 20 
but not limited to, domesticated swine, ruminants, ungu-
lates, horses (including race horses), poultry, and the like. 
The term does not denote a particular age or sex. 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 25 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 




Atomic Force Microscopy (AFM) Imaging 
Atomic force microscopy (AFM) was used to study the 
shape and size of 3 WJ-pRNA nanoparticles harboring three 
monomeric pRNA [27]. AFM images were obtained by 
imaging the nanoparticles using specially modified mica 
surfaces (APS mica) [37] with a Veeco MultiMode AFM 
NanoScope IV system (Veeco/Digital Instruments, Santa 
Barbara, Calif.), operating in tapping mode, according to the 
method previously reported [27]. 
Temperature Gradient Gel Electrophoresis (TGGE) 
The thermodynamic stability of 2'F U/C modified RNA 
3WJ nanoparticles was studied using the TGGE system 
(Biometra GmbH, Germany). The 2'F U/C modified RNA 
oligonucleotides used in this study for constructing the RNA 
3WJ nanoparticles were ordered from TriLink Bio Technolo-
gies (San Diego, Calif.). The 3WJb strand was 5'-end y-32P 
ATP (Perkin-Elmer, MA) labeled prior assembly. Assembly 
of RNA 3WJ nanoparticle was achieved by mixing 10 uM 
total RNA strands in TMS buffer, heating to 80° C. and 
cooling it down to 4 ° C. over 1 hour. RNA nanoparticles 
were subjected to a 15% native PAGE (2.5 uL of RNA per 
well) and allowed to run for 10 minutes at ambient tem-
perature at constant 100 V. After RNA entered into the gel 
matrix, the gel was transferred into TGGE apparatus and a 
linear temperature gradient was set up from 36° to 80° C. 
perpendicular to electrical current. The gel was ran at 100 V 
for 1 h, and then was dried under vacuum and imaged using 
a phosphor storage screen with Typhoon FLA 7000 (GE 
Healthcare). 
Confocal Microscopy of HT29 Colon Cancer Cells Incu-
bated with RNA Nanoparticles 
Radiation reagents that specifically target tumors are in 
high demand for the treatment of cancer. The field of RNA 
nanotechnology can provide new opportunities for targeted 
radiation therapy. We recently found that chemically modi-
fied RNA nanoparticles derived from pRNA Three-Way 
Junction (3 WJ) of phi29 DNA-packaging motor are resistant 
Colon cancer HT29 cells were plated on coverslips 
(Fisher Scientific) with folate free medium in a 24-well plate 
and cultured at 37° C. in humidified air containing 5% CO2 
35 overnight. The cells were washed with folate free medium 
twice to remove dead cells. The Alexa-647 labeled foalte-
to potent I-125 and Cs-131 radiation, which is a required 
perquisite for utilizing these RNA nanoparticles as carriers 40 
for targeted radiation therapy. Specifically, RNA nanopar-
ticles derived from the pRNA 3WJ targeted tumors in vivo 
and they were stable under irradiation of I-125 and Cs-131 
with clinically relevant doses ranging from 1 Gy to 90 Gy 
over a significantly long time up to 20 days. These studies 45 
demonstrated that the RNA nanoparticles could be used as 
carriers for radiation therapy and diagnosis. 
Materials and Methods 
3WJ and folate free 3WJ 2'F RNA nanoparticles were 
diluted in folate free medium and incubated with the cells at 
37° C. for 2 hours. After washing with PBS, the cells were 
fixed with 4% paraformaldehyde, stained with Alexa Flour® 
488 Phalloidin (Life technologies Corporation, Carlsbad, 
Calif., USA) for actin and ProLong® GoldAntifade Reagent 
with DAPI (Life technologies) for nucleus. The images were 
taken on an Olympus FVl000 confocal microscope (Olym-
pus Corporation, Tokyo, Japan). 
Flow Cytometry Analysis of Cellular Binding of RNA 
Nanoparticles 
KB cells were cultured in folate free RPMl-1640 medium 
Oligonucleotides and Assembly of RNA 3WJ Nanopar-
ticles 
(Gibco ), then digested with trypsin and rinsed with folate 
50 free medium. 3 nM of Alexa647 labeled 3WJ-Folate and 
3WJ 2'F RNA were incubated with 2xl05 KB cells at 37° C. The RNA oligonucleotides used in this study for con-
structing the RNA 3WJ nanoparticles were ordered from 
TriLink BioTechnologies (San Diego, Calif.). Assembly of 
RNA 3WJ nanoparticles was performed by mixing equal 
molar concentrations of corresponding strands (3WJa: 55 
UUGCCAUGUGUAUGUGGG (SEQ ID NO: 1); 3WJb: 
CCCACAUACUUUGUUGAUCC (SEQ ID NO: 2) and 
3WJc: GGAUCAAUCAUGGCAA (SEQ ID NO: 3)) in 
TMS(50mMTRISpH=8.0, l00mMNaCl, 10mMMgC12 ) 
buffer. The 3WJ formations were confirmed on a 12% native 60 
PAGE (polyacrylamide gel electrophoresis) with running 
buffer (89 mM Tris, 200 mM Borate acid, and 5 mM 
MgC12 ), according to published procedure [27]. Gels were 
stained with ethidium bromide (EB) or SYBR Green II and 
imaged by Typhoon FLA 7000 (GE Healthcare). The 65 
assembled RNA 3WJ nanoparticles were stored in -20° C. 
freezer prior to further characterization. 
for 1 hr. After washing with PBS twice, the cells were 
re-suspended in 200 µL of PBS buffer for flow cytometry 
analysis. Fluorescence intensity was determined with a 
FACS Calibur flow cytometer (BD Biosciences) by counting 
20 000 events each sample. 
Cytotoxicity Assay 
The cytotoxicity of RNA nanoparticles were evaluated 
with an MTT assay kit (Promega, Madison, Wis.) following 
manufacture' s instruction. Briefly, HT29 cells were plated in 
a 96-well plate and cultured at 37° C. in humidified air 
containing 5% CO2 overnight. The folate-3WJ 2'F RNA 
nanoparticles were suspended in fresh McCoy's SA with 
10% FBS medium at the indicated concentrations and added 
to the cells for incubation at 37° C. for 24 hrs. Then, 15ul 
of dye solution was added to each well and incubated at 37° 
C. for 4 hrs; 1 00ul of solubilization/stop solution was added 
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to each well and incubated at room temperature for 2 hrs for 
color development. The absorbance at 570 nm was recorded 
using a microplate reader (Synergy 4, Bio Tek Instruments, 
Inc, USA). The cell viability was calculated relative to the 
absorbance of cells only control (viability of cells only 5 
control=100%). 
Animal Trial: In Vivo Cancer Targeting of RNA 3WJ 
Nanoparticles 
In order to evaluate the cancer targeting property of RNA 
3WJ nanoparticles, an animal trial was conducted. All 10 
experiments involving animals are approved by the Univer-
sity of Kentucky Institutional Animal Care and Use Com-
mittee (IACUC). Male athymic nude nu/nu (6-8 week old) 
mice were obtained from Taconic (Hudson, N.Y.) and 
housed in clean, pathogen-free rooms in an environment 15 
with controlled temperature (27° C.), humidity, and a 12 
hour light/dark cycle. The mice were fed standard chow and 
tap water ad libitum and allowed to acclimate for one week. 
HT29 colon cancer tumor cells were injected subcutane-
ously (5xl06 cells in 100 ul lx phosphate buffered saline 20 
(PBS)). RNAnanoparticles were administered intravenously 
3 weeks after tumor cells injection. The folate and Alexa64 7 
labeled 2'F U/C modified RNA oligo strands for assembling 
the RNA 3WJ nanoparticles were custom ordered from 
TriLink BioTechnologies, Inc (San Diego, Calif.). Mice 25 
were fed a folate-free diet (Harlan Laboratories; Indianapo-
lis, Ind.) for a total of 2 weeks before the folate-pRNA 3WJ 
nanoparticles were injected. For intravenous injection mice 
were anesthetized using isoflurane gas (2% in oxygen at 0.6 
Umin flow rate) and injected with 100 µg ( 4 mg/kg) of 2'F 30 
U/C modified folate-Alexa647-labeled pRNA 3WJ nanopar-
ticles in 300 µl of PBS. Whole-body imaging (Alexa Fluor 
647, Ex=640 nm, Em=680 nm;) was carried out on IVIS 
Spectrum station (Caliper Life Sciences; Hopkinton, Mass.) 
15 min, 1 hour, 2 hour and 3 hour post injection. Composite 35 
images obtained were comprised of black and white digital 
photos with an overlay of images reflecting fluorescent 
activity. The density map, measured as photons/second/cm2/ 
steradian (p/s/cm2/sr), was created using the Living Image 
3.1 (Caliper Life Sciences; Hopkinton, Mass.) software and 40 
represented as a color gradient centered at the maximal spot. 
CO2 asphyxiation was performed by 3 hand 15 minute post 
injection. Following CO2 asphyxiation, the tumors of the 
mice were dissected. 
32 
Fetal Bovine Serum (FBS) Degradation Assay 
Stability of nanoparticles in the body is critical for its in 
vivo application, as many enzymes could degrade nanopar-
ticles rapidly and hinder their application. In the blood, the 
instability of RNA is mainly the result of enzymatic degra-
dation by ribonucleases (RNases). RNases can be divided 
into two major categories: endoribonucleases and exoribo-
nucleases. Endoribonucleases cleave phosphodiester bonds 
within the RNA backbone, while exoribonucleases cleave 
phosphodiester bonds at either the 5' end or the 3' end of an 
RNA chain. RNA is indeed very sensitive to degradation by 
RNases, which confers a very short half-life and thus, a poor 
pharmacokinetic profile for most RNA molecules. This 
limits the in vivo usage of RNA molecules as therapeutics. 
However, chemical modifications of RNA can overcome this 
shortcoming. For example, the substitution of the 2' 
hydroxyl group with a 2' fluorine (2'F) atom dramatically 
increases the stability of RNA in vivo by preventing deg-
radation by RNases [ 48-51]. To test the stability of RNA 
3WJ nanoparticles with FBS treatment, assembled RNA 
3WJ nanoparticles were incubated with 10% FBS in 1640 
cell culture medium in a 37° C. water bath for different time 
up to 36 hr. Samples were then assayed on a 12% native 
PAGE, stained with EB, and imaged by Typhoon FLA 7000 
(GE Healthcare). ImageJ software was used to integrate the 
intensities of the assembled RNA 3WJ nanoparticles in the 
gel. Integration areas for each time point were compared to 
the integration area for the 0 min time point to construct a 
serum degradation comparison between the RNA and 2'F 
RNA nanoparticles. Origin 8.6 software were used to gen-
erate the plots. 
Irradiation of RNA 3WJ Nanoparticles with I-125 and 
Cs-131 
Two brachytherapy sources were used in this study. I-125 
is an isotope that is commonly used to treat prostate cancer 
and tumors in various sites. It decays into Te-125 with 
electron capture emitting photons with a broad spectrum 
whose mean energy is 28 KeV; the half-life is 59.4 days. 
I-125 brachytherapy sources used in this study for prostate 
implants were produced by IsoAid (Port Richey, Fla.) as a 
cylindrical shape with a physical length of 4.5 mm and outer 
Confocal Microscopy of Tissue Samples 45 diameter of 0.8 mm; the I-125 material was coated onto a 
silver rod encapsulated with a thin Titanium shielding [38]. For in vivo samples, collected tissues were fixed in 4% 
paraformaldehyde (Polysciences; 18814) with 10% sucrose 
(Sigma-Aldrich; St. Louis, Mo.) for 12 h at 4° C. and 
embedded into Tissue-Tek® O.C.T. compound on dry ice 
(Tissue-Tek; Andwin Scientific, Schaumburg, Ill.) for frozen 50 
sectioning (10 µm section thickness). Sectioned tissues were 
dried overnight in the dark, washed in room temperature 
PBS, stained and mounted by ProLong® Gold Antifade 
Reagent with DAPI (Life Technologies Corporation, Carls-
bad, Calif.) overnight. The Olympus FVl000 confocal 55 
microscope (Olympus Corporation, Tokyo, Japan) was used 
to obtain the images. 
Urea Stability Assay 
Urea is a denaturing agent that is widely used in bio-
chemistry to denature RNAs or proteins. Urea stability 60 
assays were performed to assay the stability of RNA 3WJ 
nanoparticles in the presence of urea. Urea stability was 
tested by mixing assembled RNA 3WJ nanoparticles with 
different concentrations of urea (2 M, 4 M, 6 M and 8 M). 
The samples were assayed on a 12% native PAGE, stained 65 
with EB, and imaged by Typhoon FLA 7000 (GE Health-
care). 
Isotope Cs-131 is relatively new to brachytherapy, but has 
already been used for the treatment of various types of 
cancer such as prostate, breast, and eye, and recent gyne-
cological malignancies [39-44]. It is similar to I-125 in many 
aspects. It also decays in electron capture and emits photons 
with a mean energy of 30 KeV, but the half-life of Cs-131 
is only 9.7 days [45]. The Cs-131 source was provided by 
IsoRay Medical, Inc., Richland, Wash. as a small cylinder 
4.5 mm in length and 0.8 mm in diameter. 
I-125 or Cs-131 radioactive sources were immersed in the 
sample liquid (1 cc) contained in a small vial. The irradiation 
of the 2'F U/C modified RNA samples was performed for 
different time periods and doses. The purpose was to dis-
tinguish the effects of radiation on DNA and RNA structures. 
Un-irradiated samples were maintained in the same buffer 
and temperature and used as control. After irradiation, the 
integrity of the RNA 3 WJ nanoparticles and plasmid control 
were assayed by 12% native PAGE with TBM running 
buffer or 0.7% agarose gel with TAE running buffer, respec-
tively. 
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Results 
RNA 3WJ Nanoparticles Form by One-Pot Self-Assem-
bly 
34 
3 WJ 2'F RNA nanoparticles can also bind to folate receptor 
over-expressed KB cells (FIG. 2B). 
RNA 3WJ Nanoparticles Holds Low Cytotoxicity 
Revealed in Cell Assay 
The cytotoxicity offolate-3WJ 2'F RNAnanoparticles on 
colon cancer HT29 cells was evaluated with a standard 
colorimetric MTT assay that assesses the cell proliferation. 
We found that folate 3WJ 2'F RNA nanoparticles did not 
induce measurable cell viability loss on colon cancer HT29 
cells even at a high concentration of 0.4 µM (FIG. 2C), 
indicating the RNA nanoparticles are biocompatible and not 
toxic. 
RNA 3WJ Nanoparticles Targeting Xenograft Cancer by 
Systemic Injection 
Systemic injection ofRNA3WJ nanoparticles was used to 
confirm the chemical and thermodynamical stability and 
cancer targeting of these nanoparticles. Moreover, as a 
preliminary study to evaluate the feasibility of RNA nano-
particles to carry radioisotopes for cancer targeting in vivo, 
RNA 3WJ consists of three fragments: 3WJa, 3WJ6 , and 
3WJc RNA nanoparticles were formed by mixing three 5 
pieces of chemically synthesized oligos, 3WJa, 3WJ6 , and 
3WJc at 1:1:1 molar ratio (FIG. 1). The three pieces were 
assembled into nanoparticles very efficiently by simple 
mixing (FIG. lC, lane 7), indicating the thermodynamically 
stable properties of the pRNA 3WJ. Notably, with the 1:1: 1 10 
ratio of 3WJa, 3WJb, and 3WJc, almost more than 90% or 
close to 100% of the three RNA fragments assembled 
efficiently into the 3WJ complex. This feature of efficient 
self-assembly [27] suggests that pRNA 3WJ nanoparticles 
can be fabricated very simply and easily, which is advanta- 15 
geous for therapeutics development and clinical translation. 
AFM imaging also confirmed the formation of 3WJ-pRNA 
nanoparticles harboring three monomeric pRNA and 
revealed the triangular branched structure of the nanopar-
ticle with the size of 10-15 nm (FIG. 18). 20 we used fluorescent dye instead of a radioisotope in a pilot 
experiment. RNA nanoparticles was constructed with one 
RNA fragment carrying folate as a cancer-targeting ligand 
and another RNA fragment carrying the Alexa647 fluores-
Chemically Modified RNA 3WJ Nanoparticles are 
Chemically and Thermodynamically Stable 
In addition, we measured thermodynamic stability of the 
RNA 3WJ nanoparticles by temperature gradient electro-
phoresis gel (TGGE) (FIG. lD). This technique allows the 25 
determination of melting temperatures of nucleic acids by 
means of decreasing fraction of a nanoparticle with increas-
ing temperature on PAGE [46,47] (FIG. lD). The 2'F 
modified 3WJ nanoparticles remained stable at temperatures 
as high as 66.8±2° C., which is above the temperature of 30 
normal human body. 
RNA 3 WJ nanoparticles were mixed with 2 M, 4 M, 6 M, 
and 8 M urea and loaded into TBM gel (FIG. 3A). In the 
presence of 8 M urea, assembled RNA 3WJ nanoparticles 
still showed little dissociation, which is in agreement with 35 
previously published results [27]. 
The stability of RNA 3WJ nanoparticles was tested with 
up to 36 hr serum treatment (FIG. 3B). Previously published 
reports by Pieken et al. [ 48], Kawasaki et al. [ 49], Sabahi A 
et al. [50] and Liu et al. [51] have demonstrated that 40 
2'F-modified RNA has increased resistance to ribonuclease 
cent probe instead of a radioisotope. The 3WJ RNA nano-
particles were systemically injected into mice via tail vein. 
Whole body imaging of treated mice revealed a fluorescence 
signal located specifically at the cancer xenograft, which 
expressed the folate-receptor. Fluorescent signal was not 
detected in healthy tissue or normal organs in the mice body 
(FIG. 2D), indicating that the particles did not accumulate or 
become trapped in liver, lungs, or other organds after sys-
temic delivery. Further confocal microscope analysis (FIG. 
2E) also confirmed that the Alexa647 labeled RNA nano-
particles could enter into the tumor and bind to cancer cells. 
RNA 3WJ Nanoparticles are Stable Under Irradiation 
with I-125 and Cs-131 
The stability of 2'-F modified RNA 3WJ nanoparticles 
under irradiation with clinically relevant doses was crucial 
for the development of targeted radiation therapy. The 
stability tests were performed with I-125 and Cs-131 irra-
diation. DNA plasmids were included as control. The plas-
mid DNA we used was in the circular form. Cleavage of the 
circular plasmid at a random site will result in a linear DNA 
that migrates to different location in the gel. Multiple 
cleavage of the DNA will result in random sizes that form a 
as well as enhanced thermodynamic stability. Our results 
showed the similar results for the RNA 3WJ nanoparticles. 
Specifically, unmodified RNA 3WJ nanoparticles were 
degraded in serum which was revealed by the disappearance 
of the non-modified RNA 3WJ nanoparticles after serum 
treatment, indicating the majority of the unmodified RN As 
were degraded. However, 2'F-modified RNA 3WJ nanopar-
ticles were resistant to serum-induced degradation. In con-
trast to unmodified RNA nanoparticles, more than 90% of 
2'F-modified RNA 3WJ nanoparticles remained intact after 
36 hours serum treatment, which is in agreement with 
published reports [27]. 
45 smear in the gel and many individual bands with low 
concentration were not visible since each DNA will have 
several thousand random cleavage sites. The test with I-125 
was first performed for a low dose of 1 Gy to both RNA and 
DNA samples, but no change was observed. When the dose 
Folate-Conjugated RNA Nanoparticles Bind to Cancer 
Cells Specifically In Vitro 
50 
was increased to 30 Gy, a typical therapeutic dose, RNA 
3WJ nanoparticles still remained unchanged (FIG. 3C) 
while DNA smear was formed as shown in FIG. 3D, which 
provided evidence of the cleavage of the plasmid DNA by 
radiation. The upper band and lower bands in lane 1 repre-
sent linear and supercoiled plasmid DNA, respectively. 
55 These results are summarized in Table 1. 
60 
In one embodiment, the 2'F modified 3WJ RNA nano-
particles conjugated with folate were tested for specific 
binding and entry to colon cancer HT29 cells by confocal 
microscopy. In the folate-conjugated 3WJ RNA nanopar-
ticles, 3WJb strand was labelled with folate and 3WJc strand 
was labeled withAlexa647. 3WJ RNAnanoparticles without 
folate were used as a negative control. Confocal imaging 
indicated strong binding and entry of the folate-conjugated 
3WJ nanoparticles to colon cancer HT29 cells, as demon-
strated by co localization of nucleus (blue), actin (green) and 65 
Alexa647-labeled RNA nanoparticles (red) signals. (FIG. 
2A). Flow cytometry analysis indicated that folate labeled 
TABLE 1 
Results ofl-125 irradiation. 
Test Dose (Gy) Sk(U) Time (day) RNA change DNA change 
1.4 N N 
2 30 1.7 18 N y 
Y = Yes, N = No. 
Four tests were also conducted with Cs-131 for 7 Gy, 20 
Gy, 30 Gy, and 90 Gy, and the irradiation lasted up to 20 
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days (longer than 2 half-life of 9.7 days). Both DNA and 
RNA structures were intact for 7 Gy, but DNA was broken 
while RNA 3WJ nanoparticles remained intact for 20 Gy or 
higher. The results are summarized in Table 2, and the result 
for 30 Gy is shown in FIG. 3D. 
TABLE 2 





























The results showed that RNA 3WJ nanoparticles were 
stable under irradiation of I-125 and Cs-131 with doses 
ranging from 1 Gy to 90 Gy. However, the DNA plasmids 
were damaged with a dose of 20 Gy or higher, the thera-
peutic doses prescribed for cancer treatment, while the RNA 
3WJ nanoparticles remained intact. This result has indicated 
that RNA 3WJ nanoparticles may be able to carry therapeu-
tic doses of I-125 and Cs-131 for cancer treatment. 
Discussion 
RNA nanotechnology is an field with increasing popular-
36 
nanoparticles are feasible to carry radioisotope to kill cancer 
cells while remaining intact. The stability of the RNA 
nanoparticles under irradiation over a long time is important 
since the chemical conjugation of radioactive isotopes to 
5 RNA might be a time-consuming process depending on the 
rate and efficiency of the conjugation reaction. In the future 
experiments, we will also study the stability of RNA nano-
particles inside tumor tissues and try to develop the method 
to control the degradation of RNA nanoparticles as well as 
the release of radioisotope inside the tumor. In addition, 
10 
I-125 and Cs-131 are gamma emitters and presence of 
gamma emission is helpful in imaging and studying the 
biodistribution of the radiopharmaceutical for estimation of 
patient-specific dose distribution [57]. This is an advantage 
that gamma emitters have over the pure beta emitters like 
15 Y-90. In the absence of gamma emission, surrogate isotopes 
like In-111 have to be used for internal dosimetry for pure 
alpha or beta emitters such as Y-90. Compared to I-131 that 
also emits photons, I-125 and Cs-131 have much lower 
energies and easy for radiation protection. Although image 
20 quality for I-125 or Cs-131 will be affected by the low 
energies of photons, good quality I-125 image have been 
obtained using Gamma camera [58, 59]. Therefore, RNA 
nanoparticles carrying I-125 or Cs-131 have the potential to 
be used for accurate targeted radiation therapy. As disclosed 
25 herein, in some embodiments, beta emitters include but not 
limited to Strontium-90, Tritium, Carbon-14, Phosphorus-
32, Nickel-63. In some embodiments, gamma-emitting iso-
topes include but not limited to Caesium-137, Iodine-131, ity among the scientific community [13, 21, 52-56]. RNA 
3WJ-based nanoparticles have been successfully fabricated 
(FIG.1) and share the advantages ofa targeted drug delivery 30 
system of specific delivery and longer retention time, which 
reduce the dosage required and the side effects. The specific 
delivery can be achieved through EPR ( enhanced perme-
ability and retention) effect or active targeting through 
conjugation with ligands such as aptamer, folate, and RGD. 
Systemic injection of thermodynamically and chemically 
stable RNA nanoparticles into mice revealed that RNA 
nanoparticles strongly and specifically bound to cancers 
without accumulating in liver, lung, or any other vital organs 
Lanthanum-140, cobalt-60, iridium-192. 
It should be noted, however, that the sealed I-125 and 
Cs-131 sources used in this study were not carried by RNA 
nanoparticles. To be carried by RNAnanoparticles, unsealed 
I-125 or Cs-131 should be used to label RNAnanoparticles. 
The I-125 or Cs-131 labeled RNA nanoparticles will be 
35 injected into the patient body to target the tumor, and the 
radiation from I-125 or Cs-131 can thus kill the cancer cells 
guided by the nanoparticles. The I-125/Cs-131 labeled RNA 
particles will stay inside the tumor cells to deposit almost all 
the dose produced by I-125/Cs-131. Considering that the 
or tissues (FIGS. 2D and 2E). 40 blood circulation time for humans is about one minute 
compared to the half-life of I-125/Cs-131 of about 60 
days/IO days, the dose lost during circulation is negligible. 
Detailed discussion of I-125/Cs-131 labeled RNA particles 
will be addressed in our future study. Based on the biodis-
The high stability of RNA 3WJ nanoparticles in the 
presence of high concentration of denaturing agents (FIG. 
3A) is a remarkable advantage for in vivo applications, 
including radiation therapy, because remaining intact in vivo 
and being resistant to various denaturing factors will be 
crucial for fulfilling the nanoparticle's designated function 
after injection into the body. Moreover, the determined 
melting temperature of the 3WJ RNA nanoparticles (FIG. 
lD) is approximately two times higher than the normal 
human body temperature (37° C.), which also indicates that 
this physical property of the RNA 3WJ nanoparticles is 
favorable for in vivo applications including radiation 
therapy, because these RNA nanoparticles should not disas-
sociate within the normal human body temperature range. 
Furthermore, the property of resistance to serum-induced 55 
degradation (FIG. 3B) suggests that these 2'F modified RNA 
nanoparticles will also stay intact within the human body, 
and, again, should be favorable as a targeted delivery system 
for in vivo cancer therapy. 
45 tribution study of pRNA nanoparticles published by Abdel-
mawla et al. [28], we expected that 3WJ nanoparticles 
labelled with radioisotope will also have favorable biodis-
tribution profile with similar tumor-targeting efficiency as 
the previously reported pRNA nanoparticles. In the future 
50 experiments, we will radioactively label 3WJ RNA nano-
particles and use the radioactive signal to quantify the doses 
delivered in individual organs and tumor. We will also 
compare the delivered dose to that provided by brachy-
therapy implanted sources. 
Conclusions 
Chemically modified RNA nanoparticles derived from 
pRNA three-way junction (3WJ) ofphi29 DNA-packaging 
were resistant to the radiation of I-125 or Cs-131 and 
remained stable under irradiation with therapeutic doses 
60 over a significantly long time up to 20 days. Therefore, RNA 
3WJ nanoparticles have the potential to carry I-125 or 
Cs-131 for targeted radiation therapy. 
The principle of radiation therapy is to use radiation to 
break DNA helical structures in the cancer cells. However, 
RNA has similar structures. To be able to carry radioiso-
topes, RNA structures should keep intact with the radiation. 
The study has shown that, unlike DNA, RNA nanoparticles 
were resistant to the radiation of I-125 or Cs-131 and 65 
remained stable under irradiation with therapeutic doses 
(FIGS. 3C and 3D, Table I and II). This indicates that RNA 
Example 2 
This study will utilize pRNA-3WJ as a platform for 
constructing RNA-3WJ-Beacons and RNA Dendrimers as 
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multifunctional systems harboring multimodal imaging 
agents, cancer targeting ligands, and therapeutic siRNA/ 
miRNA, all in one nanoconstruct that will allow the delivery 
of therapeutics to be visualized at various spatial and tem-
poral resolutions in vivo. Example 2 focuses on the con- 5 
struction of multifunctional pRNA-3WJ nanoparticles har-
boring (1) imaging modules: NIR fluorophores, such as 
Alexa647 and IRdye800 for in vivo fluorescence imaging; 
Radionuclides, such as 177Lu, 111 In or 64Cu for PET /SPECT 
imaging; and Contrast agents, such as gadolinium (Gd3+) for 10 
MRI; (2) targeting modules: such as RNA aptamer or 
chemical ligand for binding to cancer specific cell surface 
receptors resulting in internalization of RNA nanoparticles 
into cancer cells; and (3) therapeutic modules: siRNAs or 15 
anti-miRNAs to down-regulate oncogenic genes. 
Construction of Multifunctional RNA Nanoparticles Har-
boring Multimodal Imaging Agents, TargetingAptamers and 
Therapeutic Modules Using pRNA-3WJ Platform 
Multifunctional RNA nanoparticles will be constructed 20 
using the pRNA-3WJ motif as a scaffold to harbor: (1) 
Imaging modules: NIR fluorophores for in vivo fluorescence 
imaging; Radionuclides for PET /SPECT imaging; and gado-
linium contrast agents for MRI; (2) Targeting modules: RNA 
aptamers or chemical ligands for binding to cancer specific 25 
cell surface receptors resulting in internalization of RNA 
nanoparticles into cancer cells; and (3) Therapeutic mod-
ules: siRNAs and anti-miRNAs to down-regulate oncogenic 
genes. 
1.1 Conjugation of Imaging Modules to RNA Constructs 30 
1.1.1 Nir Fluorophores: 
For in vivo imaging, NIR dyes are particularly attractive 
since they can penetrate deep into tissues and more impor-
tantly, auto-fluorescence from tissues is greatly reduced. 
without being bound by theory, a robust RNA nanotechnol- 35 
ogy will be developed utilizing the pRNA-3WJ motif for 
monitoring the in vivo delivery of therapeutics non-inva-
sively by NIRF and PET/SPECT imaging (FIG. 12). The 
RNA-3WJ-Beacon contains a 'reporter' fluorophore dark-
ened by a quencher in close proximity and will only elicit a 40 
fluorescence signal upon cleavage of the incorporated 
siRNA/anti-miRNA by Dicer in the cell (see Section 2.1, 
described herein in Example 3). The RNA-3WJ-Beacon also 
contains a 'reference' probe (either NIR dye or radiolabel), 
which remains active at all times and allows tracking of the 45 
entire RNA-3WJ-Beacon construct in the cell (FIG. 12). 
The pRNA-3WJ motif utilizes a modular design com-
posed of three individual fragments (FIG. 6F, 12). One of the 
fragments (c 3 wJ) will be end-labeled with 'reference' dye 
IRdye800 while another fragment (b3 wJ) will be end-labeled 50 
with a quencher, Iowa Black for the 'reporter' dye Alexa647 . 
The 'reporter' dye will be end-labeled on therapeutic RNA 
fragments (siRNA/miRNA). All these 2'-F modified RNA 
fragments will be custom-designed and purchased from IDT, 
TriLink or IBA, as described in our publications [G9-11, 55 
which are incorporated by reference in their entitities.] Upon 
mixing the chemically synthesized individual strands in 
stoichiometric ratio, the RNA fragments will assemble into 
38 
through FRET (FIG. 13). As alternatives, other available 
quencher/emitter pairs (Table 3) will be investigated. 
TABLE 3 
Emitter-quencher pairs for designing RNA 
molecular beacons (as alternatives) 
Emitter 
Alexa64 7 /Cy5 
IRDye 800CW 
Cy5.5/Alexa-680 
Source: Trilink, IDT, Invitrogen; Li-COR 
1.1.2 Radionuclide: 
Quencher 
Iowa Black RQ/QSY21 
IRDyeQC 
BBQ650/BHQ-3 
radiolabel peptides and proteins with various isotopes 
(1 77Lu, 111In, 64Cu, 99mTc, 203Pb, 188Re, 212Pb/212Bi) have 
been developed as tumor specific diagnostic and therapeutic 
agents [G73-77]. Similar methodologies will be applied to 
label RNA constructs used in this study. 
Radionuclide Selection: 
1 77Lu, 111 In or 64Cu ( as alternatives) will be used to label 
the RNA nanoparticles. High specific activity of these radio-
nuclides are commercially available. Metals are highly toxic 
in their free form and thus have to be chelated to minimize 
their toxicity. We will use DOTA(l,4,7,10-tetraazacyclodo-
decane-N,N'N'N""-tetraacetic acid) or NOTA (1,4,7-triaza-
cyclononane-N,N' ,N"-1,4, 7-triacetic acid) as chelating 
agents for our radionuclides. 
Lutetium-177 (t112=6.71 days, (30.497 MeV, Yavg 175 
keV) is an attractive radioisotope for targeted radionuclide 
therapy, imaged by SPECT. The DOTAmacrocyclic chelator 
can stably coordinate Lutetium-177 at 37° C. to 75° C. 
[G73]. 
Indium-Ill (t112=2.8 days, EC 100%, y 171 keV, y 245 
keV) is a gamma emitter that is routinely used in diagnostic 
SPECT nuclear medicine imaging. The DOTA macrocyclic 
chelator can stably coordinate 111 In at 3 7° C. to 7 5° C. 
[G78]. 
Copper-64 (t112=12.7 hrs, 17.4% ~+, 41% EC, 40% ~-, 
Eavg 278 keV) is a positron and beta- emitter. The NOTA 
macrocyclic chelator can efficiently and stably coordinate 
64Cu from 25° C. to 50° C.76 .79 • The 12.7 hr half-life is 
sufficiently long to radiolabel the RNA nanoparticle and 
perform biodistribution and imaging studies using PET. 
Conjugation of DOTA or NOTA to Amine Modified 
Nanoparticles: 
One of the fragments (c 3 wJ) of the pRNA-3WJ will be 
2'-F modified and end-labeled with amine (NH2 ) (custom 
ordered from Trilink). The c3 w.rNH2 RNA will be reacted 
with a 50 equivalent excess of DOTA-NHS (for 177Lu, 
111In) or NOTA-SCN (for 64Cu) (Macrocyclics Inc.) (FIG. 
14). The DOTA-NHS chelator will conjugated to the RNA 
in acetonitrile carbonate buffer (pH 10); NOTA-SCN will be 
conjugated to the RNA in sodium bicarbonate buffer (pH 8). 
The reactions will be monitored by reverse phase high 
performance liquid chromatography (RP-HPLC). Unreacted 
DOTA-NHS and NOTA-SCN will be removed from solu-
an ultrastable 3WJ nanoparticle with high efficiency, as 
shown in our publications [G9-ll]. 
tion using a 7 kDa weight cutoff spin colunm pre-equili-
60 brated in sterile water. The chelator modified nanoparticles 
will be lyophilized and stored at -80° C. It is important to note that the NIR fluorophores and 
quenchers used herein are highly soluble in physiological 
buffers, display very low nonspecific binding to cellular 
components and have high signal-to-noise ratio [G72]. In 
our RNA-Beacon constructs, the fluorescence spectrum of 65 
the 'reference' and 'reporter' dyes are designed such that 
there are no potential spectrum overlaps or quenching 
Radiolabeling DOTA and NOTA Conjugated RNA: 
The chelator conjugated RNA fragment will be radiola-
beled in acetate buffer (pH 7) over a concentration range of 
0.1-1 nM (20-200 µg) to maximize radiolabeling efficiency 
[G80]. DOTA conjugated nanoparticles will be radiolabeled 
with 40 MBq of 177LuCl3 or 
111InCl3 (>50 mCi/µg; Mall-
US 10,828,381 B2 
39 40 
inckrodt Pharmaceuticals) at 60° C. for 40 min [G78]. 
NOTA conjugated nanoparticles will be radio labeled with 7 5 
MBq of 64CuCl2 (> 100 mCi/µg; Essential Isotopes Inc.) at 
50° C. for 30 min[G76,G80]. Based on the published work 
[G76,G78,G79], it is expected to achieve >95% radiolabel- 5 
ing efficiency. Any free radionuclide will be removed using 
doses of siRNA can lead to high cytotoxicity. We have used 
the pRNA-X motif as a scaffold to conjugate multiple copies 
of luciferase siRNA targeting the same gene locus or dif-
ferent loci in one gene. Gene knock-down effects were 
progressively enhanced by increasing the number of siRNA 
in the complex [Gl0] (FIG. 17). Furthermore, 1 nM of 
7 KDa cutoff spin colunms pre-equilibrated with buffered 
saline. The radiolabeled strand will then be mixed with the 
other 3WJ component strands to assemble the 3WJ nano-
particles (FIGS. 12, 14). 
1.1.3 Gadolinium Contrast Agent: 
Gadolinium is a common T 1 -weighted MRI contrast 
agent. A similar approach using standard NHS chemistry 
will be used to couple Gd3 + to RNA using DOTA-NHS 
(FIG. 14). GdCl3 and RNA-DOTA solutions will be mixed 
slowly to avoid any precipitation. The solution will be kept 
10 
pRNA-X nanoparticles with four siRNA modules can 
achieve the same silencing effects as 100 nM unformulated 
siRNA[Gl0]. 
Alternative 1: siRNA Targets: 
As therapeutic siRNAs, we will induce apoptosis of the 
colon cancer cells by inhibiting anti-apoptotic protein sur-
vivin using siRNAs, as described in our previous publica-
tions[G9,G10,G22]. siRNAs is directed to PI3K (a ubiqui-
15 taus lipid kinase) and its downstream effector proteins (Akt 
and mTOR) can effectively inhibit CRC cell viability [G91-
93, herein incorporated by reference in their entirety]. These 
siRNAs will be used as alternatives to survivin (UniProtKB/ 
at 75° C. for 1 hr, which will result in -100% incorporation 
yield81 . The chelated RNA strand will be purified by size 
exclusion chromatography and then mixed with the other 
3WJ component strands to assemble the 3WJ nanoparticles 20 
(FIG. 12,14)) (See Section 3.1 described in Example 4 for 
constructing RNA dendrimers with gadolinium). 
Swiss-Prat: 0153023). 
Alternative 2: Anti-miRNA Targets: 
MicroRNAs are small non-coding RNAs (19-25 nt) that 
display two classes of function, either as oncogenes or tumor 
suppressors[G94-95]. The pRNA-3WJ motif was shown to 
be an effective carrier of suppressor miRNA to silence viral 
Without bound by theory, the entire synthesis is kept free 
from any metal contamination as DOTA is a strong chelator 
for almost all metal cations. If the contamination of metal 
cations, such as Zn2 +, Cu2 + and Fe2 + occurs, it is difficult to 
incorporate Gd3 + due to both kinetic and thermodynamic 
issues. 
1.2 Construct RNA Nanoparticles Harboring Targeting 
Ligands 
Colon cancer will be used as a model system to evaluate 
our multifunctional 
RNA constructs in vitro and in our established subcuta-
neous, orthotopic, and metastatic mouse models (see Section 
2.2 described in Example 3). 
1.2.1 Folate Ligand: 
Many cancer cells, especially from the epithelial origin 
overexpress the folate receptor (FR) on the surface elevated 
25 genes by targeting the 3'-UTR of coxsackievirus genome 
[G96-97]. Following a similar delivery principle, we will 
deliver anti-miRNAs to kill tumors by down-regulating 
oncogenic miR-21. MiR-21 regulates biological behavior 
through the PI3K/Akt signaling pathway[G98], and down-
30 regulating miR-21 will serve as an alternative to our siRNA 
strategy. We have constructed a miR-21-luciferase reporter 
system and found that pRNA-3WJ-Folate-anti-miR-21 
nanoparticles can effectively knockdown miR-21 expression 
after incubation (as opposed to transfection) in KB cells 
35 (FIG. 18) (Dan Shu, et al., Systemic Delivery of Anti-
miRNA for Suppression of Triple Negative Breast Cancer 
Utilizing RNA Nanotechnology, ACS NANO, (2015) Vol. 9, 
No. 10, pp 9731-9740, hereby incorporated by reference in 
its entirety) 
Alternative 3: Cytotoxic Drugs: 
We have conjugated Paclitaxel (PTX) and Camptothecin 
(CPT) to the pRNA-3WJ scaffold using 'click chemistry' 
approach and acid-labile bonds (FIG. 19) [US 20130116419; 
Kolb, Hartmuth C., M. G. Finn, and K. Barry Sharpless. 
by 1000-fold including colon cancer. Folate receptor density 
increases as the stage or grade of the cancer worsens 82 . We 40 
demonstrated that Alexa647-FA-pRNA-3WJ constructs effi-
ciently and specifically bound and internalized to FR+ HT29 
and KM20 colon cancer cells in vitro (FIG. 15). More 
importantly, the RNA constructs specifically and dose-de-
pendently targeted FR+ HT29 colon cancer subcutaneous 
xenografts in mice with little accumulation in normal organs 
and tissues (FIG. 22). However, targeting the folate receptor 
45 "Click chemistry: diverse chemical function from a few 
good reactions." Angewandte Chemie International Edition 
40.11 (2001): 2004-2021, hereby incorporated by reference 
in there entirety]. The RNA-drug-folate complex can effec-is expected to be successful only in -one-third of all colon 
cancers [G83,G84]. 
1.2.2 2'-F EpCAM RNA Aptamer: 
As an alternative to folate, we identified EpCAM (Epi-
thelial cell adhesion molecule [Homo sapiens] GenBank: 
AAH14785.1), which is over expressed in primary and 
metastatic colon cancers, including stem cells [G85-87]. We 
have developed a novel 2'-F 3WJ library system based on 
RNA nanotechnology to select 2'-F RNA aptamers using 
SELEX[G88-89]. We used this library and successfully 
isolated RNA aptamers with an unusually strong binding 
affinity for colon cancer EpCAM receptor (FIG. 16). 
1.3 Design RNA Constructs Harboring Therapeutic Mod-
ules siRNA/Anti-miRNA 
For proof-of-concept of our image-guided drug delivery 
system, we will incorporate siRNAs targeting luciferase and 
evaluate the effects in HT29 or KM20 colon cancer cells 
50 
tively induce cell apoptosis in KB cells (FIG. 20). 
1 .4: Characterize Biochemical and Biophysical Properties 
of RNA Nanoparticles 
The pRNA-3WJ scaffold harboring different functional 
modules retain their folding and independent functionalities 
of all incorporated modules9 •10 . Nevertheless, we will char-
55 acterize biochemical and biophysical properties of RNA 
constructs from Section 1.1-1.3 using well-established 
methods: (1) assay RNAnanoparticle folding and assembly 
using native gels[G9,G10]; (2) assessment of Tm by quan-
titative PCR with SYBR Green, temperature gradient gels, 
60 or UV absorbance [G9,G10]; (3) assessment of Kn by 
competition assays using radiolabeled/fluorescent labeled 
RNA[G9] or SPR; (4) evaluate chemical stability (after 2'-F 
modifications) by incubating RNA with RNase or 10% FBS 
expressing luciferase. To enhance apoptosis of cancer cells, 65 
several groups have tried repeated transfection of siRNA 
into cells [G90]. However, repeated administrations or high 
[G9,G13]; (5) examine resistance to denaturation by 2-8 M 
urea in denaturing gels[G9,G10]; (6) structural character-
ization by AFM imaging[G9-ll]; secondary structure pre-
diction by "m-fold" algorithm [G99]; (7) radiochemical 
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stability assays. Briefly, RNA nanoparticles will be initially 
examined in PBS (pH 7.4), PBS with 1 mM EDTA and in 
serum at 37° C. Samples of the radiolabeled nanoparticle 
solution will be removed at various time points over a 24 hr 
period and examined by HPLC for evidence of degradation 5 




on one end and quencher on the other (FIG. 4A). The 
fluorophore and the quencher are held in close proximity 
resulting in none or low fluorescence signal. Upon hybrid-
ization with a perfectly matching complementary RNA 
target, the 'reporter' fluorophore and quencher separate and 
fluorescence is restored. Our RNA-3WJ-Beacon that con-
tains a 'reporter' fluorophore darkened by a quencher in 
close proximity will elicit a fluorescence signal upon cleav-
age of the incorporated siRNA/miRNA by Dicer in the cell 
10 (FIG. 21). The 'reference' probe (either fluorescent dye or 
radiolabel) is present on another strand of the 3WJ complex 
and remains active regardless of the conformation of the 
RNA nanoparticles. 
Evaluation ofpRNA-3WJ-Beacon Constructs by NIRF and 
PET/SPECT Imaging in Colon Cancer Model System 
This study focuses on construction of the RNA-3WJ-
Beacon harboring targeting ligands, therapeutic siRNA/anti-
miRNA, and imaging agents to track the delivery and image 15 
therapeutic responses non-invasively by NIRF and PET/ 
SPECT in colon cancer mouse models. Detailed histological 
assays of tumors will be carried out to verify the in vivo 
non-invasive imaging evaluation. RNA-3WJ-Beacons will 
2.1: In Vitro Characterization of RNA-3WJ-Beacon-(FA 
or EpCAM Aptamer)-(siRNA or Anti-miRNA) in Colon 
Cancer Cells 
2.1.1 Assay Specific Cell Recognition and Entry of Mul-
tifunctional RNA-3WJ-Beacon: 
The RNA-3 WJ-Beacon carrying FA ( or EpCAM aptamer) 
will recognize HT29 colon cancer cells specifically and 
internalize into the cells through receptor mediated endocy-
tosis. The binding and internalization ofRNA-3WJ-Beacon 
will be examined by flow cytometry, and confocal micros-
be constructed, combining the robust features of the pRNA- 20 
3WJ delivery platform with the functional components of 
molecular beacons and therapeutic siRNA/anti-miRNA as 
well as cancer targeting ligands, all in one nanoconstruct 
(FIG. 4). Upon target recognition, the RNA-3WJ-Beacon 
will generate a 'reporter' imaging signal, which in combi-
nation with a 'reference' imaging module will enable us to 
track the distribution and transport of RNA therapeutics in 
vivo. We have successfully generated orthotopic and meta-
static colon cancer mouse models to evaluate the RNA 
constructs in vivo. 
25 copy, with appropriate controls (FIG. 15-16). These assays 
are well established in [G9-11,G22,G23]. IRdye 800 has 
excitation/emission maxima at 774 mn/789 nm, while 
Alexa647 has excitation/emission maxima at 647 nm/668 
nm. 177 Lu, 111 In or 64Cu radionuclides will serve as 
30 alternative 'reference' imaging modules to track the RNA-
3WJ-Beacons in vivo. Significant challenges exist in detecting endogenous gene 
expression and silencing in vivo, including probe design, in 
vivo delivery, specific targeting, and probe sensitivity. 
Molecular beacons to image intracellular RNA expression in 
vitro by competitive hybridization method have been 
reported[Gl00-108], but they were done in solutions with 
defined molecular beacon-target conditions. Although these 
studies showed the feasibility of detecting mRNAs and 
monitoring the transportation of RNAs in cells, the proce-
dure for delivery of the molecular beacons through micro-
injection or by liposome delivery has made it difficult to 
apply this promising technology into broad research areas or 
into a routine clinical procedure. Challenges include: (1) 
nuclease degradation of RNA or DNA in vivo; (2) low 
signal-to-background ratio; (3) inefficient competitive 
hybridization due to steric hindrances; and ( 4) lack of cell 
specificity; and (5) inefficient delivery due to non-specific 
accumulation in liver and lungs. To overcome these prob-
lems, we have developed an innovative RNA-3WJ-Beacon 
platform (FIG. 4B) that incorporates the functionality of 50 
molecular beacons into the robust pRNA-3WJ delivery 
system that displays highly efficient cancer targeting capa-
bilities with little accumulation in normal organs such as, 
liver, lungs, and kidneys. Upon target recognition, the RNA-
3WJ-Beacon will generate a 'reporter' imaging signal, 55 
which in combination with 'reference' imaging module will 
enable us to track the distribution and transport of the 
therapeutics RNA nanoparticles in vitro and in vivo using 
our well-established colon cancer model system. Our RNA 
constructs are polyanionic in nature and can therefore avoid 60 
nonspecific cell entry across the negatively charged cell 
membranes[G67-70]. In addition, they can deliver therapeu-
tics to cells after incubation as opposed to transfection and 
microporation, typically used in other systems [G101,G103, 
G 105,G 106,G 109,G 11 OJ. 
Conventional molecular beacons are stem-loop (hairpin) 
structures of oligonucleotide dual-labeled with a fluorophore 
2.1.2 Assay the Gene Silencing Effects of Multifunctional 
RNA-3WJ-Beacons: 
The RNA-3WJ-Beacon-(FAor EpCAM aptamer)-(siRNA 
35 or anti-miRNA, from Section 1.3 describe in Example 2) 
with appropriate scramble controls will be incubated with 
colon cancer cells without transfection reagents. Once inter-
nalized into the cells and released from the endosome, the 
RNAi Induced Silencing Complex (RISC) will bind to the 
40 branch of pRNA-3WJ-Beacon containing the siRNA or 
anti-miRNA. If the siRNA/anti-miRNA is processed cor-
rectly, it will be released from the 3WJ complex and away 
from the quencher, thereby restoring the fluorescence of 
'reporter' dye Alexa647 (FIG. 21). The released siRNA/anti-
45 miRNA will trigger knockdown of the target gene in a 
dose-dependent manner, which can be tracked in real-time 
by monitoring the fluorescence of 'reporter' dye Alexa647 , 
following published procedures[G 101,G 102,G 105,G 109]. 
The gene knock-down effects will be validated by functional 
assays: 
For quantification of luciferase siRNA silencing effects, 
we will use HT29-Luciferase expressing cells and image the 
cells using IVIS Spectrum system. The luminescence inten-
sity, photon counts per second from each well will be 
recorded and plotted. Cell numbers will be quantified by 
staining with sulforhodamine B (SRB) assay, as described in 
our publications[Gl0,Gll] The relative luciferase activity 
will be used to reflect the expression level of firefly 
luciferase gene by normalizing the firefly luciferase activity 
with SRB readouts. For survivin siRNA, we will use RT-
PCR and Western blot to determine gene expression at 
mRNA and protein levels, respectively, similar to our pre-
vious publications [G9,G10,G21-23]. The effects of RNA 
nanoparticles on cell growth and apoptosis will be assayed 
65 by routine assays [G9,G10,G21-23], such as WST-1, 
TUNEL, in situ caspase activity, DNA fragmentation, and 
Annexin V /PI staining. 
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For evaluating miR-21 knockdown, at different time 
points, the incubation efficiency will be monitored by fluo-
rescence microscopy or in situ hybridization with miR-
CURY™ LNA detection probes, following established pro-
tocols[G 111]. We will isolate and analyze the total RNA for 5 
miR-21 levels using real-time PCR. The functionality of 
miR-21 on its validated targets (ex. PTEN, PDCD4, RECK) 
will be assayed by RT-PCR at the mRNA level and Western 
blot at the protein level or immunostaining. 
Without being bound by theory, the Alex647 dye that is 10 
attached to the 3'-end of siRNA or anti-miRNA (FIG. 12) 
may interfere with the siRNA or miRNA function. This can 
44 
in normal organs and tissues (FIG. 22). The experimental 
designs will include: (1) pRNA-3WJ-Beacon-(FA or 
EpCAM aptamer)-(siRNA/anti-miRNA); (2) pRNA-3WJ-
Beacon-(w/o targeting ligands); and (3) pRNA-3WJ-Bea-
con-(FA or EpCAM aptamer)-(scrambled siRNA/anti-
miRNA). The frequency of dosing required to achieve tumor 
growth inhibition will be determined empirically and will be 
monitored over time by whole body NIRF and PET/SPECT 
imaging before sacrificing the mice. 
Based on previous radionuclide experiences, we will 
inject -0.5-1.5 mCi of radiolabeled (177Lu, 111 In or 65Cu) 
RNA-3WJ-Beacon into the tail vein of each mouse[G73, 
G74,G76,G119,G120]. Imaging time points and duration of 
acquisitions will be dependent on radionuclide half-life and 
be solved by alternating the sense or anti sense strand of the 
siRNA. It has been shown that modification of sense or 
antisense strands on the siRNA made a difference on the 
efficiency of gene silencing[G112]. (2) To account for non-
specific RNA-3WJ-Beacon effects, we will implement pub-
lished procedures used to determine the extent of non-
specific opening using ratiometric analysis [G113]. Briefly, 
the fluorescence ratio (total integrated 'reporter' fluores-
cence/total integrated 'reference' fluorescence) will be com-
pared with same RNA-3WJ-Beacon samples prior to intra-
cellular delivery. (3) The extent of conventional molecular 
beacon binding to target mRNA is highly dependent on the 
selection of target sequences and their accessibility[G103]. 
Our RNA-3WJ-Beacon construct design does not utilize a 
hairpin with extended sequences. Once Dicer processes the 
siRNA off the 3WJ, the siRNA retains its authentic size and 
shape (-21 nt dsRNA) for optimum function. 
15 biodistribution data. Whole body small animal SPECT and 
PET images will be obtained on a Siemens INVEON mul-
timodality SPECT/CT system combined with a docking 
Siemens INVEON PET system (FIG. 23). Anatomical imag-
ing and X-ray computed tomography (CT) will be per-
Alternative Approaches: 
(1) In one embodiment, a disulfide linkage between the 
siRNA strand and 3WJ core complex will be incorporated. 
In presence of a reductive environment in cytoplasm, the 
disulfide bond will cleave and trigger activation of the 
siRNA and conjugated 'reporter' fluorescence[G104]. (2) 
We will employ a photo-decaging strategy using photo-
cleavable linkers, whereby the molecular activity of the 
molecular beacon is masked by a photo-responsive caging 
group and then recovered by specific light irradiation at a 
designated time and location[G114]. In another embodi-
ments, Acid-labile linkers will be used between the siRNA 
strand and 3WJ core complex. 
2.1.3 Determine the Toxicity Profiles of RNA-3WJ-Bea-
con Harboring FA (or EpCAM Aptamer), siRNA, (or Anti-
miRNA) In Vitro: 
20 formed immediately prior to the PET study. 
Organ and tumor imaging, full necropsy, and histological 
profiles will be conducted to evaluate tumor regression, 
tumor growth delay, survival time extension, and tumor-free 
cures. Detailed target gene expression profiles for siRNA 
25 and anti-miRNA mediated therapies will be determined on 
both mRNA and protein levels (see Section 2.1.2). 
2.2.2 Orthotopic Model: 
Orthotopic models more closely mimic the microenviron-
ment of the tumor, since cancer cells grow in their natural 
30 location and therefore replicate colon cancer with high 
fidelity. We will generate several orthotopic xenografts in 
nude mice by injecting lxl06 HT29 cells expressing 
luciferase directly into the cecum of nude mice after surgical 
procedures (laparotomy for exposure of the cecum). The 
35 tumor growth will be monitored by bioluminescence imag-
ing (FIG. 24A). The promising RNA constructs from sub-
cutaneous xenograft assays will then systemically injected in 
mice monitored over time by whole body fluorescence and 
PET/SPECT imaging before sacrificing the mice, as 
40 described in Section 2.2.1. 
Alternative Approach: 
Xenografts derived directly from patients have better 
retention of the morphological features, such as human 
stroma and are more heterogeneous than tumors derived 
45 from established cell lines, and, therefore, represent impor-
tant in vivo models. We will generate orthotopic xenografts 
using these heterogeneous patient-derived tumor cells and 
evaluate the therapeutic effects of our RNA nanoparticles. 
An issue concern regarding the evaluation of RNA inter-
ference is the activation of innate immune responses[G 115-
117]. We have shown that our pRNA nanoparticles display 
favorable pharmacological profiles[G12]. We will use RT-
PCR analysis, ELISA, and flow cytometry to scout for the 50 
activation of protein kinase R (PKR), toll-like receptor 
(TLR) and interferon (INF) pathways in human peripheral 
blood mononuclear cells (PBMC)[G12,G118] (FIG. 25). 
Cell proliferation (MTT) and apoptosis assays (TUNEL) 
will also be performed to assay for cytotoxic effects. 
2.2.3 Metastasis Model: 
We will test whether our new RNA constructs can be used 
to track down colon cancer metastasis. Liver metastasis will 
be established by injecting HT29 cells expressing luciferase 
directly into the spleen or the wall of the cecum and 
monitored by bioluminescence imaging (FIG. 21A). Pre-
55 liminary data demonstrated that after systemic injection in 
mice, Alexa647-labeled pRNA-3WJ nanoparticles efficiently 
targeted HT29 liver metastatic cells, but not the normal liver 
parenchyma cells (FIG. 24). The RNA-3WJ-Beacon will be 
2.2 Validation of Our Multivalent RNA Nanoparticles In 
Vivo Using Mouse Models 
2.2.1 Subcutaneous Xenograft Model: 
Subcutaneous xenograft are good model systems since 
they mimic the tumor-extracellular matrix interactions, 60 
inflammation and angiogenesis. We will establish subcuta-
neous xenografts first by injecting lxl06 HT29 tumor cells 
directly into the flank and then intravenously inject the 
multifunctional RNA constructs. Preliminary data demon-
strated that Alexa647 labeled pRNA-3WJ-Folate constructs 65 
can efficiently target subcutaneous HT29 colon cancer xeno-
grafts in mice after systemic injection without accumulating 
injected intravenously and monitored over time by whole 
body NIRF and PET/SPECT imaging before sacrificing the 
mice, as described in Section 2.2.1., described here in 
Example 3. 
Without being bound by theory, targeting a single path-
way, such as anti-apoptotic machinery may not result in 
significant tumor regression in vivo. We will therefore 
evaluate cocktail treatment strategies using multifunctional 
RNA constructs harboring siRNA/anti-miRNA. (2) For in 
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vivo delivery of RNA therapeutics, an important consider-
ation is endosome escape. We are currently developing a 
'click chemistry' approach to incorporate endosome disrupt-
ing agents (for proton sponge effect) to our 3WJ scaffold. (3) 
Lack of an immune system in SCID mice can profoundly 5 
affect tumor development and progression. We will use 
IL2rg_1_ NOG (NOD-SCID IL2rg_1_) mice, which can be 
readily humanized using hemopoietic stem cells. After 
establishing orthotopic xenografts in mice, we will inject 
human PBMCs, and bone marrow to develop functional 10 
blood and immune systems[G121]. We can then systemi-
cally inject the RNA constructs and assay the therapeutic 
effects. 
46 
lation time, slowed down molecular rotation which resulted 
in a short relaxation time, and increase in relaxivity, and this 
in tum improved resolution and sensitivity. 
Without being bound by theory, if the negatively charged 
RNA polymer can replace PAMAM and PPI to build den-
drimers, it will avoid the interaction with negatively charged 
cell membrane and will not trigger non-specific cell entry 
and associated toxicity [G134,G135]. The body treats RNA 
as a material of its own and will reduce liver/lung accumu-
lation due to phagocytosis. Compared to other chemical 
polymers, the degradation of RNA can be timely controlled 
by adjusting the percent and location of chemically modified 
stable nucleotides [G13,G56-58]. Furthermore, our RNA-
based Dendrimer-Gd(III)-chelate complex will retain the 2.2.4 Assessment of Biodistribution and Pharmacokinetic 
Profiles in Mice: 
Our pRNA scaffold display favorable pharmacological 
profiles: 10-fold (5-10 hrs) enhancement in half-life com-
pared to regular siRNA counterparts (0.25-0.75 hrs); CL of 
<0.13 L/kg/hour; V d of 1.2 L/kg; non-induction of inter-
feron-I or cytokine production in mice. Repeated intrave-
nous administrations in mice, up to 30 mg/kg, did not result 
in any toxicity (FIG. 25) [G12]. Previous studies were done 
using Alexa647 labeled RNA nanoparticles, and due to 
quenching by the blood, the overall uptake by tumors and 
organs can be underestimated. We will add an additional 
radiolabel component (177Lu, 111 In or 64Cu) to quantita-
tively assess the biodistribution (organ and tumor accumu-
lation), PK/PD, and toxicity profiles of RNA constructs, 
following our previous publications [G12,G76,G77]. The 
percent injected dose per gram(% ID/g) and percent injected 
dose (% ID) will be calculated for each tissue. 
15 reported favorable attributes of the pRNA-3WJ nanopar-
ticles[G9-12], such as thermodynamic stability, desirable 
pharmacokinetic profiles including free of normal organ 
accumulation and strong cancer targeting, non-toxic nature, 
and well-defined structure (monodisperse), while providing 
20 additional high relaxivity properties of MRI contrast agents. 
3.1 Construction of RNA Dendrimers Using pRNA-3WJ 
Motif Harboring Gadolinium Contrast Agents, Radionu-
clides and Targeting Ligands 
We previously applied a RNA nanotechnology based 
25 bottom-up approach to construct large macromolecular 
assemblies of RNA nanoparticles by branch extension of 
pRNA-3WJ motif (FIG. 26)[Gll]. More recently, we solved 
the crystal structure of the pRNA-3WJ scaffold 14 , which will 
facilitate the design of RNA Dendrimers. The 3 WJ motif is 
Example 4 
30 a highly programmable building block and can be used to 
generate square shaped architectures (consisting of 3WJ 
motifs at each comer) to serve as GO core. The square shape 
will eliminate any steric hindrances that may arise in the 
Design pRNA-3WJ Dendrimers to Carry MRI Contrast 35 
Agent and Radionuclides for Imaging in Colon Cancer 
Mouse Models 
course of building higher-ordered structures. A step-wise 
iterative assembly approach will then be applied via intra-
molecular interactions between pRNA-3WJ motifs to con-
struct highly branched Generation-3 (G3) RNA Dendrimers 
with precise control of size (-60 nm), shape (3D globular) 
and stoichiometry (FIG. 26). From Section 1.1-1.2 of 
This study focuses on construction of RNA Dendrimers 
harboring targeting ligands, contrast agents for MRI, and 
radioisotopes for PET/SPECT imaging and evaluate their 
functionalities non-invasively in colon cancer mouse mod-
els. 
40 Example 2 we will have constructed pRNA-3WJ harboring 
NIR fluorophores, radionuclides, galodinium contrast agents 
and folate targeting ligand. These functionalized pRNA-
3WJ units will be placed with control at any desired location 
within the G3 construct to generate multifunctional G3 RNA 
MRI is a powerful imaging modality owing to its non-
invasive nature, superb spatial resolution at the sub-milli-
meter range, and excellent potential for longitudinal stud-
ies109·122. Contrast agents have been employed to enhance 
the sensitivity of the MRI scan. Clinically used FDA-
approved low molecular weight contrast agents, such as 
Gd(DTPA) (Magnevist®) or Gd(DOTA) (Dotarem®) suffer 
from non-specificity; relative low signal enhancing effects; 
rapid extravasation from the blood vessels; and fast elimi-
nation from the circulatory system. Therefore they often 
require repeated administrations and high dosages, which in 
turn induces false-positive contrast enhancements and Gd-
mediated toxicity (Nephrogenic Systemic Fibrosis)[G123]. 55 
45 Dendrimers harboring gadolinium for MRI, radionuclides 
for PET/SPECT imaging and folate, as a targeting ligand 
(FIG. 26). 
Our approach does not require any linkers, such as PEG 
which has been used in higher-ordered Dendrimers to 
50 increase Gd-payload, but with modest increase in relaxivity 
( due to large amount of internal motion caused by PEG 
linkers within Dendrimers)[G124]. In addition, our con-
struct can be labeled with Gd-chelates on the outer surface 
In recent years, extensively branched 3D structures called 
dendrimers have become an attractive platform for building 
multifunctional macromolecular nanomaterials as diagnos-
tic and therapeutic agents[G124-131]. MRI contrast agents 
composed of multiple Gd(III) chelates assembled on a 60 
dendrimer platform are much more efficient and effective in 
modulating the longitudinal relaxation rate and time of water 
protons, as compared to a single chelate unit analogue 
[G109]. This was demonstrated with Gd(III) chelates to high 
molecular weight carrier poly(amidoamine) (PAMAM) and 65 
poly(propyleneimine) (PPI) dendrimers [G125,G127,G129, 
G131-133] that prolonged intravascular retention and circu-
as well as inner core (which is readily accessible to water), 
thereby ensuring higher Gd payloads without any cross-
linking, such as those recently used to generate Dendrimer 
porous nanoclusters[G124]. This in tum will reduce the dose 
(lower than 0.2 mmol/kg that is clinically used for Magn-
evist™) employed for in vivo imaging and associated metal 
toxicities. Finally, RNA Dendrimer constructs allow inte-
gration of targeting and imaging modules leading to the new 
design of targeted contrast agents. 
We will conjugate Gd(DOTA) to our RNA Dendrimers 
(see Section 1.1.3 of Example 2 for conjugation), which is 
known to be a better contrast agent in terms of chemical 
stability ( dissociation of the metal ion was exceedingly slow 
even at low pH (2-4), on the order of days) and thus 
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potentially less toxic as compared to Gd(DTPA)[G136]. The 
assembly of RNA Dendrimers will be verified by gel assays 
and AFM (see Section 1.4 of Example 2). Transmission 
Electron Microscopy (TEM) will then be used to confirm the 
labeling of RNA Dendrimers with Gd. Since Gd ions are 5 
electron dense, RNA-Gd Dendrimers can be directly imaged 
on a carbon-coated copper grid without any additional 
staining reagents. 
3.2 In Vitro Characterization of RNA Dendrimers 
3.2.1. Molar relaxivity measurements: Relaxivity 10 
expresses the ability of a paramagnetic material to perform 
48 
surrounding muscle. Over time, specific signal enhancement 
will be observed from the tumors compared to surrounding 
tissues. Blood clearance rates will be determined from 
intensity measurements of the jugular vein. Alternatively, 
blood samples will be collected at various time points and 
analyzed for Gd content. Detailed biodistribution and phar-
macokinetic properties will be evaluated, following our 
publication[G12] and as described in Example 3 at Section 
2.2.4. 
Due to the multimodal nature of the RNA Dendrimers, the 
targeting of tumors and metastatic cells can be further 
verified by fluorescence (using Alexa647) and SPECT/PET 
(using 177Lu, 111 In or 64Cu) imaging. There is a critical need 
in medical imaging to co-register functional PET images 
with MRI that offers detailed anatomical structures. PET 
offers highest tumor detection sensitivity because of the use 
of radiotracers. However, tumor sites with high radioactivity 
cannot be accurately located in the abdomen or near the 
boundary of a moving organ owing to a lack of anatomical 
structure in PET images. MRI offers excellent soft-tissue 
contrast and thus facilitates tumor localization in co-regis-
tered MRI and PET images. 
Example 5 
This study relates to programmable self-assembly of 
branched, 3D globular, monodisperse and nanoscale sized 
dendrimers using RNA as building blocks. The central core 
and repeating units of the RNA dendrimer are derivatives of 
the ultrastable three-way junction (3WJ) motif from the 
bacteriophage phi29 motor pRNA. RNA dendrimers were 
constructed by step-wise self-assembly of modular 3WJ 
building blocks initiating with a single 3WJ core (Genera-
tion-0) with overhanging sticky-end and proceeding in a 
as a MRI contrast agent. The water proton relaxation 
enhancement by the Gd compound is dependent on the 
concentration. It is quantitatively described by the equation 
(1/T 1)=(1/T 1 )+rl [Gd], where T 1 is the relaxation time of the 15 
water proton: T 10 is the water proton relaxation time of pure 
water, [Gd] is the concentration of the gadolinium com-
pound, and rt is defined as the compound's relaxivity. The 
relaxivity of a gadolinium compound can be quantitatively 
described by the Solomon-Bloembergen-Morgan theory137 . 20 
The simplified model is represented by the equation rl =qP ml 
(Tlm+-cm), where Pm is the concentration of water proton, 
which is constant, q is the hydration number (the number of 
water molecules bound to each Gd cation), and -cm is the 
lifetime of the bound water molecule. Finally, Tim is a fitted 25 
parameter (the bound water proton relaxation time), and is 
decided by factors such as the strength of the magnetic field 
and the size of the Gd compound. The Solomon-Bloember-
gen-Morgan theory precisely predicts the performance of the 
Gd-based MRI contrast agents and aids the design of con- 30 
trast agents with high relaxivity and 'smart' characteristics. 
The relaxivity and relaxation rate constants of the RNA-Gd 
Dendrimers will be compared to commercial contrast agent 
Dotarem® at different magnetic field strengths and solution 
conditions. 35 radial manner in layers up to Generation-4. The final con-
structs were generated under control without any structural 
defects in high yield and purity, as demonstrated by gel 
electrophoresis and AFM imaging. Upon incorporation of 
3.2.2. Assay Cell Binding and Uptake: 
To confirm the folate receptor targeting capabilities of the 
multifunctional RNA Dendrimers, HT29 colon cancer cells 
will be incubated with RNA Dendrimer-Gd-FA-Alexa647 
constructs, with appropriate controls and subsequently ana- 40 
lyzed by flow cytometry and confocal fluorescence micros-
copy (FIG. 15-16), as described in Example 3 at Section 2.1. 
Cell proliferation (MTT) and apoptosis (TUNEL) assays 
will also be performed to assay for specific cytotoxic effects. 
To further investigate the MRI contrast capabilities, HT29 45 
cells will be incubated with RNA Dendrimer-Gd-FA-Al-
folate on the peripheral branches of the RNA dendrimers, the 
resulting constructs showed high binding and internalization 
into cancer cells. RNA dendrimers are envisioned to have a 
major impact in targeting, disease therapy, molecular diag-
nostics and bioelectronics in the near future. 
Methods 
RNA Synthesis and Purification: 
RNA oligonucleotides were prepared by chemical syn-
thesis using a oligo synthesizer, custom ordered from Trilink 
Biotechnologies, Inc. (San Diego, Calif., USA) or generated 
by in vitro transcription of respective PCR amplified dsDNA 
exa647 constructs and assessed by acquiring Tl-weighted 
magnetic resonance images of HT29 cells that pelleted in 
PCR tubes. HT29 cells in presence of Gd will exhibit a 
significant enhancement in MR signal intensity compared 
with control cells. 
3.3 Characterization of RNA Dendrimers in Colon Cancer 
Mouse Models 
50 containing the T7 promoter46 . RNA strands were purified by 
HPLC or by 8% Urea-PAGE. Single-stranded DNA tem-
plates and primers were purchased from Integrated DNA 
Technologies (Coralville, Iowa, USA). 
An advanced 3T Siemens Magnetom Trio scanner with 
high performance gradients, echo-planar whole body imag- 55 
ing and hydrogen spectroscopic capabilities for both human 
and animal studies. For dedicated animal studies, a modern 
Brnker/Siemens 7T MR scanner will be used [G138,G139] 
(FIG. 27) to evaluate our RNA Dendrimers. 
We will generate subcutaneous, orthotopic and metastatic 60 
colon cancer mouse models (see Section 2.2, described in 
Example 3) to evaluate the multifunctional RNA Dendrimer-
Gd-Folate-radiolabel constructs, with appropriate controls. 
Axial MR images of mice harboring tumors will be acquired 
pre-contrast and at various time-points after intravenous 65 
injection of RNA Dendrimers. In the pre-contrast images, 
there will be little intrinsic contrast between the tumors and 
Construction of G-0 to G-4 Dendrimers: 
Dendrimers structure G-0, G-1, G-2 and G-3 were con-
structed using one-pot self-assembly of component strands 
(see sequences below). For G-0, the three component strands 
(3WJ-a):(3WJ-b):(3WJ-c)=l:1:1 molar ratio; For G-1, the 
five component strands (SquareA): (SquareB):(SquareC): 
(SquareD):(SquareE)=l:1:1:1:1 molar ratio. For G-2, the 
seven component strands (b-SquareA):(b-SquareB):(b-
SquareC):(b-SquareD):(SquareE): (3WJ-a):(3WJ-c )=1: 1: 1: 
1:1:4:4 molar ratio. For G-3, the nine component strands 
(b-SquareA):(b-SquareB):(b-SquareC):(b-SquareD):(Squa-
reE):(3WJ-c-b_rev):(3WJ-a-b_rev):(3WJ-a_rev): (3WJ-
c_rev)=l: 1: 1:1:1 :4:4:8:8 molar ratio. The required den-
drimer RNA strands were mixed together in stoichiometric 
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ratio in TMS buffer (25 mM Tris, 50 mM NaCl, 5 mM 
MgC12 ) and the mixture was heated to 95° C. for 5 min and 
then slowly cooled to 4° C. at a rate of 2° C./min on an 




(SEQ ID NO, 11) 
GGG ACC AGC CAA UCA UGG CAA UAU ACA CGC AUA CUU 
fied using 8% native PAGE or 2% agarose gel. 5 
For the construction of G-4 dendrimer, a two-step 
approach was used. First, the dendrimer nanostructure G-2 
with sticky ends was constructed by mixing together 
required RNA strands with appropriate stoichiometry in 
TMS buffer. The mixture was heated to 95° C. for 5 min and 10 
then slowly cooled as described above for the construction 
ofG-1, G-2 and G-3 dendrimer generations. The free strands 
were removed by passing the mixture through Amicon 
Ultracentrifugal spin filters with 100 KDa cut off following 
manufacturer protocol and washed twice with TMS buffer. 15 
The pure G-2 with sticky ends was collected from colunm. 
UGU UGA CGG CGG 
( 12) SquareE, 
( SEQ ID NO, 12) 
GGA CAC UUG UCA UGU GUA UGC GUG UAU AUU GUC AUG 
UGU AUG CUC UAU CGU UGU CAU GUG UAU GCG AUG CGC 
UUG UCA UGU GUA UGG C 
(13) b-SquareA, 
( SEQ ID NO, 13) 
GGC CCA CAU ACU UUG UUG AUC CAU GGU GCG UAG GGU 
In second step, the G-2 with sticky ends was mixed in 
stoichiometric ratio with other RNA strands needed to form 
G-4. The final molar ratio of the 11 G-4 component strands 
CGU CAA UCA UGG CAA GUG UCC GCC AUA CUU UGU UGC 
ACU CCC UUG CUC AUC A 
are (b-SquareA):(b-SquareB):(b-SquareC):(b-SquareD): 20 (14) b-SquareB, 
(SquareE):(3WJ-c-b_rev):(3WJ-a-b_rev):(3WJ-b-a_rev): 
(3WJ-b-c_rev):(3WJ-a):(3WJ-c )=1: 1: 1: 1: 1 :4:4:8:8: 16: 16. 
The mixture was incubated at room temperature for 1 hour. 
Then, an agarose gel was run to check assembly efficiency. 
G-4 was constructed with a maximum final concentration of 
1 µM in TMS buffer. 
The sequences of all the strands of the RNA dendrimers 
are as follows (Sequence 5'----;.3'): 
(1) 3WJ-a, 
(SEQ ID NO, 1) 
UUG CCA UGU GUA UGU GGG 
( SEQ ID NO, 14) 
GGC CCA CAU ACU UUG UUG AUC CUG AUG AGC AAG GGA 
GUG CAA UCA UGG CAA GCG UAU CGC AUA CUU UGU UGA 
25 GAA CCC UAU GUG ACU U 
(15) b-SquareC, 
(SEQ ID NO, 15) 
GGC CCA CAU ACU UUG UUG AUC CAA GUC ACA UAG GGU 
30 UCG CAA UCA UGG CAA CGA UAG AGC AUA CUU UGU UGG 
AGU CCC UUA GAG UAG A 
(16) b-SquareD, 
(2) 3WJ-b, (SEQ ID NO, 16) 
(SEQ ID NO, 2) 35 GGC CCA CAU ACU UUG UUG AUC CUC UAC UCU AAG GGA 
CCC ACA UAC UUU GUU GAU CC 
(3) 3WJ-c, 
GGA UCA AUC AUG GCA A 
(4) 3WJ-a rev, 
GGG UGU AUG UGU ACC GUU 
(5) 3WJ-b rev, 
(SEQ ID NO, 3) 
(SEQ ID NO, 4) 
CUC CAA UCA UGG CAA UAU ACA CGC AUA CUU UGU UGA 
CGA CCC UAC GCA CCA U 
(17) 3WJ-a-b rev, 
40 ( SEQ ID NO, 1 7) 
UUG CCA UGU GUA UGU GGG CCU AGU UGU UUC AUA CAC 
cc 
(SEQ ID NO, 5) (18) 3WJ-c-b rev, 
CCU AGU UGU UUC AUA CAC CC 45 (SEQ ID NO, 18) 
(6) 3WJ-c rev, 
(SEQ ID NO, 6) 
AAC GGU ACU AAC UAG G 
(7) 3WJ-c-folate, 50 
GGA UCA AUC AUG GCA A CCU AGU UGU UUC AUA CAC CC 
(19) 3WJ-b-a rev, 
(SEQ ID NO, 19) 
CCC ACA UAC UUU GUU GAU CC GGG UGU AUG UGU ACC 
(SEQ ID NO, 7) GUU 
GGA UCA AUC AUG GCA A - folate 
(8) SquareA, 
(SEQ ID NO, 8) 
GGG AGC CGU CAA UCA UGG CAA GUG UCC GCC AUA CUU 
UGU UGC ACG CAC 
(9) SquareB, 
(SEQ ID NO, 9) 
GGG AGC GUG CAA UCA UGG CAA GCG CAU CGC AUA CUU 
UGU UGC GAC CUA 
(10) SquareC, 
(SEQ ID NO, 10) 
GGG AGG UCG CAA UCA UGG CAA CGA UAG AGC AUA CUU 
UGU UGG CUG GAG 
55 
(20) 3WJ-b-c rev, 
(SEQ ID NO, 20) 
CCC ACA UAC UUU GUU GAU CC AAC GGU ACU AAC UAG G 
Gel Analysis: 
RNA dendrimers were analyzed using 2% agarose gel and 
6-8% PAGE. The gels were prepared and ran in TMS buffer 
at 90 V for 1 hr. The gels were stained with ethidium 
60 bromide and scamied using Typhoon FLA 7000 (GE Health-
care, Cincinnati, Ohio, USA). 
AFM Imaging: 
Dendrimer structures were imaged using APS modified 
mica surfaces with a Multi-Mode AFM Nano-Scope IV 
65 system (Veeco/Digital Instruments, Town of Oyster Bay, 
N.Y., USA), operating in tapping mode, as described pre-
viously47. 
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Serum Stability Assay: 
The chemical stability ofRNAdendrimers was studied by 
incubating the dendrimers with 50% Fetal Bovine Serum 
(FBS) at 37° C. at final concentration of 1 µM. 10 µL of 
samples were collected at each time point (0, 0.16 hr, 1 hr, 
3 hr, 6 hr, 18 hr, and 24 hr) and were subjected to a 2% 
agarose gel assay with TBM running buffer. The gel was run 
52 
ends thereby generating module-2 with high efficiency (FIG. 
29). Module-2 is composed of 5 component strands and has 
6 terminal ends. 
Similarly, module-3 was constructed from iterative step-
5 wise assembly on top of module-2 complexes by branch 
extension using one of the 3WJ component strands as sticky 
ends. The final complex is composed of 7 strands and 12 
terminal ends with alternating pRNA-3WJ core and pRNA-
3WJ-rev cores (FIG. 29). 
at 120 V for 120 minutes, imaged by Typhoon FLA 7000 
(GE Healthcare, Cincinnati, Ohio, USA), and gel bands 
10 quantified by Image J. All three modules can be assembled either in one step or 
step-wise by simply mixing the strands at room temperature 
in TMS buffer (40 mM Tris, 10 mM MgCl2 , 100 mM NaCl) 
or by annealing (heating to 95° C. and cooling to room 
temperature over the course of 1 hour). The use of these 
Flow Cytometry Analysis: 
Folate receptor ( +) KB Cells were cultured in T75 flask 
and harvested at a density of lxl06 cells/ml with 0.25% 
trypsin. Cells were washed with Opti-MEM medium once 
and then incubated with different concentration of Cy5 
labeled 2'-F RNAdendrimers in Opti-MEMmedium for 1 hr 
at 37° C., protected from light. Cells were then washed three 
times and suspended in PBS (137 mM NaCl, 2.7 mM KC!, 
100 mM Na2 HPO4 , 2 mM KH2PO4 , pH 7.4) for analysis. 
Confocal Imaging: 
KB cells were grown in cover glass (Thermo Fisher 
Scientific, Waltham, Mass., USA) in 24 well bottom culture 
dishes in its complete medium overnight. Cells were seeded 
at a density of 2xl 05 cells/ml in a volume of 500 µI. On the 
day of testing, cells were washed with Opti-MEM medium 
twice, and RNA dendrimer (with whole chain Cy5 labeled 
SquareE-strand) were suspended in 200 µI of Opti-MEM 
medium and incubated with cells at 37° C. for 1 hr. Cells 
were washed with PBS twice, fixed with 4% paraformalde-
hyde solution (Microscopy Sciences, Hatfield, Pa., USA) in 
PBS at room temperature for 20 min, then washed with PBS 
and permeabilized with 0.05% Triton-X 100 in PBS at room 
temperature for 3 min. The cells were then stained with 
Alexa488 phallodin (Thermo Fisher Scientific, Waltham, 
Mass., USA) at room temperature for 20 min, the wells 
washed with PBS and air dried. The cells were stained with 
gold antifade (Thermo Fisher Scientific, Waltham, Mass., 
USA) for DAPI staining for confocal microscopy imaging 
with Zeiss LSM 510 laser scanning system. 
Results 
Design and Assembly of Parts and Intermediates for RNA 
Dendrimers 
15 modules will enable construction of RNA dendrimers with 
desired functional moieties, such as RNAi reagents siRNA, 
miRNA, anti-miRNA; chemotherapeutic drug; receptor tar-
geting RNA aptamer or chemical ligand; riboswitch; 
ribozyme; endosome disrupting agents; and imaging fluo-
20 rophores or radiolabels (FIG. 30). 
Design and Assembly of RNA Dendrimers G-0 to G-4 
RNA dendrimers have similar architectures as small mol-
ecule based dendrimers consisting of an initiating core, 
interior layer of repeating units, and terminal units at the 
25 peripheral ends of the outermost generation. In the tradi-
tional sense, we adopted a 'divergent growth' method, 
whereby the dendrimer initiates from a core site and grows 
in a radial manner layer by layer. We used the pRNA-3WJ 
as G-0 initiating core (FIG. 29A, 32A-B) and then con-
30 structed a planar square nanoparticle to serve as G-1 (FIG. 
31A, 32A-B). The pRNA-3WJ scaffold is highly tunable and 
the internal angle can be stretched from native 60° to 90° in 
the square configuration, as demonstrated previously30 . The 
pRNA-3WJ cores at each vertex is linked by double 
35 stranded RNA sequences, with the entire square construct 
(G-1) composed of 5 strands and 4 terminal ends (MW -83 
KDa) (FIG. 31A). The square pattern ensures equal spacing 
between the protruding corner branches and minimizes 
steric hindrances for addition of building blocks. We then 
40 adopted a similar strategy as aforementioned using one of 
the 3WJ component strands as sticky ends to sequentially 
construct G-2 (7 unique strands; 8 terminal ends; MW -187 
kDa) (FIG. 318, 32A-B), G-3 (9 unique strands; 16 terminal 
ends; MW -328 kDa) (FIG. 31C, 32A-B) and finally G-4 (11 
unique strands; 32 terminal ends; MW -610 kDa) (FIG. 
31D, 32A-B) (Table 4). G-0 through G-3 dendrimers can be 
assembled with high yield by mixing the component strands 
in equimolar ratio followed by annealing, except for G-4, 
which requires an additional incubation step with module-2 
We developed three modules as building blocks for con-
struction of RNA dendrimers. Module-I is the 3WJ motif 45 
composed of three individual strands (3WJ-a, 3WJ-b and 
3WJ-c) with three terminal ends (FIG. 28A). In order to 
build higher order structures, we need to interconnect the 
3WJ motifs in a radial manner, and this requires using two 
different 3WJs with near identical folding properties to 
avoid cross-talk between layers. Otherwise, misfolding and 
aggregation can occur. We generated a reverse pRNA-3WJ, 
denoted pRNA-3WJ-rev, which is a mirror image of the 
pRNA-3WJ with the 5'- and 3'-ends switched (FIG. 28B). 
The pRNA-3WJ-rev has identical properties as the conven-
tional pRNA-3WJ with regards to thermodynamic stability, 
50 (FIG. 29, 31D). Our design does not require any enzymatic 
ligation step and simply relies on self-assembly of individual 
blocks for the construction of higher order dendrimers. All 
the sequences for dendrimer generations were optimized to 
avoid any nonspecific interactions using the Mfold algo-
55 rithm [D48]. 
as well as assembly in native and 8 M denaturing PAGE. 
Module-2 consists of three sets of pRNA-3WJ building 
blocks, each harboring one of the component strands of the 
pRNA-3WJ-rev serving as sticky ends (3WJ-a_rev, 3WJ- 60 
b_rev and 3WJ-c_rev). The use of3WJ core strands as sticky 
ends ensures near spontaneous 3WJ assembly with minimal 
non-specific hybridization, which can otherwise lead to 
misfolding, and also eliminates the need for additional 
linking sequences between 3WJs. 65 
Upon mixing the three building blocks in stoichiometric 






Characteristics of RNA dendrimers 
Predicted Molecular 
Size Weight # of 
(nm) (kDa) strands 
6 17784 3 unique 
3 total 
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TABLE 4-continued 
Characteristics of RNA dendrimers 
54 
To further confirm the results, all constructed dendrimer 
generations from G-0 to G-4 were examined by AFM 
imaging, which strongly support the formation of all den-
drimers with branched conformations (FIG. 32A). For G-4 
Predicted Molecular 
RNA Size Weight 
Dendrimer (nm) (kDa) 
G-2 37 186675 














5 dendrimers, the bifurcation in the arms of outer layer can be 
easily observed and the central square is visible in most of 
the structures from G-1 to G-4. The dendrimer structures are 
indeed three dimensional as designed in silica utilizing the 
crystal structure of the planer 3WJ structural motif]D44]. 
29 total 
G-4 65 609675 11 unique 
61 total 
Characterization of RNA dendrimers for thermodynamic 
stability and serum stability 
10 Swiss PDB Viewer (www.spdbv.vital-it.ch) and Pymol 
(https://www.pymol.org/) were used to align 3WJ building 
blocks into three dimensional structure models (FIG. 32A), 
based on the available crystal structure of pRNA-3WJ (PDB 
ID: 4KZ2)[D44]. The three dimensional nature of dendrimer 
15 make the structures to appear in different orientations on the 
surface for AFM imaging thus bringing dendrimer arms 
appear close or farther away from each other in different 
images. RNA dendrimers are highly negatively charged and 
do not aggregate in solution. This anionic nature and aggre-
The thermodynamic stability of individual building 
blocks is of paramount importance to ensure that the RNA 
dendrimers remain intact without dissociating in vivo. Both 
the pRNA-3WJ and pRNA-3WJ-rev scaffold assemble with 
high efficiency, as shown in native PAGE (FIG. 28A-B; top 
gel). Both 3WJs remain stable in presence of strongly 
denaturing 8 M urea, thereby demonstrating the robust 
attributes (FIG. 28A-B; bottom gel). Melting experiments 
indicated that the three component strands have a much 
higher affinity to interact with one another than any of the 25 
one or two component strands. The slope of the melting 
curve is very steep indicating cooperative assembly of the 
three strands with very low free energy (li.G0 38- c. of -28 
kcal/mo!), as calculated previously37 . The Tm values are near 
identical for pRNA-3WJ and pRNA-3WJ-rev scaffolds with 
59±0.5° C. and 58.5±0.5° C., respectively (FIG. 28A-B). Tm 
analysis of RNA dendrimers is challenging involving mul-
tiple strands and multi-step folding intermediates. 
20 gation-free physical property will minimize non-specific cell 
entry, and entrapment by lung and spleen macrophages and 
liver Kupffer cells[D53]. 
Characterization of RNA Dendrimers for Cell Receptor 
Targeting 
To study the potential applications of RNA dendrimers in 
targeting specific cells, 2'-F modified RNA dendrimers were 
assembled with targeting ligands at peripheral ends. 
Increased expression of folate receptors are frequently 
observed in cancer cells of epithelial origin54. Herein, we 
30 used folate as a targeting ligand. Within G-4, the core 
SquareE strand of G-1 was fluorescently tagged with Cy5 
for detection. One of the terminal end sequences (3WJ-c) 
was labeled with folate at 3'-end (custom ordered from 
Trilink) and then used to assemble G-4 dendrimers resulting For successful clinical application of RNA dendrimers, a 
major hurdle is their stability in biological media, such as 
serum. Unmodified RNAs are intrinsically sensitive to deg-
radation because of presence of nucleases in serum or in 
cells with a half-life varying from a few minutes to several 
hours[D40,D49,D50]. Chemical modifications, such as 
2'-Fluoro (2'-F) modification on the ribose sugar of the 40 
RNA, have been shown to be nuclease resistant [D22,D51, 
D52] and also enhance the thermodynamic stability of RNA 
nanoparticles [D37]. Within the dendrimer RNA sequences, 
the U and C nucleotides were replaced by 2'-F modified U 
and C nucleotides during solid state synthesis or in vitro 45 
transcription. The 2'-F modified G-4 RNA dendrimers were 
assembled and showed similar assembly efficiency as 
unmodified G-4 RNA dendrimers in native gel assays. To 
test the serum stability, 2'-F modified G-4 dendrimers were 
incubated with 10% Fetal Bovine Serum (FBS) at 37° C. At 50 
specific time points, aliquots were extracted and snap frozen. 
Gel assays demonstrated that the 2'-F G-4 RNA dendrimers 
are resistant to nuclease degradation for more than 24 hours 
(FIG. 32C), while unmodified constructs are degraded 
within 10-15 minutes. 
Characterization of RNA Dendrimer Assembly by Atomic 
Force Microscopy (AFM) and Gel Electrophoresis 
35 in 16 folates distributed evenly across the G-4 dendrimer 
surface. Folate receptor positive KB cells were incubated 
with G-4 dendrimers at different concentrations and the 
incubation efficiencies were analyzed using flow cytometry 
(FIG. 33A). G-4 dendrimers with folate displayed increase 
in intracellular uptake with increasing RNA concentrations 
from 1 nM to 3 nM to 6 nM, compared to G-4 dendrimers 
without any folate. This is attributed to folate receptor 
mediated endocytosis. Confocal fluorescence microscopy 
(FIG. 33B) images further confirmed the internalization of 
G-4 dendrimers with folates as indicated by strong overlap 
of cytoplasma (green) and dendrimers (red). The results 
demonstrate that RNA dendrimers would be useful to deliver 
various payloads including radioligand, drug molecules, and 
RNAi modules into the cells. 
Discussion 
We demonstrated that RNA can serve as a new generation 
of building blocks to form homogenous supramolecular 3D 
dendrimers with defined size and shape. Our step-wise self 
assembly strategy utilizing a robust pRNA-3WJ motif is 
55 highly efficient and can generate homogeneous dendrimers 
under control with high yield and purity. Introduction of2'-F 
RNA makes the dendrimers serum resistant and decoration 
of the dendrimers with targeting ligands results in high The assembly of dendrimers was tested by native gel 
electrophoresis (FIG. 32B). G-0, G-1, G-2, G-3 and G-4 
dendrimers all display a single band in the gels without any 60 
smears indicating high efficiency of the adopted assembly 
strategy. No significant change in assembly efficiency was 
observed by going from lower to higher generations. The 
free RNA strands were removed after dendrimer assembly 
using centrifugal membrane filter colunms. The slow migra-
tion of the gel band from G-0 to G-4 clearly indicates the 
increasing size of the constructs, as expected. 
intracellular delivery to specific target cells. 
Compared to small molecule based chemical polymers, 
RNA dendrimers can be made large enough (>10 nm) to 
avoid rapid renal excretion, yet small enough ( 65 nm for G-4 
dendrimers) to enter cells via receptor-mediated endocyto-
sis. The degradation of RNA can be timely controlled by 
65 adjusting the percent and location of chemically modified 
2'-F nucleotides. Moreover, individual nucleotides within 
the RNA dendrimer can be labeled during chemical synthe-
US 10,828,381 B2 
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sis prior to dendrimer self-assembly, thus ensuring full 
utilization of void-spaces, which is an arduous challenge for 
small molecule based dendrimers. Compared to DNA coun-
terparts, in addition to enhanced chemical stability after 2'-F 
modifications, RNA dendrimers are thermodynamically 5 
more stable[D15-16,D22,D37,D55-56] and will therefore 
not dissociate at ultra-low concentrations in vivo, and thera-
peutic RNA interference modules, such as siRNA and 
miRNA can be seamlessly integrated into the sequence 
design. 10 
The ease of chemical synthesis of RNA strands, the 
simplicity of self-assembly without synthetic reactions, the 
ease of functionalization of modular units prior to assembly, 
and the multivalent nature of RNA dendrimers will help in 
high loading of desired functional modules, such as drugs, 15 
targeting, therapeutic, and imaging agents for myriad of 
applications in bioelectronics, biomimetic membranes, 
imaging, diagnostics and therapeutics. 
All publications, patents, and patent applications men-
tioned in this specification are herein incorporated by ref- 20 
erence to the same extent as if each individual publication, 
patent, or patent application was specifically and individu-
ally indicated to be incorporated by reference, including the 
references set forth in the following list: 
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It will be understood that various details of the presently 
disclosed subject matter can be changed without 
departing from the scope of the subject matter disclosed 
herein. Furthermore, the foregoing description is for the 
purpose of illustration only, and not for the purpose of 
limitation. 
<160> NUMBER OF SEQ ID NOS, 37 
<210> SEQ ID NO 1 
<211> LENGTH, 18 
<212> TYPE, RNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 1 
uugccaugug uauguggg 
<210> SEQ ID NO 2 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 2 
cccacauacu uuguugaucc 
<210> SEQ ID NO 3 
<211> LENGTH, 16 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 3 
ggaucaauca uggcaa 
<210> SEQ ID NO 4 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 4 
ggguguaugu guaccguu 
<210> SEQ ID NO 5 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 5 
ccuaguuguu ucauacaccc 
<210> SEQ ID NO 6 
<211> LENGTH, 16 







<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 10,828,381 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 6 
aacgguacua acuagg 
<210> SEQ ID NO 7 
<211> LENGTH, 16 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<220> FEATURE, 
<223> OTHER INFORMATION, 3'-folate 
<400> SEQUENCE, 7 
ggaucaauca uggcaa 
<210> SEQ ID NO 8 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 8 
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac 
<210> SEQ ID NO 9 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 9 
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua 
<210> SEQ ID NO 10 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 10 
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggag 
<210> SEQ ID NO 11 
<211> LENGTH, 48 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 11 
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg 
<210> SEQ ID NO 12 









<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 10,828,381 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 12 
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug 60 
uaugcgaugc gcuugucaug uguauggc 88 
<210> SEQ ID NO 13 
<211> LENGTH, 88 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 13 
ggcccacaua cuuuguugau ccauggugcg uagggucguc aaucauggca aguguccgcc 60 
auacuuuguu gcacucccuu gcucauca 88 
<210> SEQ ID NO 14 
<211> LENGTH, 88 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 14 
ggcccacaua cuuuguugau ccugaugagc aagggagugc aaucauggca agcguaucgc 60 
auacuuuguu gagaacccua ugugacuu 88 
<210> SEQ ID NO 15 
<211> LENGTH, 88 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 15 
ggcccacaua cuuuguugau ccaagucaca uaggguucgc aaucauggca acgauagagc 60 
auacuuuguu ggagucccuu agaguaga 88 
<210> SEQ ID NO 16 
<211> LENGTH, 88 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 16 
ggcccacaua cuuuguugau ccucuacucu aagggacucc aaucauggca auauacacgc 60 
auacuuuguu gacgacccua cgcaccau 88 
<210> SEQ ID NO 17 
<211> LENGTH, 38 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 




<400> SEQUENCE, 17 
uugccaugug uaugugggcc uaguuguuuc auacaccc 
<210> SEQ ID NO 18 
<211> LENGTH, 36 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 10,828,381 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 18 
ggaucaauca uggcaaccua guuguuucau acaccc 
<210> SEQ ID NO 19 
<211> LENGTH, 38 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 19 
cccacauacu uuguugaucc ggguguaugu guaccguu 
<210> SEQ ID NO 20 
<211> LENGTH, 36 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 20 
cccacauacu uuguugaucc aacgguacua acuagg 
<210> SEQ ID NO 21 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule, 
Synthetic oligonucleotide 
<400> SEQUENCE, 21 
ggaccaccgc aucucuacat t 
<210> SEQ ID NO 22 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule, 
Synthetic oligonucleotide 
<400> SEQUENCE, 22 
ttccuggugg cguagagaug u 








<211> LENGTH, 21 
<212> TYPE, RNA 
79 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 23 
aagcugucac agaggggcua c 
<210> SEQ ID NO 24 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 24 
guagccccuc ugugacagcu u 
<210> SEQ ID NO 25 
<211> LENGTH, 25 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 25 
ccaugugcua uacagucauu acuuu 
<210> SEQ ID NO 26 
<211> LENGTH, 25 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 26 
aaaguaauga cuguauagca caugg 
<210> SEQ ID NO 27 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 27 
uuggacaaug gacugguuga 
<210> SEQ ID NO 28 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 28 
ucaaccaguc cauuguccaa 
<210> SEQ ID NO 29 









<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 10,828,381 B2 
-continued 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 29 
ccacauaaag ggcccacua 
<210> SEQ ID NO 30 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 30 
uagugggccc uuuaugugg 
<210> SEQ ID NO 31 
<211> LENGTH, 9 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 31 
Gly Ser Gly Lys Cys Cys Tyr Ser Leu 
1 5 
<210> SEQ ID NO 32 
<211> LENGTH, 6 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
peptide 
<400> SEQUENCE, 32 
Lys Cys Cys Tyr Ser Leu 
1 5 
<210> SEQ ID NO 33 
<211> LENGTH, 117 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polynucleotide 
<400> SEQUENCE, 33 
19 
19 
gcaaugguac gguacuucca uugucaugug uauguugggg auuaggaccu gauugaguuc 60 
agcccacaua cuuuguugau ugcgcgucaa ucauggcaaa agugcacgcu acuuugc 117 
<210> SEQ ID NO 34 
<211> LENGTH, 16 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 34 
ggaucaacca uggcaa 16 
82 
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-continued 
<210> SEQ ID NO 35 
<211> LENGTH, 34 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (1) .. (6) 
<223> OTHER INFORMATION, a, c, t, g, unknown or other 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (29) .. (34) 
<223> OTHER INFORMATION, a, c, t, g, unknown or other 
<400> SEQUENCE, 35 
nnnnnntcaa catcagtctg ataagctann nnnn 
<210> SEQ ID NO 36 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
34 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 36 
uugucaugug uauguugg 
<210> SEQ ID NO 37 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
18 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
oligonucleotide 
<400> SEQUENCE, 37 
ggguuguaug uguacuguu 
What is claimed is: 
1. A RNA dendrimer molecule, the molecule comprising 
(a) a central core multi-branched RNA junction motif, 
wherein the central core motif comprises a plurality of 
branches, wherein a branch comprises at least one RNA 
oligonucleotide, and wherein the central core motif com-
prises at least one RNA oligonucleotide having at least 90% 
identity to SEQ ID NO: 12 (SquareE); and (b) an outer 
surface multi-branched RNA junction motif comprising at 
least one repeating multi-branched RNA junction motif unit, 
wherein the repeating unit comprises a plurality of branches, 
and wherein a branch comprises at least one RNA oligo-
nucleotide. 
2. The RNA dendrimer molecule of claim 1, further 
comprising at least one imaging module, at least one target-
ing module, at least one therapeutic module, or a combina-
tion thereof. 
19 
branched RNA junction motif unit comprises a three-
branched RNA junction motif, or a four-branched RNA 
junction motif, a six-branched RNA junction motif, and an 
45 eight-branched RNA junction motif. 
5. The RNA dendrimer molecule of claim 3 or 4, wherein 
the three-branched RNA junction motif comprises an a3WJ 
RNA module having at least 90% identity to nucleotide 
50 
sequence 5'-UUG CCA UGU GUA UGU GGG-3' (SEQ ID 
NO: 1); a b3WJ RNA module having at least 90% identity 
to nucleotide sequence 5'-CCC ACA UAC UUU GUU 
GAUCC-3' (SEQ ID NO: 2); or a c3WJ RNA module having 
at least 90% identity to nucleotide sequence 5'-GGA UCA 
55 AUC AUG GCA A-3' (SEQ ID NO: 3), or a combination 
thereof. 
3. The RNA dendrimer molecule of claim 1, wherein the 60 
plurality of branches comprising the central core multi-
branched RNA junction motif comprises a three-branched 
RNA junction motif, or four-branched RNA junction motif, 
6. The RNA dendrimer molecule of claim 3 or 4, wherein 
the central core multi-branched RNA junction motif is a 
polygon shaped architecture comprising a three-branched 
RNA junction motif at each comer. 
7. The RNA dendrimer molecule of claim 1, wherein the 
imaging module comprises a fluorescent dye, a radionuclide, 
a contrast agent, a reporter imaging molecule, a reference 
imaging molecule, or any combination thereof. a six-branched RNA junction motif, or an eight-branched 
RNA junction motif. 
4. The RNA dendrimer molecule of claim 1, wherein the 
plurality of branches comprising the repeating multi-
65 8. The RNA dendrimer molecule of claim 7, wherein the 
reference imaging module comprises a reference dye and a 
quencher. 
US 10,828,381 B2 
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9. The RNA dendrimer molecule of claim 7, wherein the -continued 
contrast agent comprises at least one MRI contrast agent, at 
least one gadolinium contrast agent, or both. SquareA, (SEQ ID NO, 8) 
10. The RNA dendrimer molecule of claim 2, wherein the GGG AGC CGU CAA UCA UGG CAA GUG UCC GCC AUA CUU 
targeting module comprises a cancer targeting module. 5 
UGU UGC ACG CAC 
11. The RNA dendrimer molecule of claim 10, wherein 
the cancer targeting module is a ligand that binds to at least SquareB, 
one cancer cell surface marker. (SEQ ID NO, 9) 
GGG AGC GUG CAA UCA UGG CAA GCG CAU CGC AUA CUU 
12. The RNA dendrimer molecule of claim 10, wherein 10 
the targeting module comprises chemical ligand or RNA UGU UGC GAC CUA 
aptamer. SquareC, 
13. The RNA dendrimer molecule of claim 11, wherein (SEQ ID NO, 10) 
the ligand comprises folate. GGG AGG UCG CAA UCA UGG CAA CGA UAG AGC AUA CUU 
14. The RNA dendrimer molecule of claim 11, wherein 
15 
UGU UGG CUG GAG 
the cell surface markers comprises a folate receptor. 
SquareD, 
15. The RNA dendrimer molecule of claim 11, wherein (SEQ ID NO, 11) 
the ligand binds to an epithelial cell adhesion molecule GGG ACC AGC CAA UCA UGG CAA UAU ACA CGC AUA CUU 
(EpCAM). 20 UGU UGA CGG CGG 
16. The RNA dendrimer molecule of claim 11, wherein 
the cell surface marker comprises an epithelial cell adhesion SquareE, 
molecule (EpCAM). 
(SEQ ID NO, 12) 
GGA CAC UUG UCA UGU GUA UGC GUG UAU AUU GUC AUG 
17. The RNA dendrimer molecule of claim 12, wherein 
25 
the aptamer is an EpCAM RNA aptamer. UGU AUG CUC UAU CGU UGU CAU GUG UAU GCG AUG CGC 
18. The RNA dendrimer molecule of claim 2, wherein the UUG UCA UGU GUA UGG C 
therapeutic module comprises a siRNA, a miRNA, an anti-
b-SquareA, 
mRNA, a ribozyme RNA, an antisense RNA, a chemothera- (SEQ ID NO, 13) 
peutic drug, a cytotoxic drug, a riboswitch, or an endosome 30 GGC CCA CAU ACU UUG UUG AUC CAU GGU GCG UAG GGU 
disrupting agent. 
19. The RNA dendrimer molecule of claim 18, wherein 
CGU CAA UCA UGG CAA GUG ucc GCC AUA cuu UGU UGC 
the cytotoxic drug comprises doxorubicin, paclitaxel, pacli- ACU CCC UUG CUC AUC A 
taxel derivatives and analogues, cytochalasin D, rapamycin, 
b-SquareB, rapamycin derivatives and analogues, camptothecin, dexam- 35 (SEQ ID NO, 14) 
ethasone, and 5-fluorouracil, a quinazolinone derivative, GGC CCA CAU ACU UUG UUG AUC CUG AUG AGC AAG GGA 
metallic silver, tranilast, everolimus and/or related com-
pounds. GUG CAA UCA UGG CAA GCG UAU CGC AUA CUU UGU UGA 
20. The RNA dendrimer molecule of claim 1, wherein the GAA CCC UAU GUG ACU U 
RNA dendrimer molecule further comprises an oligonucle- 40 
otide having at least 90% identity to nucleotide sequences of b-SquareC, 
at least one of (SEQ ID NO, 15) 
GGC CCA CAU ACU UUG UUG AUC CAA GUC ACA UAG GGU 
45 UCG CAA UCA UGG CAA CGA UAG AGC AUA CUU UGU UGG 3WJ-a, 
(SEQ ID NO, 1) 
AGU CCC UUA GAG UAG A UUG CCA UGU GUA UGU GGG 
3WJ-b, b-SquareD, 
(SEQ ID NO, 2) (SEQ ID NO, 16) 
CCC ACA UAC UUU GUU GAU CC 50 GGC CCA CAU ACU UUG UUG AUC CUC UAC ucu AAG GGA 
3WJ-c, CUC CAA UCA UGG CAA UAU ACA CGC AUA cuu UGU UGA 
(SEQ ID NO, 3) 
GGA UCA AUC AUG GCA A CGA CCC UAC GCA CCA U 
3WJ-a rev: 55 3WJ-a-b rev: 
(SEQ ID NO, 4) (SEQ ID NO, 17) 
GGG UGU AUG UGU ACC GUU UUG CCA UGU GUA UGU GGG CCU AGU UGU UUC AUA CAC 
3WJ-b rev, cc 
(SEQ ID NO, 5) 
CCU AGU UGU UUC AUA CAC CC 
60 3WJ-c-b rev: 
3WJ-c rev: (SEQ ID NO, 18) 
(SEQ ID NO, 6) GGA UCA AUC AUG GCA A CCU AGU UGU UUC AUA CAC CC 
AAC GGU ACU AAC UAG G 
3WJ-b-a rev, 
3WJ-c-folate, (SEQ ID NO, 19) 
(SEQ ID NO, 7) 65 CCC ACA UAC UUU GUU GAU CC GGG UGU AUG UGU ACC GUU 
GGA UCA AUC AUG GCA A - folate or 




(SEQ ID NO, 20) 
CCC ACA UAC UUU GUU GAU CC AAC GGU ACU AAC UAG G. 
21. A composition comprising a therapeutically effective 
amount of the RNA dendrimer molecule of claim 1 and a 
pharmaceutically effective carrier. 
22. The RNA dendrimer molecule of claim 1, wherein the 
central core motif further comprises an RNA oligonucleotide 10 
having at least 90% identity to at least one of SEQ ID NO: 
8 (SquareA), SEQ ID NO: 9 (SquareB), SEQ ID NO: 10 
(SquareC), SEQ ID NO: 11 (SquareD), SEQ ID NO: 13 
(b-SquareA), SEQ ID NO: 14 (b-SquareB), SEQ ID NO: 15 
(b-SquareC), or SEQ ID NO: 9 (b-SquareD). 15 
* * * * * 
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